




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(S1) International Patent Classification ⁶ :		A1	(11) International Publication Number: WO 96/25405
C07D 261/08, 413/04, 261/18, 261/12, 261/10, A61K 31/42			(43) International Publication Date: 22 August 1996 (22.08.96)
(21) International Application Number: PCT/US96/01869		(72) Inventors; and	
(22) International Filing Date: 12 February 1996 (12.02.96)		(75) Inventors/Applicants (for US only): TALLEY, John, J. [US/US]; 8772 Pine Avenue, Brentwood, MO 63144 (US). BROWN, David, L. [US/US]; 15504 Twingate, Chesterfield, MO 63017 (US). NAGARAJAN, Srinivasan [IN/US]; 16209 Forest Meadows Drive, Chesterfield, MO 63005 (US). CARTER, Jeffery, S. [US/US]; 15321 Grantley Drive, Chesterfield, MO 63017 (US). WEIER, Richard, M. [US/US]; 240 Hickory Crescent, Lake Bluff, IL 60044 (US). STEALEY, Michael, A. [US/US]; 502 Juniper Parkway, Libertyville, IL 60048 (US). COLLINS, Paul, W. [US/US]; 1557 Hawthorne Place, Deerfield, IL 60015 (US). SEIBERT, Karen [US/US]; 11930 Greenwalk Drive, St. Luis, MO 63146 (US). GRANETO, Matthew, J. [US/US]; 1510 Voltaire Drive, St. Louis, MO 63146 (US). XU, Xiangdong [CN/US]; Apartment 715, 855 Hinman Avenue, Evanston, IL 60202 (US). PARTIS, Richard [US/US]; 221 Noyes Street, Evnaston, IL 60201 (US).	
(30) Priority Data:		(74) Agents: BULOCK, Joseph, W. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
08/387,680 08/473,884	13 February 1995 (13.02.95) 7 June 1995 (07.06.95)	US US	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(60) Parent Applications or Grants		(73) Related by Continuation	
US Filed on	13 February 1995 (13.02.95)	08/387,680 (CIP)	US Filed on
US Filed on	7 June 1995 (07.06.95)	08/473,884 (CIP)	7 June 1995 (07.06.95)
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(71) Applicant (for US only): ROGERS, Kathy, L. (legal representative of the deceased inventor) [US/US]; 7431 Arlington Drive, Richmond Heights, MO 63117 (US).			
(72) Inventor: ROGERS, Roland, S. (deceased).			
Published With international search report.			

(54) Title: SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION



(57) Abstract

A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) wherein R⁷ is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxy carbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxy carbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R⁸ is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxy carbonyl, lower haloalkyl, hydroxyl, lower hydroxylalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SUBSTITUTED ISOXAZOLES
FOR THE TREATMENT OF INFLAMMATION

FIELD OF THE INVENTION

5 This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.

10 BACKGROUND OF THE INVENTION

Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of 15 PGG₂, PGH₂ and PGE₂, has been a common target of antiinflammatory drug discovery. However, common non-steroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are 20 also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening 25 ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.

Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in 30 the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). The recent discovery of an inducible enzyme associated with inflammation (named "cyclooxygenase-2 (COX-2)" or "prostaglandin G/H synthase II") provides a viable 35 target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

The references below that disclose antiinflammatory activity, show continuing efforts to

find a safe and effective antiinflammatory agent. The novel isoxazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts. The invention's compounds are found to show 5 usefulness in vivo as antiinflammatory agents with minimal side effects. The substituted isoxazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase-2 over cyclooxygenase-1.


Isoxazoles have been described for various uses, 10 including the treatment of inflammation. DE 4,314,966, published November 10, 1994, describes 3-(2-hydroxyphenyl)isoxazoles for the treatment of inflammatory disorders. WO 92/05162, published April 4, 1992, describes 5-piperazinyl-3,4-diaryl-isoxazoles 15 as having medicinal use.

WO 92/19604, published November 12, 1992, describes 5-alkene-3,4-diaryl-isoxazoles as having cyclooxygenase inhibition activity. EP 26928, published April 15, 1981, describes 3,4-diaryl- 20 isoxazole-5-acetic acids as having antiinflammatory activity. WO 95/00501, published January 5, 1995, generically describes 3,4-diaryl-isoxazoles as cyclooxygenase inhibitors.

The invention's isoxazolyl compounds are found to 25 show usefulness in vivo as antiinflammatory agents with minimal side effects.

DESCRIPTION OF THE INVENTION

A class of substituted isoxazolyl compounds useful 30 in treating inflammation-related disorders is defined by Formula I:



wherein R¹ is selected from alkyl, carboxyalkyl, alkoxycarbonyl, aminocarbonyl, aminocarbonylalkyl, alkoxycarbonylalkyl, carboxyl, cyano, alkoxy, 5 haloalkoxy, aralkoxy, heteroaralkoxy, cycloalkylalkoxy, alkylthio, aralkylthio, heteroaralkylthio, cycloalkylalkylthio, alkoxyalkyl, aralkoxyalkyl, alkylthioalkyl, aralkylthioalkyl, alkylaminoalkyl, aryloxyalkyl, arylthioalkyl, hydroxyl, amino, 10 hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo, heterocycloalkyl, aralkyl, halo, alkylamino, aralkylamino, N-alkyl-N-aralkylamino, heteroaralkylamino, N-alkyl-N-heteroaralkylamino, N-alkyl-N-cycloalkylalkylamino, alkoxyalkyloxyalkyl, 15 aryl(hydroxylalkyl), haloalkylsulfonyloxy, arylcarbonyloxyalkyl, arylcarbonylthioalkyl, alkoxycarbonyloxyalkyl, carboxyalkoxyalkyl, carboxyaryloxyalkyl, alkoxycarbonylaryloxyalkyl, alkylaminocarbonyloxyalkyl, alkoxycarbonylthioalkyl, 20 and alkylaminocarbonylthioalkyl;

wherein R² is selected from alkylsulfonyl, hydroxysulfonyl, and aminosulfonyl; and

wherein R³ is selected from cycloalkyl, cycloalkenyl, aryl and heterocyclo; wherein R³ is 25 optionally substituted at a substitutable position with one or more radicals independently selected from alkyl, cyano, carboxyl, alkoxycarbonyl, haloalkyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, aminoalkyl, nitro, alkoxyalkyl, alkylsulfinyl, 30 alkylsulfonyl, aminosulfonyl, halo, alkoxy and alkylthio;

provided R² is aminosulfonyl when the R²-substituted phenyl radical is at isoxazole position 3; or a pharmaceutically-acceptable salt thereof.

35 Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for treatment of other inflammation-associated disorders, such as, as an analgesic in the

treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, compounds of the invention would be useful to treat arthritis, including but not limited to rheumatoid arthritis,

5 spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such compounds of the invention would be useful in the treatment of asthma, bronchitis, menstrual cramps, tendinitis, bursitis, and skin-related conditions such

10 as psoriasis, eczema, burns and dermatitis. Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis, and for the

15 prevention or treatment of cancer, such as colorectal cancer. Compounds of the invention would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarthritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease,

20 sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis,

25 hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like. The compounds would also be useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis, conjunctivitis, and of acute injury to the eye tissue.

30 The compounds would also be useful in the treatment of pulmonary inflammation, such as that associated with viral infections and cystic fibrosis. The compounds would also be useful for the treatment of certain central nervous system disorders such as cortical

35 dementias including Alzheimers disease. The compounds of the invention are useful as anti-inflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less

harmful side effects. These compounds would also be useful in the treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis and central nervous system 5 damage resulting from stroke, ischemia and trauma.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of mammals, including companion animals and farm animals, such as, but not limited to, horses, dogs, cats, cows, sheep and 10 pigs.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional antiinflammatories, such as together with steroids, NSAIDs, 5-lipoxygenase inhibitors, LTB₄ 15 receptor antagonists and LTA₄ hydrolase inhibitors.

Suitable LTB₄ receptor antagonists include, among others, ebselen, Bayer Bay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compound ETH-615, Lilly compound LY-293111, Ono compound ONO-4057, Terumo 20 compound TMK-688, Lilly compounds LY-213024, 264086 and 292728, Ono compound ONO-LB457, Searle compound SC-53228, calcitrol, Lilly compounds LY-210073, LY223982, LY233469, and LY255283, Ono compound ONO-LB-448, Searle compounds SC-41930, SC-50605 and SC-51146, 25 and SK&F compound SKF-104493. Preferably, the LTB₄ receptor antagonists are selected from ebselen, Bayer Bay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compound ETH-615, Lilly compound LY-293111, Ono compound ONO-4057, and Terumo compound TMK-688.

30 Suitable 5-LO inhibitors include, among others, masoprolol, tenidap, zileuton, pranlukast, tepoxalin, rilopirox, flezelastine hydrochloride, enazadrem phosphate, and bunaprolast.

The present invention preferably includes 35 compounds which selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Preferably, the compounds have a cyclooxygenase-2 IC₅₀ of less than about 0.5 μ M, and also have a selectivity ratio of cyclooxygenase-2

inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1 IC₅₀ of greater than about 1 μ M, and more preferably of 5 greater than 20 μ M. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.

A preferred class of compounds consists of those compounds of Formula I wherein R¹ is selected from 10 hydroxyl, amino, lower alkyl, lower carboxyalkyl, lower alkoxy carbonyl, aminocarbonyl, carboxyl, cyano, lower aminocarbonylalkyl, lower alkoxy carbonylalkyl, lower alkoxy, lower haloalkoxy, lower aralkoxy, lower heteroaralkoxy, lower cycloalkylalkoxy, lower 15 alkylthio, lower aralkylthio, lower heteroaralkylthio, lower cycloalkylalkylthio, lower alkoxyalkyl, lower alkoxyalkyloxyalkyl, lower aralkoxyalkyl, lower alkylthioalkyl, lower aralkylthioalkyl, lower alkylaminoalkyl, lower aryloxyalkyl, lower 20 arylthioalkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, 5- or 6-membered heterocyclo, lower heterocycloalkyl, lower aralkyl, halo, lower haloalkylsulfonyloxy, lower aryl(hydroxylalkyl), lower alkylamino, lower 25 aralkylamino, lower N-alkyl-N-aralkylamino, lower heteroaralkylamino, lower N-alkyl-N-heteroaralkylamino, lower N-alkyl-N-cycloalkylalkylamino, lower arylcarbonyloxyalkyl, lower alkoxy carbonyloxyalkyl, lower alkylaminocarbonyloxyalkyl, lower 30 carboxyalkoxyalkyl, lower carboxyaryloxyalkyl, lower alkoxy carbonylaryloxyalkyl, lower alkoxy carbonylthioalkyl, and lower alkylaminocarbonylthioalkyl; wherein R² is selected from lower alkylsulfonyl, hydroxysulfonyl, and 35 aminosulfonyl; and wherein R³ is selected from lower cycloalkyl, lower cycloalkenyl, aryl, and heteroaryl; wherein R³ is optionally substituted at a substitutable position with one or more radicals independently


selected from lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxy carbonyl, lower haloalkyl, hydroxyl, lower hydroxylalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, 5 nitro, halo, lower alkoxy, lower alkylsulfonyl, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

A more preferred class of compounds consists of those compounds of Formula I wherein R¹ is selected 10 from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxy carbonylalkyl, lower aralkyl, lower alkoxyalkyl, lower alkoxyalkyloxyalkyl, lower aralkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower 15 aryl(hydroxylalkyl), lower carboxyalkoxyalkyl, lower carboxyaryloxyalkyl, lower alkoxy carbonylaryloxyalkyl, lower cycloalkyl and lower cycloalkylalkyl; wherein R² is selected from methylsulfonyl, hydroxysulfonyl, and aminosulfonyl; and wherein R³ is selected from phenyl 20 and 5-6 membered heteroaryl; wherein R³ is optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxy carbonyl, lower haloalkyl, hydroxyl, lower 25 hydroxylalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest 30 consists of those compounds of Formula I wherein R¹ is selected from hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, chloro, carboxyl, carboxypropyl, carboxymethyl, carboxyethyl, 35 carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, methoxymethyl, methoxyethyloxymethyl, benzyloxymethyl, phenylethoxymethyl, fluoromethyl, difluoromethyl,

chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl, fluoromethyl,
difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, hydroxymethyl, hydroxylpropyl,
5 hydroxylethyl, trifluoromethylsulfonyloxy, 2-(4-
chlorophenyl)-2-hydroxylethyl, carboxymethoxymethyl,
(4-carboxyphenyl)oxymethyl, (4-
methoxycarbonylphenyl)oxymethyl, cyclohexyl,
cyclobutyl, cyclopentyl, cycloheptyl, cyclohexylmethyl,
10 cyclohexylethyl, cyclobutylethyl, cyclopentylmethyl,
cycloheptylpropyl, and lower aralkyl selected from
benzyl and phenylethyl, wherein the phenyl ring is
optionally substituted at a substitutable position with
fluoro, chloro, bromo, iodo, methyl, and methoxy;
15 wherein R² is selected from methylsulfonyl,
hydroxysulfonyl, and aminosulfonyl; and wherein R³ is
selected from phenyl, pyridyl, thieryl, thiazolyl,
oxazolyl and furyl; wherein R³ is optionally
substituted at a substitutable position with one or
20 more radicals independently selected from
trifluoromethoxy, N-methylamino, N,N-dimethylamino, N-
ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-
N-ethylamino, phenylamino, N-methyl-N-phenylamino,
methylsulfinyl, ethylsulfinyl, methyl, ethyl,
25 isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl,
cyano, carboxyl, methoxycarbonyl, fluoromethyl,
difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, pentafluoroethyl,
heptafluoropropyl, fluoromethyl, difluoroethyl,
30 difluoropropyl, dichloroethyl, dichloropropyl,
hydroxyl, hydroxymethyl, amino, nitro, fluoro, chloro,
bromo, iodo, methoxy, ethoxy, propoxy, n-butoxy,
pentoxy, hexyloxy, methylenedioxy, aminosulfonyl,
methylthio, ethylthio, butylthio, and hexylthio; or a
35 pharmaceutically-acceptable salt thereof.

Within Formula I there is a subclass of compounds
of high interest represented by Formula II:




II

wherein R⁴ is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower 5 alkoxy carbonylalkyl, lower aralkyl, lower alkoxyalkyl, lower alkoxyalkyloxyalkyl, lower aralkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower aryl(hydroxylalkyl), lower carboxyalkoxyalkyl, lower carboxyaryloxyalkyl, lower 10 alkoxy carbonylaryloxyalkyl, lower cycloalkyl and lower cycloalkylalkyl; wherein R⁵ is selected from methyl, hydroxy, and amino; and wherein R⁶ is selected from 15 aryl and 5-6 membered heteroaryl; wherein R⁶ is optionally substituted at a substitutable position with one or more radicals independently selected from lower 20 alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxy carbonyl, lower haloalkyl, hydroxyl, lower hydroxylalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compounds of Formula II wherein R⁴ is selected from hydroxyl, methyl, ethyl, propyl, 25 isopropyl, butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, chloro, carboxyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, methoxymethyl, 30 methoxyethoxyethyl, benzylmethoxyethyl, phenylethoxyethyl, fluoromethyl, difluoromethyl, chloromethyl, dichloromethyl, trichloromethyl,


pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxylpropyl, hydroxylethyl, trifluoromethylsulfonyloxy, 2-(4-5 chlorophenyl)-2-hydroxylethyl, (4-carboxyphenyl)oxymethyl, carboxymethoxymethyl, (4-methoxycarbonylphenyl)oxymethyl, cyclohexyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexylmethyl, cyclohexylethyl, cyclobutylethyl, cyclopentylmethyl, 10 cycloheptylpropyl, and lower aralkyl selected from benzyl and phenylethyl, wherein the phenyl ring is optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; and wherein R⁶ is selected from phenyl and 3-pyridyl; 15 wherein R⁶ is optionally substituted at a substitutable position with one or more radicals independently selected from trifluoromethoxy, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, phenylamino, N-methyl-N-phenylamino, methylsulfinyl, ethylsulfinyl, 20 methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, cyano, carboxyl, methoxycarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 25 pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, hydroxymethyl, amino, aminomethyl, nitro, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, hexyloxy, 30 methylenedioxy, methylthio, ethylthio, butylthio, and hexylthio; or a pharmaceutically-acceptable salt thereof.

Within Formula I there is a subclass of compounds of high interest represented by Formula III:



wherein R⁷ is selected from hydroxyl, lower alkyl,
 carboxyl, halo, lower carboxyalkyl, lower
 5 alkoxy carbonylalkyl, lower alkoxyalkyl, lower
 carboxyalkoxyalkyl, lower haloalkyl, lower
 haloalkylsulfonyloxy, lower hydroxylalkyl, lower
 aryl(hydroxylalkyl), lower carboxyaryloxyalkyl, lower
 alkoxy carbonylaryloxyalkyl, lower cycloalkyl, lower
 10 cycloalkylalkyl, and lower aralkyl; and wherein R⁸ is
 one or more radicals independently selected from
 hydrido, lower alkylsulfinyl, lower alkyl, cyano,
 carboxyl, lower alkoxy carbonyl, lower haloalkyl,
 hydroxyl, lower hydroxylalkyl, lower haloalkoxy, amino,
 15 lower alkylamino, lower arylamino, lower aminoalkyl,
 nitro, halo, lower alkoxy, aminosulfonyl, and lower
 alkylthio; or a pharmaceutically-acceptable salt
 thereof.

Within Formula I there is a subclass of compounds
 20 of high interest represented by Formula IV:




wherein R⁹ is selected from lower alkyl, lower
 carboxyalkyl, lower alkoxy carbonylalkyl, lower
 25 alkoxyalkyloxyalkyl, lower hydroxylalkyl, and lower

aralkyl; wherein R^{10} is one or more radicals independently selected from hydrido, lower alkyl, lower haloalkyl, halo and lower alkoxy; and wherein R^{11} is selected from methyl and amino; or a pharmaceutically-
5 acceptable salt thereof.

A class of compounds of particular interest consists of those compounds of Formula IV wherein R^9 is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, 10 hexyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, methoxyethyloxymethyl, hydroxymethyl, hydroxylpropyl, hydroxylethyl, and lower aralkyl selected from benzyl and phenylethyl, 15 wherein the phenyl ring is optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; wherein R^{10} is one or more radicals independently selected from hydrido, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, 20 hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, methoxy, 25 ethoxy, propoxy, n-butoxy, pentoxy, and methylenedioxy; and wherein R^{11} is methyl or amino; or a pharmaceutically-acceptable salt thereof.

Within Formula I there is a subclass of compounds of high interest represented by Formula V:

30



wherein R¹² is one or more radicals independently selected from hydrido, halo, lower haloalkyl, lower alkoxy and lower alkyl; wherein R¹³ is selected from lower alkyl, lower carboxyalkyl, lower 5 alkoxycarbonylalkyl and lower aralkyl; and wherein R¹⁴ is selected from methyl and amino; or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compounds of Formula V wherein R¹² is 10 one or more radicals independently selected from hydrido, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, 15 fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and methylenedioxy; and wherein R¹³ is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, 20 isobutyl, pentyl, isopentyl, neopentyl, hexyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, and lower aralkyl selected from benzyl and phenylethyl, wherein the phenyl ring is 25 optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; or a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula I consists of compounds and 30 pharmaceutically-acceptable salts thereof as follows:

[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid;
[[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-35 methyloxy]acetic acid;
4-[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]butanoic acid;
4-[5-cyano-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-chloro-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-phenyl-5-trifluoromethansulfonyloxy-isoxazol-4-
5 yl]benzenesulfonamide;
4-[3-(3,5-difluorophenyl)-5-methylisoxazol-4-
5 yl]benzenesulfonamide;
4-[3-(4-bromophenyl)-5-methylisoxazol-4-
5 yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-
4-10 yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(4-methoxyphenyl)isoxazol-4-
5 yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(4-methylphenyl)isoxazol-4-
5 yl]benzenesulfonamide;
5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-
15 phenylisoxazole;
4-[3-(3-chlorophenyl)-5-methylisoxazol-4-
5 yl]benzenesulfonamide;
4-[3-(3,4-difluorophenyl)-5-methylisoxazol-4-
5 yl]benzenesulfonamide;
20 methyl 4-[[4-[4-(aminosulfonyl)phenyl]-3-
phenylisoxazol-5-yl]methoxy]benzoate;
4-[[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
5 yl]methoxy]benzoic acid;
4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
25 4-[3-isopropyl-5-phenylisoxazol-4-
5 yl]benzenesulfonamide;
4-[5-phenyl-3-propylisoxazol-4-yl]benzenesulfonamide;
4-[3-ethyl-5-(4-methylphenyl)isoxazol-4-
5 yl]benzenesulfonamide;
30 4-[3-butyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-(4-methylphenyl)isoxazol-4-
5 yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-methylisoxazol-4-
5 yl]benzenesulfonamide;
35 4-[5-(4-fluorophenyl)-3-methylisoxazol-4-
5 yl]benzenesulfonamide;
3-methyl-5-(4-methylsulfonylphenyl)-4-phenylisoxazole;
4-[3-methyl-4-phenylisoxazol-5-yl]benzenesulfonamide;

4-[3-methyl-5-(3-chlorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-hydroxymethyl-5-phenylisoxazol-4-
yl]benzenesulfonamide;
5 4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-acetic
acid;
3-methyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;
4-[3-[2-(4-chlorophenyl)-2-hydroxyethyl]-5-phenylisoxazol-
4-yl]benzenesulfonamide;
10 3-ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;
4-[3-ethyl-5-(4-fluorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(3-fluorophenyl)isoxazol-4-
yl]benzenesulfonamide;
15 4-[3-ethyl-5-(3-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(2-fluorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(2-methylphenyl)isoxazol-4-
20 yl]benzenesulfonamide;
4-[5-(3-chloro-4-methoxyphenyl)-3-ethylisoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(3-fluoro-4-methoxyphenyl)isoxazol-4-
yl]benzenesulfonamide;
25 4-[3-ethoxyethyloxymethyl-5-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(3-fluoro-4-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-isobutyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
30 4-[3-benzyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-
propanoic acid;
4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-
butanoic acid;
35 4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-
pentanoic acid;
4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-
hexanoic acid;

4-[5-methyl-4-phenylisoxazol-3-yl]benzenesulfonamide;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-
propanoic acid;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-
5 butanoic acid;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-
pentanoic acid;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-
hexanoic acid;
10 4-[3-ethyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-isopropyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-isobutyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-benzyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-propyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
15 4-[4-(4-fluorophenyl)-3-methylisoxazol-5-
yl]benzenesulfonamide;
4-[3-methyl-4-(4-methylphenyl)isoxazol-5-
yl]benzenesulfonamide;
4-[3-methyl-4-(4-trifluoromethylphenyl)isoxazol-5-
20 yl]benzenesulfonamide;
4-[3-ethyl-4-(4-methylphenyl)isoxazol-5-
yl]benzenesulfonamide;
4-[3-ethyl-4-(4-trifluoromethylphenyl)isoxazol-5-
yl]benzenesulfonamide;
25 4-[3-ethyl-4-(4-fluorophenyl)isoxazol-5-
yl]benzenesulfonamide;
[3-(3-fluoro-4-methoxyphenyl)-4-[4-
(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid;
[3-(3-chloro-4-methoxyphenyl)-4-[4-
30 (methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid;
5-methyl-4-[4-(methylsulfonyl)phenyl]-3-phenyl-
isoxazole;
3-(3-chloro-4-methoxyphenyl)-5-methyl-4-[4-
(methylsulfonyl)phenyl]isoxazole;
35 3-(3-chloro-4-methoxyphenyl)-5-ethyl-4-[4-
(methylsulfonyl)phenyl]isoxazole;
3-(3-fluoro-4-methoxyphenyl)-5-ethyl-4-[4-
(methylsulfonyl)phenyl]isoxazole;

3-(3,4-dichlorophenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

3-(3,4-difluorophenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

5 3-(3,5-difluoro-4-methoxyphenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

3-(4-methoxyphenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

3-(4-chlorophenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

10 3-(4-fluorophenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

3-(4-methylphenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;

15 4-[5-ethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-propyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-isopropyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-butyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

20 4-[5-isobutyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-cyclohexyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-neopentyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

25 4-[5-cyclohexylmethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-(4-chlorophenyl)methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-trifluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

30 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-chloromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

35 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonic acid;

4-[5-propyl-3-phenylisoxazol-4-yl]benzenesulfonic acid;

4-[5-methoxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-(3-hydroxypropyl)-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-(4-chlorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
5 4-[3-(4-fluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-fluoro-4-methylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
10 4-[3-(3-aminosulfonyl-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-chloro-4-methylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[5-methyl-3-(3-pyridyl)isoxazol-4-yl]benzenesulfonamide;
15 4-[5-methyl-3-(4-pyridyl)isoxazol-4-yl]benzenesulfonamide;
4-[3-(3-fluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
20 [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]carboxylic acid;
4-[5-hydroxy-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
25 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-fluoro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
30 4-[3-(3,5-difluoro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-chloro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3,5-dichloro-4-methoxyphenyl)-5-methylisoxazol-4-
35 yl]benzenesulfonamide;
4-[3-(4-methylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;

4-[5-methyl-3-(4-trifluoromethoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[5-methyl-3-(4-trifluoromethylphenyl)isoxazol-4-yl]benzenesulfonamide;

5 4-[3-(4-cyanophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;

4-[3-(4-methylsulfinylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;

4-[3-(4-methylthiophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;

10 4-[3-(4-hydroxymethylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;

4-[5-ethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

15 4-[5-benzyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-methoxyisoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-phenoxyisoxazol-4-yl]benzenesulfonamide;

20 4-[5-benzylloxymethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-methoxymethylisoxazol-4-yl]benzenesulfonamide;

25 4-[3-(3-fluoro-4-methoxyphenyl)-5-methylthiomethylisoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-(3-thienyl)methylthioisoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-

30 methoxycarbonylmethylisoxazol-4-yl]benzenesulfonamide;

4-[5-(aminocarbonylmethyl)-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-(methylthio)isoxazol-4-yl]benzenesulfonamide;

35 4-[3-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethoxy)isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-(N-methylamino)isoxazol-4-yl]benzenesulfonamide;

[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetic acid;
[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]carboxamide;
5 methyl [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetate;
[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]propanoic acid;
ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
10 yl]propanoate; and
[4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]propanoic acid.

A second family of specific compounds of particular
15 interest within Formula I consists of compounds and
pharmaceutically-acceptable salts thereof as follows:

[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid;
20 [[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-methoxy]acetic acid;
4-[4-[4-(aminosulfonyl)phenyl]]-3-phenylisoxazol-5-
yl]butanoic acid;
4-[5-cyano-3-phenylisoxazol-4-yl]benzenesulfonamide;
25 4-[5-chloro-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-phenyl-5-(trifluoromethansulfonyloxy)isoxazol-4-
yl]benzenesulfonamide;
4-[3-(3,5-difluorophenyl)5-methylisoxazol-4-
yl]benzenesulfonamide;
30 4-[3-(4-bromophenyl)-5-methylisoxazol-4-
yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-
4-yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(4-methoxyphenyl)isoxazol-4-
35 yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(4-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;

5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole;
4-[3-(3-chlorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
5 4-[3-(3,4-difluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
methyl 4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-methoxybenzoate;
4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
10 methoxy]benzoic acid;
4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-isopropyl-5-phenylisoxazol-4-
15 yl]benzenesulfonamide;
4-[5-phenyl-3-propylisoxazol-4-yl]benzenesulfonamide;
15 4-[3-ethyl-5-(4-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-butyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-(4-methylphenyl)isoxazol-4-
20 yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-methylisoxazol-4-
yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-3-methylisoxazol-4-
25 yl]benzenesulfonamide;
3-methyl-5-(4-methylsulfonylphenyl)-4-phenylisoxazole;
25 4-[3-methyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-methyl-5-(3-chlorophenyl)isoxazol-4-
30 yl]benzenesulfonamide;
4-[3-hydroxymethyl-5-phenylisoxazol-4-
yl]benzenesulfonamide;
30 4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-acetic
acid;
3-methyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;
4-[3-[2-(4-chlorophenyl)-2-hydroxyethyl]-5-phenylisoxazol-
35 4-yl]benzenesulfonamide;
3-ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;
4-[3-ethyl-5-(4-fluorophenyl)isoxazol-4-
40 yl]benzenesulfonamide;

4-[3-ethyl-5-(3-fluorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-ethyl-5-(3-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;
5 4-[3-ethyl-5-(2-fluorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[5-methyl-4-phenylisoxazol-3-yl]benzenesulfonamide;
4-[5-ethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-phenyl-5-propylisoxazol-4-yl]benzenesulfonamide;
10 4-[5-isopropyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-butyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-isobutyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-cyclohexyl-3-phenylisoxazol-4-
15 yl]benzenesulfonamide;
4-[5-neopentyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-cyclohexylmethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
20 4-[5-(4-chlorophenyl)methyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-trifluoromethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-difluoromethyl-3-phenylisoxazol-4-
25 yl]benzenesulfonamide;
4-[5-chloromethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonic acid;
4-[5-propyl-3-phenylisoxazol-4-yl]benzenesulfonic acid;
30 4-[5-methoxymethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-(3-hydroxypropyl)-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[3-(4-chlorophenyl)-5-methylisoxazol-4-
35 yl]benzenesulfonamide;
4-[3-(4-fluorophenyl)-5-methylisoxazol-4-
yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-aminosulfonyl-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
5 4-[3-(3-chloro-4-methylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide;
4-[5-methyl-3-(3-pyridyl)isoxazol-4-yl]benzenesulfonamide;
4-[5-methyl-3-(4-pyridyl)isoxazol-4-yl]benzenesulfonamide;
4-[3-(3-fluorophenyl)-5-methylisoxazol-4-
10 yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
y1]carboxylic acid;
15 4-[5-hydroxy-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-(3-fluoro-4-methoxyphenyl)-5-methylisoxazol-4-
y1]benzenesulfonamide;
20 [3-(3-chloro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid;
5-methyl-4-[4-(methylsulfonyl)phenyl]-3-phenyl-
isoxazole;
3-(3-chloro-4-methoxyphenyl)-5-methyl-4-[4-
25 (methylsulfonyl)phenyl]isoxazole;
[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
y1]acetic acid;
[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
y1]propanoic acid;
30 ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
y1]propanoate;
[4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-
methoxyphenyl)isoxazol-5-yl]propanoic acid; and
[3-(3-fluoro-4-methoxyphenyl)-4-[4-
35 (methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid.

The term "hydrido" denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical

or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH₂-) radical. Where used, either alone or within other terms such as "haloalkyl", "alkylsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms.

Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl" embraces partially saturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having one to six carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,

dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The terms 5 "hydroxyalkyl" and "hydroxylalkyl" embrace linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred "hydroxyalkyl" radicals are "lower hydroxyalkyl" radicals having one 10 to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkoxyalkyl" 15 embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term "alkoxyalkyl" embraces alkyl 20 radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy 25 radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and 30 fluoropropoxy. The term "cycloalkylalkoxy" embraces radicals having cycloalkyl radicals, as defined above, attached to an alkoxy radical. More preferred "cycloalkylalkoxy" radicals are "lower cycloalkylalkoxy" radicals having cycloalkyl radicals 35 of three to six carbon atoms attached to an alkoxy radical of one to six carbon atoms. Examples of such radicals include cyclohexylmethoxy. The term "aryl", alone or in combination, means a carbocyclic aromatic

system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, 5 indane and biphenyl. The terms "heterocyclic" and "heterocyclo" embrace saturated, partially saturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated 10 heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms 15 and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially saturated heterocyclic radicals include 20 dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. The term "heteroaryl" embraces unsaturated heterocyclic radicals. Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals include unsaturated 3 to 6 25 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl 30 (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., 35 tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group

containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl 5 (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered 10 heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclic group containing 1 15 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term also embraces radicals where heterocyclic radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, 20 benzothiophene, and the like. Said "heterocyclic group" may have 1 to 3 substituents such as lower alkyl, hydroxy, oxo, amino and lower alkylamino. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon 25 atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term "alkylthioalkyl" embraces radicals 30 containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl radicals are "lower alkylthioalkyl" radicals having alkyl radicals of one to six carbon atoms. Examples of 35 such lower alkylthioalkyl radicals include methylthiomethyl. The term "cycloalkylalkylthio" embraces radicals having cycloalkyl radicals, as

defined above, attached to an alkylthio radical. More preferred cycloalkylthio radicals are "lower cycloalkylalkylthio" radicals having cycloalkyl radicals of three to six carbon atoms. The term

5 "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent $-S(=O)-$ radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon

10 atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals $-SO_2-$.

15 "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include

20 methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl"

25 denote H_2NO_2S- . The term "hydroxysulfonyl" denotes $HO(O_2)S-$. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-CO_2H$. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More

30 preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl, carboxypropyl and carboxybutyl. The term "carbonyl", whether used alone or with other terms,

35 such as "alkoxycarbonyl", denotes $-(C=O)-$. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. Examples of such

"alkoxycarbonyl" ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.

The term "alkoxycarbonylalkyl" means a radical

5 containing an alkoxycarbonyl radical, as defined above, attached to an alkyl radical. Examples of such "alkoxycarbonylalkyl" ester radicals include substituted or unsubstituted methoxycarbonylmethyl, butoxycarbonylmethyl and hexyloxycarbonylethyl. The

10 terms "alkylcarbonyl", "arylcarbonyl" and "aralkylcarbonyl" include radicals having alkyl, aryl and aralkyl radicals, as defined above, attached via an oxygen atom to a carbonyl radical. Examples of such radicals include substituted or unsubstituted

15 methylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl. The term "aralkyl" embraces aryl-substituted alkyl radicals. More preferred aralkyl radicals are "lower aralkyl" radicals having aryl substituted lower alkyl radicals, as defined above.

20 Examples include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable.

25 The term "heterocycloalkyl" embraces heterocyclo-substituted alkyl radicals, such as pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, furanylethyl, tetrahydrofuryl ethyl and heteroaralkyl radicals. The term "heteroaralkyl" embraces heteroaryl-substituted

30 alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The term "cycloalkylalkyl" embraces

35 radicals having cycloalkyl radicals, as defined above, attached to an alkyl radical. More preferred "cycloalkylalkyl" radicals are "lower cycloalkylalkyl" radicals having cycloalkyl radicals of three to six

carbon atoms attached to an alkyl radical of one to six carbon atoms. The term "cycloalkylalkyl" embraces cycloalkyl-substituted alkyl radicals such as cyclohexylmethyl, cyclopentylethyl, cyclopentylmethyl, 5 cyclohexylethyl, and cyclobutylpropyl. The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkoxyalkyl" embraces aralkoxy radicals attached through an oxygen atom to an alkyl radical. The term 10 "aralkylthio" embraces aralkyl radicals attached to a sulfur atom. The term "aralkylthioalkyl" embraces aralkylthio radicals attached through a sulfur atom to an alkyl radical. The term "heteroaralkoxy" embraces heteroaralkyl radicals attached through an oxygen atom 15 to other radicals. The term "heteroaralkylthio" embraces heteroaralkyl radicals attached through a sulfur atom to other radicals. The term "aminoalkyl" embraces alkyl radicals substituted with amino radicals. The term "alkylamino" denotes amino groups 20 which have been substituted with one or two alkyl radicals. Suitable "alkylamino" may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term "cycloalkylamino" denotes amino groups which have been 25 substituted with one or two cycloalkyl radicals, as defined above. The term "aryl amino" denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The "aryl amino" radicals may be further substituted on the aryl ring 30 portion of the radical. The term "aralkylamino" embraces aralkyl radicals attached through an nitrogen atom to other radicals. The term "heteroaralkylamino" embraces heteroaralkyl radicals, as defined above, attached through an nitrogen atom to other radicals. 35 The term "aminocarbonyl" denotes an amide group of the formula -C(=O)NH₂. The term "alkylcarbonylaminooalkyl" embraces radicals having one or more alkyl radicals attached to a carbonyl radical further attached to an

aminoalkyl radical. The term "alkylaminoalkyl" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical. The term "aryloxyalkyl" embraces radicals having an aryl 5 radicals attached to an alkyl radical through a divalent oxygen atom. The term "arylthioalkyl" embraces radicals having an aryl radicals attached to an alkyl radical through a divalent sulfur atom. The terms "N-alkyl-N-aralkylamino" "N-alkyl-N- 10 heteroaralkylamino", and "N-alkyl-N-cycloalkylalkylamino" embrace amino radicals substituted with one alkyl radical and with an aralkyl, heteroaralkyl or cycloalkylalkyl radical, respectively. The term "alkoxyalkyloxyalkyl" or "alkoxyalkoxyalkyl" 15 denotes radiclas having alkoxy radiclas attached to an alkoxyalkykl radical as defined above. The term "aryl(hydroxylalkyl)" denotes a radical having an aryl radical attached to a hydroxylalkyl radical. The aryl portion may be optionally further substituted with 20 alkyl, halo, alkoxy and the like. The term "haloalkylsulfonyloxy" denotes radicals having a haloalkyl substituted sulfonylk radical, which is attached to other radicals via a divalent oxygen atom. An example of a haloalkylsulfonyloxy radical is 25 "trifluorosulfonyloxy." The terms "arylcarbonyloxyalkyl," "alkylaminocarbonyloxyalkyl," and "alkoxycarbonyloxyalkyl," denote -C(O)-O-alkyl radicals substituted with aryl, alkylamino, and alkoxy radicals, respectively. The terms 30 "alkoxycarbonylthioalkyl," "arylcarbonylthioalkyl", and "alkylaminocarbonylthioalkyl," denote -C(O)-S-alkyl radicals substituted with alkoxy, aryl and alkylamino radicals, respectively. The term "carboxyalkoxyalkyl" denotes carboxy substiured alkoxyalkyl radicals, as 35 defined above. The term "carboxyaryloxyalkyl" denotes carboxy substiured aryloxyalkyl radicals, as defined above. The term "alkoxycarbonylaryloxyalkyl" denotes

alkoxycarbonyl substituted alkoxyalkyl radicals, as defined above.

Compounds of Formula I, where R³ is a nitrogen containing heteroaryl radical, would also be capable of 5 inhibiting cytokines, such as TNF, IL-1, IL-6, and IL-8. As such, the compounds can be used in the manufacture of a medicament or in a method for the treatment for the prophylactic or therapeutic treatment of diseases mediated by cytokines, such as TNF, IL-1, IL-6, and IL-8.

10 The present invention comprises a pharmaceutical composition comprising a therapeutically-effective amount of a compound of Formulas I-V in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

15 The present invention also comprises a method of treating inflammation or inflammation-associated disorders in a subject, the method comprising treating the subject having such inflammation or disorder with a therapeutically-effective amount of a compound of 20 Formulas I-V.

Also included in the family of compounds of Formulas I-V are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts 25 and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulas I-V may be prepared from an 30 inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, 35 heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic,


fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, *p*-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, 5 pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formulas I-IV include metallic 10 salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may 15 be prepared by conventional means from the corresponding compound of Formulas I-V by reacting, for example, the appropriate acid or base with the compound of Formulas I-V.

20

GENERAL SYNTHETIC PROCEDURES


The compounds of the invention can be synthesized according to the following procedures of Schemes I-XVII, wherein the R¹-R⁴ substituents are as defined for 25 Formulas I-V, above, except where further noted.

Scheme I



Scheme I illustrates the two step procedure used to prepare substituted desoxybenzoin derivatives 3. In step one, 4-methylthiophenylacetic acid 1 is converted to the corresponding acid chloride 2 with thionyl chloride. A variety of aromatic compounds are then acylated with 2 in the presence of a Lewis acid such as aluminum chloride to provide the desired desoxybenzoins 3 in high yield. This Friedel Crafts acylation can be performed in an inert solvent, such as dichloromethane, chloroform, nitrobenzene, 1,2-dichloroethane, 1,2-dichlorobenzene and similar solvents.

Scheme II



15


7

Synthetic Scheme II shows the four step procedure which can be used to prepare substituted ketone compounds 7 from aldehyde 4 and acid 5. In step one, aldehyde 4 and substituted acetic acid 5 are heated together in acetic anhydride and triethylamine to form the 2,3-disubstituted acrylic acids 6 via a Perkin condensation. In step two, the addition of water produces the acids 6 free from any mixed acetic-acrylic anhydrides. The acrylic acids 6 are reacted with diphenylphosphorylazide (DPPA) and triethylamine in

toluene at about 0 °C and then at room temperature to form acylazides. The crude acylazides are heated to form a vinyl isocyanate via a Curtius rearrangement. The vinyl isocyanates are trapped with tert-butyl 5 alcohol to produce N-tert-butoxycarbonyl enamine derivatives. Acidic hydrolysis using concentrated HCl provides the substituted ketone 7 intermediates.

Scheme III

10




Synthetic Scheme III illustrates an alternative approach which can be used to prepare substituted ketone 15 intermediates 7 via the Claisen reaction of a substituted phenylacetonitrile 8 and a acid ester 9. In the first step, a mixture of substituted phenylacetonitrile 8 and acid ester 9 are treated with a base such as sodium methoxide in a protic solvent like methanol to provide the cyanoketone 10. In step two, the cyanoketone 10 is hydrolyzed in aqueous acid such as concentrated HBr to effect hydrolysis of the nitrile and decarboxylation of the incipient carboxylic acid to produce the substituted ketone intermediates 7.

25 Other synthetic approaches are possible to form the desired ketones 7. These alternatives include reacting the appropriate Grignard or lithium reagents with Weinreb amides of substituted acids or acetic acids.

The Weinreb methodology has been reported in *Tetrahedron Letters*, 4171 (1977).

Scheme IV

5




Synthetic Scheme IV shows the procedure which can be used for the preparation of oxime intermediates 12.

10 Treatment of ketone intermediates 7 with hydroxylamine, generally prepared from hydroxylamine hydrochloride by sodium acetate, provides the oxime intermediates 12. A wide variety of solvents can be used for this reaction including ethanol, toluene and tetrahydrofuran.

15

Scheme V




20 Synthetic Scheme V shows the procedure which can be used for the preparation of hydrated isoxazole derivatives 13. The substituted oximes 12 are treated with two equivalents of a base such as n-butyllithium in hexanes to produce a dianion which is subsequently acylated.

Suitable acylating agents are anhydrides, acyl imidazoles, esters and the like. Upon quenching the reaction mixture with dilute aqueous acid, hydrated isoxazole derivatives 13 can be isolated by crystallization or chromatography.

5


Scheme VI



10 Synthetic Scheme VI shows the procedure which can be
used for the preparation of isoxazole analogs 14 by
dehydration of the hydrated isoxazole derivatives 13.
Substituted hydrated isoxazoles 13 are dissolved in an
appropriate solvent such as toluene and then treated with
15 a catalytic to stoichiometric amount of concentrated
sulfuric acid to effect dehydration and thereby produce
isoxazole derivatives 14. Other acids can also be
employed to effect this transformation such as
concentrated HCl, concentrated HBr and many others.


20

Scheme VII



Synthetic Scheme VII shows the procedure which can be used for the preparation of substituted 4-[4-(methylsulfonyl)phenyl]isoxazole analogs 16 from the corresponding 4-[4-(methylthio)phenyl]isoxazoles 15. The oxidation of an aromatic methythio derivative 15 to the corresponding aromatic methylsulfonyl compound 16 can be accomplished in a variety of ways such as with two equivalents of meta-chloroperoxybenzoic acid (MCPBA), two equivalents of Oxone® (potassium peroxyomonosulfate) and many other oxidizing agents.


Scheme VIII



15 17

Synthetic Scheme VIII shows the procedure which can be used for the preparation of substituted 4-(4-aminosulfonyl)phenylisoxazole analogs 17 from the corresponding 4-phenylisoxazoles 14. The procedure is a two step process for the direct introduction of the sulfonamide moiety into 4-phenylisoxazoles 14 or hydrated isoxazoles 13. In step one, isoxazole 14 or hydrated isoxazole 13 is treated at about 0 °C with two or three equivalents of chlorosulfonic acid to form the corresponding sulfonyl chloride. In step two, the sulfonyl chloride thus formed is treated with concentrated ammonia to provide the sulfonamide derivative 17.


Scheme IX



5

Synthetic Scheme IX shows the three step procedure used to prepare sulfonamide antiinflammatory agents 17 from their corresponding methyl sulfones 16. In step one, a tetrahydrofuran solution (THF) of the methyl sulfones 16 are treated with an alkylolithium or alkylmagnesium (Grignard) reagent at -78 °C, such as n-propyl magnesium bromide. In step two, the anion generated in step one is treated with an organoborane, such as tri-n-butylborane at -78 °C then warmed to room temperature and then heated to reflux. In step three, an aqueous solution of hydroxylamine-o-sulfonic acid is added to provide the corresponding sulfonamide antiinflammatory agents 17. This procedure is essentially that of Huang et. al., *Tetrahedron Letters*, 35, 7204 (1994).


Scheme X



5 Synthetic Scheme X shows the three step procedure used to prepare sulfonamide antiinflammatory agents 17 from their corresponding methylsulfinyl analogs 18. Methylsulfinyl derivatives 18 are available from the corresponding methylthio compounds 15 by oxidation with 10 one equivalent of an oxidizing agent such as MCPBA. In step one, the methylsulfinyl compounds 18 are treated with trifluoroacetic anhydride to effect Pummerer rearrangement. In step two, the crude Pummerer rearrangement product dissolved in acetic acid is treated 15 with chlorine gas to produce a sulfonyl chloride. In step three, the sulfonyl chloride is converted to the corresponding sulfonamide antiinflammatory agents 17 by treatment with concentrated ammonia. This procedure was adapted from Kharash, J. Am. Chem. Soc., 73, 3240 (1951).

20


Scheme XI



5 Synthetic Scheme XI shows the two step procedure used to
 prepare sulfonamide antiinflammatory agents 17 from their
 corresponding 4-phenyl isoxazole derivatives 14. In step one
 a mixture of sulfonyl chloride and dimethylformamide (DMF)
 are allowed to react at room temperature and then mixed with
 10 4-phenylisoxazoles 14 and heated to about 100 °C. The
 sulfonyl chloride thus formed is then treated with an excess
 of concentrated ammonia to provide the antiinflammatory
 sulfonamides 17.

15

Scheme XII




20 Synthetic Scheme XII shows the three step procedure
 used to prepare sulfonamide antiinflammatory agents 20

from 4-phenyl isoxazoles 19. In step one, the 4-phenylisoxazoles 19 are converted into the corresponding sulfonic acid by treatment with sulfur trioxide pyridine complex at about 100 °C. In step two, the sulfonic acid 5 is converted into the sulfonyl chloride by the action of phosphorus oxychloride and in step three the sulfonyl chloride is treated with excess concentrated ammonia to provide the antiinflammatory sulfonamides 20.

10


Scheme XIII



Synthetic Scheme XIII shows the three step procedure 15 used to prepare 4,5-diphenylisoxazole antiinflammatory agents 24 from 1,2-diphenylbutenones 21. In step one, the 1,2-diphenylketones 21 are converted to the corresponding oximes 22 by treatment with hydroxylamine in a manner similar to that shown in Scheme IV. In step two, the oxime 22 is converted to the 4,5-diphenylisoxazole 23 in two steps. The oxime 22 is reacted with potassium iodide and iodine in the presence 20

of base, such as sodium bicarbonate and heated to form the halo intermediate. Sodium bisulfite is added to form the isoxazole 23. The isoxazole 23 is converted to the sulfonamide by any of the procedures shown in Schemes 5 VIII, XI or XII.

Scheme XIV




10

Scheme XIV illustrates the five step procedure for the preparation substituted isoxazole derivatives. In step one substituted desoxybenzoin 25 is converted to the corresponding sulfonamide derivative 26 by 15 first treatment with chlorosulfonic acid followed by conversion of the incipient sulfonyl chloride to the sulfonamide by treatment with aqueous ammonia. In the second step the sulfonamide of 26 is protected as the 2,5-dimethylpyrrole derivative by treatment with 20 acetonylacetone in the presence of hydrochloric acid and ethanol. The 2,5-dimethylpyrrole thus formed is converted into oxime 27 by treatment with hydroxylamine hydrochloride in the presence of sodium

acetate in aqueous ethanol. The oxime 27 is treated with slightly more than two equivalents of lithium diisopropylamide (LDA) and then the resulting dianion is quenched by a suitable acylating agent such as an 5 anhydride, acid chloride, ester, acyl imidazole and the like to afford a hydrated isoxazole. In the last step, the hydrated isoxazole is dehydrated by an acid and the sulfonamide unmasked by treatment with warm aqueous trifluoroacetic acid (TFA) to form the final 10 sulfonamide derivative 20.


Scheme XV



15

Synthetic Scheme XV shows the three step one pot procedure for the preparation of substituted isoxazole derivatives 20. In the first step the desoxybenzoin sulfonamide derivative 26 is protected as the cyclic 20 disilylamine derivative by treatment with 1,2-bis-(chlorodimethylsilyl)ethane in the presence of triethylamine. In step two the cyclic disilylamine protected sulfonamide is treated with excess lithium diisopropylamide followed by quenching of the resulting 25 dianion with an ester to afford the corresponding hydrated isoxazole derivative. In the third step the reaction mixture is treated with aqueous trifluoroacetic acid that effects dehydration of the 30 hydrated isoxazole and unmasks the sulfonamide moiety to afford the desired isoxazole derivative 20.

Scheme XVI




5 Synthetic Scheme XVI illustrates the three step procedure for the preparation of aromatic sulfonamides from aromatic bromides. In step one, the aromatic bromide is transmetallated to the corresponding lithium derivative that is immediately treated with gaseous
10 sulfur dioxide to form an aromatic sulfinic acid. The sulfinic acid is converted directly to the sulfonamide by treatment with aqueous hydroxylamine-O-sulfonic acid and sodium acetate.

15 Similarly, starting with compounds having a (4-bromophenyl) substituent at isoxazole position three, one can prepare isoxazoles having a benzenesulfonamide at position three via this method.

Scheme XVII

20




25 Synthetic Scheme XVII shows the four step one-pot procedure for the preparation of selected desoxybenzoin derivatives 30. In the first step a substituted benzaldehyde 29 is converted to the

corresponding trimethylsilyl cyanohydrin by condensation with trimethylsilyl cyanide and a catalytic amount to zinc iodide. In step two the trimethylsilyl cyanohydrin is treated with lithium 5 disopropylamide to form the acyl anion equivalent that is alkylated by a substituted benzyl bromide to afford the trimethylsilyl cyanohydrin of desoxybenzoin 30. In steps three and four the trimethylsilyl cyanohydrin is first hydrolyzed with aqueous 10 trifluoroacetic acid and hydrochloric acid to produce the corresponding cyanohydrin that is converted to 30 upon treatment with sodium hydroxide.

The following examples contain detailed 15 descriptions of the methods of preparation of compounds of Formulas I-V. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are 20 presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned 25 structures.

25

Example 1



30

4-[5-Methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of desoxybenzoin keto-oxime.

Hydroxylamine hydrochloride (9.21 g, 0.132 mol) and potassium hydroxide (7.43 g, 0.132 mol) were suspended in absolute ethanol (50 mL) and stirred at room temperature for thirty minutes. A solution of desoxybenzoin (20.0 g, 0.102 mol) in toluene (200 mL) was added in one portion, and the yellow suspension was held at reflux under a nitrogen blanket for 16 hours. The suspension was cooled to room temperature and poured into water (200 mL). The system was extracted with ethyl acetate (2x150 mL), and the combined organic solution was washed with brine (200 mL), dried over magnesium sulfate, and filtered. The solvents were evaporated under reduced pressure to yield a crude solid. The solid was recrystallized from hot ethanol/water, filtered and washed with water to yield, upon drying, desoxybenzoin keto-oxime as white crystals (17.7 g, 82%): mp 87-90 °C. Mass spectrum, $\text{MH}^+ = 212$. High resolution mass spectrum Calc'd. for $\text{C}_{14}\text{H}_{13}\text{NO}$: 211.0997. Found: 211.0949.

Step 2. Preparation of 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide.

A solution of desoxybenzoin keto-oxime from Step 1 (6.00 g; 28.40 mmol) in anhydrous tetrahydrofuran (THF, 80 mL) was cooled to -20 °C. To this cold solution, n-butyllithium (1.6 N in hexanes, 44.4 mL) was added, via syringe, over 35 minutes, such that the reaction temperature remained at or below -10 °C. The deep red solution was stirred at -10 °C for 1 hour, warmed to room temperature, then stirred at room temperature for an additional hour. Acetic anhydride (3.2 mL, 34.1 mmol) was added in one portion, and the resulting suspension was stirred without temperature control for 2 hours. Water (100 mL) was added, the solution was poured into 1 N HCl (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic solution

was washed with hydrochloric acid (1 N HCl, 100 mL) and brine (100 mL), dried over magnesium sulfate and filtered. The resulting solution was evaporated under reduced pressure to yield a crude oil. The oil was 5 applied to a column of silica gel and eluted with ethyl acetate/hexane (10-50% ethyl acetate) to yield, upon concentration of the appropriate fractions, 5.0 g of 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole. The solid was cooled to 0 °C, then dissolved in cold 10 chlorosulfonic acid (15 mL). The brown solution was stirred at 0 °C for 2 hours, then added dropwise to a stirred suspension of ice (200 mL) and dichloromethane (200 mL). The layers were separated, and the organic phase was added directly to a saturated ammonium 15 hydroxide solution (100 mL) at 0 °C. This biphasic solution was vigorously stirred at 0 °C for 2 hours, the layers were separated, and the aqueous phase was washed with dichloromethane (50 mL). The combined organic solution was dried over magnesium sulfate, 20 filtered and evaporated under reduced pressure to approximately one-half of its original volume. Crystals formed. The stirred suspension was cooled to 0 °C and held for 30 minutes. The crystals were filtered, washed with cold dichloromethane and dried to 25 yield 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide (2.7 g, 30%): mp 172-173 °C. ^1H NMR (CD₃CN/500 MHz) δ 7.86 (d, J=8.39 Hz, 2H), 7.45 (m, 1H), 7.39 (s, 4H), 7.37 (d, J=8.39 Hz, 2H), 5.70 (s, 2H), 2.46 (s, 3H). Mass Spectrum, MH^+ = 315.

30

Proceeding in a like manner but replacing the anhydrides with other appropriately substituted anhydrides and esters, the following compounds were prepared:

35

1a) 4-[5-ethyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 140-141 °C. ^1H NMR (CDCl₃) δ

7.93 (d, $J = 8.66$, 2 H), 7.28-7.42 (m, 7 H), 4.81 (s, 2H), 2.83 (q, $J = 7.65$ Hz, 2 H), 1.34 (t, $J = 7.45$, 3 H). Mass spectrum M^+H 329. Anal. Calc'd. for $C_{17}H_{16}N_2O_3S$: C, 62.18; H, 4.91; N, 8.53; S, 9.76.

5 Found: C, 62.07; H, 4.88; N, 8.42; S, 9.61.

1b) 4-[5-propyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 147-148 °C. 1H NMR ($CDCl_3$) δ 7.92 (d, $J = 8.46$, 2 H), 7.28-7.44 (m, 7 H), 4.83 (s, 2 H), 2.77 (t, $J = 7.25$, 2 H), 1.71-1.85 (m, 2H), 0.98 (t, $J = 7.45$, 3 H). Anal. Calc'd. for $C_{18}H_{18}N_2O_3S_1$: C, 63.14; H, 5.30; N, 8.18; S, 9.36. Found: C, 63.19; H, 5.32; N, 8.23; S, 9.44. Mass spectrum M^+H 343.

15 1c) 4-[5-isopropyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 166-168 °C. 1H NMR ($CDCl_3$) δ 7.93 (d, $J = 8.46$ Hz, 2 H), 7.27-7.40 (m, 7H), 4.80 (s, 2 H), 3.08-3.20 (m, 1 H), 1.36 (d, $J = 6.58$ Hz, 6 H). Mass spectrum M^+H 343.

20 1d) 4-[5-butyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 129-131 °C. 1H NMR ($CDCl_3$) δ 7.93 (d, $J = 8.46$ Hz, 2H), 7.30-7.40 (m, 7H), 4.81 (s, 2H), 2.79 (t, $J = 7.45$, 2H), 1.67-1.79 (m, 2H), 1.30-25 1.42 (m, 2H), 0.91 (t, $J = 7.25$, 3 H). Anal. Calc'd. for $C_{19}H_{20}N_2O_3S_1$: C, 64.02; H, 5.66; N, 7.86; S, 8.99. Found: C, 63.22; H, 5.52; N, 7.51; S, 8.67.

30 1e) 4-[5-isobutyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 159-160 °C. 1H NMR ($CDCl_3$) δ 7.93 (d, $J = 8.46$, 2 H), 7.28-7.42 (m, 7H), 4.84 (s, 2H), 2.66 (d, $J = 7.25$ Hz, 2H), 2.08-2.22 (m, 1 H), 0.94 (d, $J = 6.65$ Hz, 6 H). High resolution mass spectrum Calc'd. for $C_{19}H_{20}N_2O_3S$: 221.0841. Found: 35 221.0827. Anal. Calc'd. for $C_{19}H_{20}N_2O_3S_1$: C, 64.02; H, 5.66; N, 7.86; S, 8.99. Found: C, 63.94; H, 5.65; N, 7.86; S, 8.90.

1f) 4-[5-cyclohexyl-3-phenyloxazol-4-yl]benzenesulfonamide: mp 191-193 °C. ^1H NMR (CDCl_3) δ 7.94 (d, $J = 8.46$ Hz, 2 H), 7.27-7.41 (m, 7H), 4.85 (s, 2H), 2.62-2.85 (m, 1H), 1.67-1.95 (m, 7 H), 1.22-1.38 (m, 3 H). Mass spectrum M^+H 383. High resolution mass spectrum Calc'd. for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_3\text{S}$: 383.1429. Found: 383.1452.

10 1g) 4-[5-neopentyl-3-phenyloxazol-4-yl]benzenesulfonamide: ^1H NMR (CDCl_3) δ 7.94 (d, $J = 8.46$, 2 H), 7.26-7.39 (m, 7 H), 4.82 (s, 2 H), 2.71 (s, 2 H), 0.94 (s, 9H). Mass spectrum M^+H 371.

15 1h) 4-[5-cyclohexylmethyl-3-phenyloxazol-4-yl]benzenesulfonamide: mp 151-153 °C. ^1H NMR (CDCl_3) δ 7.93 (d, $J = 8.46$, 2 H), 7.29-7.43 (m, 7H), 4.82 (s, 2H), 2.67 (d, $J = 7.05$ Hz, 2 H), 1.60-1.92 (m, 5 H), 0.85-1.30 (m, 6 H). Mass spectrum M^+H 397.

20 1i) 4-[5-(4-chlorophenyl)methyl-3-phenyloxazol-4-yl]benzenesulfonamide: mp 107-108 °C. ^1H NMR (CDCl_3 and CD_3OD) δ 7.91 (d, $J = 8.46$, 2 H), 7.26-7.42 (m, 9H), 7.14 (d, $J = 8.46$ Hz, 2 H), 4.85 (s, 2 H), 4.10 (s, 2 H). Mass spectrum $\text{M}^+\text{H} = 425$. High resolution mass spectrum Calc'd. for $\text{C}_{22}\text{H}_{17}\text{ClN}_2\text{O}_3\text{S}$: 425.0727. Found: 425.0736.

30 1j) 4-[5-difluoromethyl-3-phenyloxazol-4-yl]benzenesulfonamide: mp 172-175 °C. ^1H NMR (CDCl_3) δ 7.97 (d, $J = 8.46$, 2 H), 7.30-7.50 (m, 7H), 6.72 (t, $J = 52.57$ Hz, 1 H), 4.87 (s, 2H). ^{19}F NMR (CHCl_3) -116.45 (d, $J = 53.02$ Hz). Mass spectrum M^+H 351.

35 1k) 4-[5-chloromethyl-3-phenyloxazol-4-yl]benzenesulfonamide: mp 131-133 °C. ^1H NMR (CDCl_3) δ 7.98 (d, $J = 8.46$, 2 H), 7.34-7.46 (m, 7H), 4.84 (s,

2H), 4.61 (s, 2 H). Mass spectrum M^+H 349. High resolution mass spectrum for $C_{16}H_{13}ClN_2O_3S$: 348.0335. Found: 348.0316.


5 11) 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonic acid: mp 260-269 °C. 1H NMR (CD_3OD) δ 9.03 (s, >1 H exch), 8.42 (d, J = 8.06 Hz, 2H), 8.12-8.28 (m, 5 H), 7.97 (d, J = 8.26 Hz, 2 H). Mass spectrum M^+H 316.

10 1m) 4-[5-propyl-3-phenylisoxazol-4-yl]benzenesulfonic acid: 1H NMR ($CDCl_3$ and CD_3OD) δ 7.95-7.78 (m, 2 H), 7.10-7.40 (m, 7H), 2.65-2.78 (m, 2 H), 1.65-1.80 (m, 2H), 0.88-0.99 (m, 3H). Mass spectrum M^+H 344.

15 1n) 4-[5-methoxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 82-118 °C. 1H NMR ($CDCl_3$) δ 7.93 (d, J = 8.66 Hz, 2 H), 7.31-7.45 (m, 7 H), 4.81 (s, 2 H), 4.51 (s, 2 H), 3.48 (s, 3 H). Mass spectrum M^+H 345. High resolution mass spectrum Calc'd. for $C_{17}H_{16}N_2O_4S$: 344.0831. Found: 344.0807.

20 1o) 4-[5-(3-hydroxypropyl)-3-phenylisoxazol-4-yl]benzenesulfonamide: mp 88-142 °C. 1H NMR ($CDCl_3$ and CD_3OD) δ 7.90 (d, J = 8.66 Hz, 2 H), 7.26-7.42 (m, 7H), 3.66 (t, J = 6.04 Hz, 2 H), 2.91 (t, J = 7.45 Hz, 2 H), 1.93-2.02 (m, 2H). Mass spectrum M^+H 349. High resolution mass spectrum Calc'd. for $C_{18}H_{18}N_2O_4S$: 358.0987. Found: 358.0958.

EXAMPLE 2



5 [4-[4-(Aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]propanoic acid

Step 1: Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one.

A suspension of aluminum chloride (9.4 g, 70.5 mmol) in a solution of 2-fluoroanisole (6.6 mL, 58.8 mmol) and anhydrous chloroform (200 mL) was cooled to 0 °C under a blanket of dry nitrogen. A solution of phenylacetyl chloride (8.6 mL, 64.7 mmol) in anhydrous chloroform (50 mL) was added to the vigorously stirred suspension over 20 minutes keeping the reaction temperature <5 °C. The yellowish solution was stirred at 0 °C for 1 hour, then poured into ice (200 mL) and stirred without temperature control for 16 hours. The layers were separated, and the aqueous layer was extracted with dichloromethane (2x100 mL). The combined organic solution was dried over magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure. The resulting solid was recrystallized from boiling hexane to yield, upon filtration and drying, 12.9 g (90%) of 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one as white crystals: ^1H NMR ($\text{CDCl}_3/300$ MHz) δ 7.82-7.72 (m, 2H), 7.35-7.24 (m, 5H), 6.98 (dd, $J=8.46, 8.26$ Hz, 1H), 4.22 (s, 2H), 3.94 (s, 3H). ^{19}F NMR ($\text{CDCl}_3/282.2$ MHz) -134.875 (m).

Step 2: Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one oxime.

Hydroxylamine hydrochloride (3.7 g, 53.2 mmol) and 5 potassium hydroxide (2.98 g, 53.2 mmol) were suspended in absolute ethanol (25 mL) and stirred for 30 minutes. To this, a suspension of 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one from Step 1 (10.0 g, 40.9 mmol) in toluene (150 mL) was added in one portion. The yellow 10 suspension was warmed to reflux for 16 hours, then the suspension was cooled to room temperature. Water (100 mL) was added, and the resulting solution was extracted with ethyl acetate (2 X 100 mL). The combined organic solution was washed with brine (100 mL), dried over 15 magnesium sulfate and filtered. The resulting solution was evaporated under reduced pressure to yield a crude residue. The residue was crystallized from boiling ethanol/water to yield, upon filtration and drying 1-(3-fluoro-4-methoxyphenyl)-2 phenyl-ethan-1-one oxime 20 as ivory-colored crystals (10.0 g 94%): ^1H NMR ($\text{CDCl}_3/300$ MHz) δ 7.42 (dd, $J=12.69, 2.01, 1\text{H}$), 7.36- 7.19 (m, 6H), 6.89 (dd, $J=8.66, 8.46$ Hz, 1H), 4.16 (s, 2H), 3.88 (s, 3H). ^{19}F NMR ($\text{CDCl}_3/282.2$ MHz): 135.517 (m).

25

Step 3: [3-(3-fluoro-4-methoxyphenyl)-4-phenyl-isoxazol-5-yl]propanoic acid:

1-(3-Fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one 30 oxime from Step 2 (2.00 g, 7.71 mmol) and anhydrous THF (80 mL) under a nitrogen blanket was cooled to -20 °C, and n-butyllithium (1.6 N, 12.0 mL) was added, via syringe, over 20 minutes, keeping the reaction temperature <-10 °C. The deep red suspension was stirred at -20 °C for 1 hour, warmed to room 35 temperature, and stirred at room temperature for 1 hour. Succinic anhydride (926 mg, 9.26 mmol) was added in one portion, and the yellow reaction was stirred for


16 hours without temperature control. Sulfuric acid (conc., 2.1 mL) was added, and the reaction was warmed to reflux. After 2 hours, the brown mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ether (2 X 100 mL). The ethereal solution was extracted with dilute sodium hydroxide (2 X 100 mL), and the combined basic extracts were acidified to pH < 2 with hydrochloric acid (conc.). The acidic aqueous phase was extracted with ether (2 X 100 mL). This ethereal solution was evaporated under reduced pressure to a residue. The residue was applied to a column of silica gel (200 cc) and eluted (10% methanol in dichloromethane) to yield, upon concentration of the appropriate fractions, a crude solid. The solid was recrystallized from hot ethanol and 0.1 N HCl to yield, upon filtration and drying, [3-(3-fluoro-4-methoxyphenyl)-4-phenylisoxazol-5-yl]propanoic acid as ivory colored crystals (367 mg, 14%): mp 129-131 °C (dec). Mass Spectrum: MH⁺ = 342. ¹H NMR (CDCl₃/300 MHz) δ 7.39 (m, 3H), 7.22-7.12 (m, 4H), 6.87 (t, J=8.46 Hz, 1H), 3.88 (s, 3H), 3.09 (t, J=8.05 Hz, 2H), 2.80 (t, J=8.05 Hz, 2H). ¹⁹F NMR (CDCl₃/282.2 MHz): -135.466 (m).

25 Step 4: Preparation of [4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]propanoic acid:

[3-(3-Fluoro-4-methoxyphenyl)-4 phenylisoxazol-5-yl]propanoic acid from Step 3 (250 mg, 0.73 mmol) and sulfuric acid (1 mL) were dissolved in absolute ethanol (10 mL). The colorless solution was warmed to reflux and held for 16 hours. The solution was cooled to room temperature and diluted with water (20 mL). The aqueous solution was extracted with ether (2 X 50 mL), and the combined ethereal solution was washed with diluted sodium hydr(30 mL). The organic solution was dried over magnesium sulfate, filtered and evaporated

under reduced pressure to yield an oil. The oil was cooled to 0 °C, and chlorosulfonic acid (0 °C, 12 mL) was added. The reaction was kept at 0 °C under a nitrogen blanket for 2 hours, and carefully poured into 5 ice. The ice was extracted with dichloromethane (2 X 20 mL) and the organic extract was added directly to a stirred, 0 °C saturated NH₄OH solution (40 mL). The biphasic reaction was stirred at 0 °C for 3 hours. The layers were separated, and the aqueous layer was 10 extracted with dichloromethane (30 mL). The combined organic solution was dried over magnesium sulfate, filtered and evaporated under reduced pressure to yield a crude foam. The foam was dissolved in dioxane (30 mL), aqueous sodium hydroxide (10%, 0.9 mL) was added 15 and the solution was heated to reflux for 1 hour. The solution was cooled to room temperature and diluted with water (20 mL). The aqueous solution was extracted with ether (2 X 30 mL) and the combined ethereal solution was extracted with dilute sodium hydroxide 20 (5%, 2 X 30 mL). The aqueous phases were combined and acidified with hydrochloric acid (conc.) to pH < 2. The acidic aqueous phase was extracted with ether (2 X 30 mL). The final ether solution was dried over magnesium sulfate, filtered and evaporated under 25 reduced pressure to yield a crude solid. The solid was recrystallized from ethanol/0.1 N HCl to yield, upon filtration and drying, [4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]propanoic acid as cream-colored crystals (182 mg, 59%): mp = 159-161 30 °C (dec). ¹H NMR (CDCl₃/300 MHz) δ 7.91 (d, J=8.66 Hz, 2H), 7.34 (d, J=8.66 Hz, 2H), 7.14 (dd, J=11.88, 2.01 Hz), 7.02 (d, J=8.46 Hz), 6.87 (t, J=8.46 Hz, 1H), 3.86 (s, 3H), 3.05 (t, J=7.45 Hz, 2H), 2.74 (t, J=7.45 Hz, 2H). ¹⁹F NMR (CDCl₃/282.2 MHz): -135.020 (m).

EXAMPLE 3



5 [4-[4-(Aminosulfonyl)phenyl]-3-phenylisoxazol-
5-yl]propanoic acid

Step 1. Preparation of [3,4-diphenylisoxazol-5-
yl]propanoic acid.

[3,4-Diphenylisoxazol-5-yl]propanoic acid was prepared in 45% yield from desoxybenzoin oxime (Example 1, Step 1) and succinic anhydride according to the procedure outlined in Example 2, Step 3: mp 123-125 °C (dec). Anal. Calc'd for C₁₈H₁₅NO₃: C, 73.71; H, 5.15; N, 4.78. Found: C, 73.78; H, 5.18; N, 4.72.

15

Step 2. Preparation of ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
yl]propanoate:


A solution of [3,4-diphenylisoxazol-5-yl]propanoic acid was treated with ethanol in the presence of a catalytic amount of sulfuric acid to prepare the corresponding ethyl ester which was immediately treated with chlorosulfonic acid followed by ammonia according to the procedure from Example 2, Step 4. The crude sulfonamide was purified by flash chromatography eluting with ethyl acetate/hexane (10-50% ethyl acetate) to yield, upon concentration of the appropriate fractions, ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]propanoate as a glassy solid (248 mg, 60%): Mass spectrum: M⁺ =

401. ^1H NMR ($\text{CDCl}_3/300$ MHz) δ 7.93 (d, $J=8.46$ Hz, 2H);
7.41-7.30 (m, 7H), 4.84 (s, 2H), 4.14 (q, $J=7.04$ Hz,
2H), 3.12 (t, $J=7.45$ Hz, 2H), 2.81 (t, $J=7.45$ Hz, 2H),
1.25 (t, $J=7.04$ Hz, 3H). This material was used
5 directly in the next step without further purification.

Step 3. Preparation of [4-[4-(aminosulfonyl)phenyl]-
3-phenylisoxazol-5-yl]propanoic acid.

Ethyl [4-[4-(aminosulfonyl)phenyl]-3-
10 phenylisoxazol-5-yl]propanoate from Step 2 (198 mg,
0.495 mmol) and aqueous sodium hydroxide (10%, 0.30 mL)
were dissolved in dioxane (15 mL). The solution was
heated to reflux and held for 16 hours. Upon cooling
15 to room temperature, water (20 mL) was added, and the
solution was extracted with ether (2 X 30 mL). The
combined ethereal solution was extracted with dilute
sodium hydroxide (5%, 2 X 30 mL). All of the aqueous
phases were combined and acidified with hydrochloric
acid (conc.) to pH < 2. The acidic aqueous phase was
20 extracted with ether (2 X 30 mL). The final ether
solution was dried over magnesium sulfate, filtered and
evaporated under reduced pressure to yield a crude
solid. Trituration with dichloromethane yielded
crystals. The suspension was cooled to 0 °C, filtered,
25 washed with hexane and dried to yield [4-[4-
(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]propanoic
acid as a white crystalline solid (135 mg, 73%):
mp 207 °C. Mass spectrum: $\text{MH}^+ = 373$. Anal. Calc'd.
for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_5\text{S}$: C, 58.06; H, 4.33; N, 7.52; S, 8.61.
30 Found: C, 57.87; H, 4.35; N, 7.49; S, 8.54.

EXAMPLE 4



5 4-[3-(3-Fluoro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide

Step 1: Preparation of 3-[3-fluoro-4-methoxyphenyl]-5-methyl-4-phenylisoxazole.

10 1-(3-Fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one oxime (from Example 2, Step 2) (2.50 g, 9.64 mmol) and anhydrous THF (100 mL) under a nitrogen blanket, was cooled to -20 °C, and n-butyllithium (1.6 N, 15.0 mL) was added, via syringe, over 20 minutes, keeping the reaction temperature < -10 °C. The deep red suspension

15 was stirred at -20 °C for 1 hour, warmed to room temperature, and stirred at room temperature for 1 hour. Acetic anhydride (1.1 mL, 11.6 mmol) was added in one portion, and the yellow reaction was stirred for 2 hours without temperature control. The reaction was

20 poured into aqueous hydrochloric acid (1 N, 100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic solution was washed once each with aqueous hydrochloric acid (1 N, 100 mL) and brine (100 mL), dried over magnesium sulfate, filtered and

25 evaporated under reduced pressure to yield a crude oil. The oil was applied to a column of silica gel (250 mL) and eluted with ethyl acetate/hexane (10-40% ethyl acetate) to yield, upon concentration of the appropriate fractions 3-(3-fluoro-4-methoxyphenyl)-4-

hydrido-5-hydroxy-4-phenyl-5-methylisoxazole (986 mg). This intermediate was dissolved in tetrahydrofuran (40 mL). Sulfuric acid (conc., 0.9 mL) was added, and the reaction was warmed to reflux. After one hour, the 5 solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (2 x 50 mL). The combined organic solution was washed with aqueous hydrochloric acid (1 N, 50 mL), saturated aqueous sodium bicarbonate (2 x 50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and evaporated under reduced pressure to yield a crude, dark oil. Washing the oil with 50% dichloromethane in hexane dissolved the compound but did not dissolve the dark impurities. The resulting solution was evaporated 10 under reduced pressure to yield 797 mg (29%) of 3-(3-fluoro-4-methoxyphenyl)-5-methyl-4-phenylisoxazole as a foam. Mass Spectrum: MH^+ = 284. Anal. Calc'd. for $C_{17}H_{14}NO_2F$: C, 72.07; H, 4.98; N, 4.94. Found: C, 72.13; H, 4.98; N, 4.92.

20

Step 2: Preparation of [3-(3-fluoro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide:

Chlorosulfonic acid (8 mL) was cooled to 0 °C. 3-(3-Fluoro-4-methoxyphenyl)-5-methyl-4-phenylisoxazole 25 from Step 1 (375 mg, 1.32 mmol) was added in one portion. The brown solution was stirred at 0 °C under a nitrogen blanket for 2 hours, then added dropwise to ice (50 mL). The ice was extracted with dichloromethane (2 x 30 mL), and the organic extracts 30 were added directly to a 0 °C saturated aqueous NH_4OH solution. The biphasic reaction was vigorously stirred at 0 °C for 2 hours, then the layers were separated. The aqueous solution was extracted with dichloromethane, the combined organic solutions were 35 dried over magnesium sulfate, filtered and evaporated under reduced pressure to yield a crude solid. The solid was recrystallized from ethanol and water to

yield, upon filtration and drying, 4-[3-(3-fluoro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide as ivory colored crystals (275 mg, 55%): mp 175 °C (dec). Mass Spectrum: $\text{MH}^+ = 363$. Anal. Calc'd. for 5 $\text{C}_{17}\text{H}_{15}\text{N}_2\text{O}_4\text{FS}$: C, 56.47; H, 4.17; N, 7.73; S, 8.85. Found: C, 56.47; H, 4.19; N, 7.66; S, 8.81.

Proceeding in a like manner but replacing desoxybenzoin with other appropriately substituted 10 ketones, the following compounds were prepared:

4a) 4-[3-(4-chlorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide: mp 162-164 °C. $^1\text{H NMR}$ (CDCl_3) 7.97 (d, 2H, $J = 8.46$ Hz), 7.33-7.26 (m, 7H), 2.48 (s, 3H). Elemental analysis Calc'd. for $\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}_3\text{SCl}$: C, 55.1; H, 3.76; N, 8.03. Found: C, 55.12; H, 3.78; N, 8.03.

4b) 4-[3-(4-fluorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide: mp 152-156 °C. $^1\text{H NMR}$ (CDCl_3) 2.48 (s, 3H), 4.84 (bs, 2H), 7.04 (t, 1H, $J = 8.6$ Hz), 7.33 -7.40 (m, 4H), 7.94 (d, 2H, $J = 8.4$). High resolution mass spectrum Calc'd for $\text{C}_{16}\text{H}_{13}\text{FN}_2\text{O}_3\text{S}$: 333.0709. Found: 333.0704.

4c) 4-[3-(3-fluoro-4-methylphenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide: mp 146-150 °C. $^1\text{H NMR}$ (CDCl_3) 2.24 (s, 3H), (2.48 (s, 3H), 4.97 (bs, 2H), 6.93 (t, 1H, $J = 9.1$ Hz), 7.04 (m, 1H), 7.26 -7.37 (m, 3H), 7.94 (d, 2H, $J = 8.3$). High resolution mass spectrum Calc'd for $\text{C}_{17}\text{H}_{15}\text{FN}_2\text{O}_3\text{S}$: 347.0866. Found: 347.0865. Anal. Calc'd. for $\text{C}_{17}\text{H}_{15}\text{FN}_2\text{O}_3\text{S}$: C, 58.95; H, 4.37; N, 8.03. Found: C, 58.09; H, 4.47; N, 8.03.

35 4d) 4-[3-(3-chloro-4-methylphenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide: mp 120-122 °C. $^1\text{H NMR}$ (CD_3OD) 2.30 (s, 3H), 2.48 (s, 3H) 4.84 (bs, 2H), 7.11

(m, 1H), 7.33-7.40 (m, 4H), 7.92 (d, 2H, J = 8.4). High resolution mass spectrum Calc'd for $C_{17}H_{15}FN_2O_3S$: 363.0570. Found: 363.0584. Elemental analysis. Calc'd for $C_{17}H_{15}ClN_2O_3S$: C, 56.28; H, 4.17; N, 7.72.

5 Found: C, 56.02; H, 4.38; N, 7.54.


4e) 4-[5-methyl-3-(3-pyridyl)isoxazol-4-yl]benzenesulfonamide: mp 110-115 °C (dec). 1H NMR ($CDCl_3$) 8.57 (br s, 1H), 8.47 (s, 1H), 7.88, 7.24 (AB

10 quartet, 4H), 7.51-7.41 (m, 2H), 2.43 (s, 3H). Mass spectrum M^+H 316.

4f) 4-[5-methyl-3-(4-pyridyl)-isoxazol-4-yl]benzenesulfonamide: mp 108-110 °C (dec). 1H NMR ($CDCl_3$) 8.51 (d, 2H, J=6.0 Hz), 7.9 (d, 2H, J=8.46 Hz), 7.30-7.26 (m, 4H), 6.11 (s, 2H), 2.44 (s, 3H). Mass spectrum M^+H 316. Anal. Calc'd. for $C_{15}H_{13}N_3O_3S \cdot H_2O$: C, 54.05; H, 4.54; N, 12.62. Found: C, 53.65; H, 4.08; N, 12.42.

20 4g) 4-[3-(3-fluorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide: mp 130-136 °C (dec). 1H NMR ($CDCl_3$) 7.95 (d, 2H, J=8.5 Hz), 7.33 (d, 2H), 7.33-7.11 (m, 4H), 2.50 (s, 3H). Mass spectrum M^+H 333. Anal. Calc'd. for $C_{16}H_{13}N_2O_3SF$: C, 57.82; H, 3.94; N, 8.43. Found: C, 57.42; H, 4.57; N, 7.50.

EXAMPLE 5



5-Methyl-4-[4-(methylsulfonyl)phenyl]-3-phenylisoxazole

Step 1. Preparation of 1-phenyl-2-[4-(methylthio)phenyl]-ethan-1-one.

This ketone was prepared from the Friedel Crafts acylation of benzene with 4-methylthiophenylacetyl chloride in the presence of aluminum chloride: ^1H NMR ($\text{CDCl}_3/300$ MHz) δ 7.92 (d, $J=8.66$ Hz, 2H), 7.32-7.22 (m, 7H), 4.24 (s, 2H), 2.51 (s, 3H).

Step 2. Preparation of 1-phenyl-2-[4-(methylthio)phenyl]-ethan-1-one oxime.

This oxime was prepared from 1-phenyl-2-[4-(methylthio)phenyl]-ethan-1-one (Step 1) and hydroxylamine in 80% yield by the method outlined in Example 1, Step 1: ^1H NMR ($\text{CDCl}_3/300$ MHz) δ 7.54 (d, $J=8.66$ Hz, 2H), 7.32-7.17 (m, 7H), 4.19 (s, 2H), 2.36 (s, 3H).

Step 3. Preparation of 5-methyl-4-[4-(methylthio)phenyl]-3-phenylisoxazole:

5-Methyl-4-[4-(methylthio)phenyl]-3-phenylisoxazole was prepared in 48% yield from the reaction of 1-phenyl-2-[4-(methylthio)phenyl]-ethan-1-one oxime (Step 2) and acetic anhydride according to the procedure outlined in Example 4, Step 1: Mass Spectrum: $\text{MH}^+ = 282$. High resolution mass spectrum Calc'd. for $\text{C}_{17}\text{H}_{15}\text{NOS}$: 281.0874. Found: 281.0875.


Anal. Calc'd.: C, 72.57; H, 5.37; N, 4.98; S, 11.39. Found: C, 72.56; H, 5.41; N, 5.00; S, 11.34.

Step 4. Preparation of 5-methyl-4-[4-(methylsulfonyl)phenyl]-3-phenylisoxazole:

5-Methyl-4-[4-(methylthio)phenyl]-3-phenylisoxazole from Step 3 (100 mg, 0.355 mmol) was dissolved in methanol (20 mL). Oxone® (0.765 g, 1.24

mmol) and water (2 mL) were added, and the suspension was stirred at room temperature for 2 hours. Water was added (30 mL) and the resulting suspension was cooled to 0 °C and held for 30 minutes whereupon the product 5 crystallized. The product was isolated by filtration, washed with water and dried to yield 5-methyl-4-[4-(methylsulfonyl)phenyl]-3-phenylisoxazole (32 mg, 29%): mp 54-56 °C. Mass Spectrum: M⁺Li = 320. High resolution mass spectrum Calc'd for C₁₇H₁₅NO₃S: 10 313.077. Found: 313.078.

EXAMPLE 6



15

[3-[3-Fluoro-4-methoxyphenyl]-4-[4-(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid.

Step 1. Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]ethan-1-one.

1-(3-Fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]ethan-1-one was prepared by Friedel Crafts acylation of 2-fluoroanisole with 4-(methylthio)phenylacetyl chloride in the presence of 25 aluminum chloride: ¹H NMR (CDCl₃/300 MHz) δ 7.80-7.70 (m, 2H), 7.24-7.15 (m, 4H), 6.98 (t, J=8.26 Hz), 4.17 (s, 2H), 3.95 (s, 3H), 2.46 (s, 3H). ¹⁹F NMR (CDCl₃/282.2 MHz): -134.804 (m).

Step 2. Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime.

1-(3-Fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime was prepared in 5 91% yield by treatment of 1-(3-fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one from Step 1 with hydroxylamine: ^1H NMR (CDCl₃/300 MHz) δ 7.40 (dd, J=12.69, 2.22 Hz, 1H), 7.30 (d, J=8.66 Hz, 1H), 7.18-10 7.12 (m, 4H), 6.88 (dd, J=8.66, 8.46 Hz, 1H), 4.10 (s, 2H), 3.87 (s, 3H), 2.43 (s, 3H).

Step 3. Preparation of 3-(3-fluoro-4-methoxyphenyl)-5-methyl-4-[4-(methylthio)phenyl]isoxazole:


3-(3-Fluoro-4-methoxyphenyl)-5-methyl-4-[4-(methylthio)phenyl]isoxazole was prepared in 30% yield 15 from 1-(3-fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime from Step 2 and acetic anhydride by the procedure described in Example 4, Step 1 and used directly in the next step.

20 Step 4. Preparation of [3-[3-fluoro-4-methoxyphenyl]-4-[4-(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid.

Anhydrous THF (35 mL) was added to 3-(3-fluoro-4-methoxyphenyl)-5-methyl-4-[4-(methylthio)phenyl]isoxazole (326 mg, 0.99 mmol) and the solution was cooled to -78 °C under a dry nitrogen 25 blanket. To this solution, n-butyllithium (1.6 N in hexane; 0.74 mL) was added, via syringe over approximately 3 minutes, keeping the reaction temperature < -75 °C. The deep red suspension was 30 stirred at -78 °C for 1 hour. Simultaneously, anhydrous tetrahydrofuran (80 mL) was cooled to -78 °C and saturated with carbon dioxide gas. The red reaction solution was quenched into the carbon dioxide-saturated THF. The yellow reaction was warmed to room 35 temperature over 2 hours, then diluted with water (50 mL) and ether (80 mL). The solution was extracted with

aqueous sodium hydroxide (5%, 2 X 50 mL), and the combined aqueous solution was acidified to pH <2 with aqueous hydrochloric acid (conc.). The acidic solution was extracted with dichloromethane (2 X 50 mL). The 5 combined organic solution was dried over magnesium sulfate, filtered and evaporated under reduced pressure to a crude solid. The solid was dissolved in methanol (20 mL) and Oxone® (2.13 g, 3.47 mmol) and water (3 mL) were added. The suspension was stirred at room 10 temperature for 2 hours, warmed to reflux and held for an additional 2 hours. Upon cooling to room temperature, water (35 mL) and aqueous hydrochloric acid (6 N, 1 mL) were added. The resulting suspension was cooled to 0 °C, held for 30 minutes, filtered and 15 washed with cold water to yield, upon drying, [3-(3-fluoro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid as white crystals (173 mg, 43%): mp 89 °C. Mass spectrum: $\text{MH}^+ = 406$. Anal. Calc'd. for $\text{C}_{19}\text{H}_{16}\text{NO}_6\text{FS}$: C, 56.29; H, 3.98; N, 3.46; S, 7.91. Found: C, 56.22; H, 4.00; N, 3.44; S, 7.85.

EXAMPLE 7



25

3-(3-Chloro-4-methoxyphenyl)-5-methyl-4-[4-methylsulfonylphenyl]isoxazole

Step 1. Preparation of 3-chloro-4-methoxyacetophenone.

Anhydrous aluminum chloride (281 g, 2.104 mol) and 1 L of ethanol-free chloroform were maintained at 0 °C with an ice bath while a solution of acetyl chloride (162 g, 2.28 mol) in 300 mL of chloroform was added from the addition funnel over 25 minutes. To this solution was added 2-chloroanisole (250 g, 1.75 mol) in 250 mL of chloroform over 1 hour. The solution was stirred at room temperature for 16 hours and was poured into a mixture of ice and water. The phases were separated and the aqueous phase extracted with dichloromethane and combined with the original organic phase, dried over anhydrous MgSO₄, filtered and concentrated in vacuo to afford a solid that was crystallized from dichloromethane/hexane to give 3-chloro-4-methoxyacetophenone (246 g, 76%) that was used directly in the next step without further purification.

Step 2. Preparation of 3-chloro-4-methoxyphenylacetic acid.

A mixture of 3-chloro-4-methoxyacetophenone from Step 1 (10.0 g, 54.2 mmol) and boron trifluoride etherate complex (26.6 mL, 0.216 mol) in 20 mL of methanol was added to a suspension of lead tetraacetate (24 g, 54.2 mmol) in 50 mL of toluene. The mixture was stirred at room temperature for 16 hours, treated with 50 mL of water. The phases were separated and the aqueous phase was washed with toluene. The toluene solution was dried over anhydrous MgSO₄, filtered and concentrated in vacuo to provide an oil that was dissolved in 40 mL of dioxane and treated with excess 2.5 N sodium hydroxide solution. The solution was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was extracted with dichloromethane and the aqueous phase acidified with concentrated HCl. The acidic solution was extracted

with dichloromethane. The dichloromethane extract was dried over anhydrous MgSO₄, filtered and concentrated in vacuo to afford pure 3-chloro-4-methoxyphenylacetic acid (9.11 g, 84%) that was used directly in the next 5 step.

Step 3. Preparation of 2-(3-chloro-4-methoxyphenyl)-3-[4-(methylthio)phenyl]-2-propenoic acid.

A mixture of 3-chloro-4 methoxyphenylacetic acid 10 from Step 2 (4.50 g, 22.4 mmol), 4-methylthiobenzaldehyde (2.70 g, 20.4 mmol) and triethylamine (2.8 mL, 20.4 mmol) were dissolved in 40 mL of acetic anhydride and heated to reflux for 3 hours. The solution was cooled to 110 °C, treated 15 cautiously with 70 mL of water and cooled to room temperature, whereupon crystals of 2-(3-chloro-4-methoxyphenyl)-3-[4-(methylthio)phenyl]-2-propenoic acid formed that were isolated by filtration and air dried to afford 5.68 g (75%) of pure compound which was 20 used directly in the next step.

Step 4. Preparation of 1-(3-chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one.

A solution of 1-(3-chloro-4 methoxyphenyl)-3-[4-(methylthio)phenyl]propenoic acid from Step 3 (5.00 g, 14.9 mmol) and triethylamine (2.20 g, 15.7 mmol) in 50 mL of toluene was cooled to 0 °C and treated with diphenylphosphoryl azide (3.20 g, 14.9 mmol) via syringe. The solution was maintained at 0 °C for 30 minutes and then diluted with water. The phases were separated and the aqueous phase was washed with ether. The original toluene solution was combined with the ethereal extract, dried over anhydrous MgSO₄, filtered and concentrated to remove the ether. The remaining 30 toluene solution was heated to 115 °C for 90 minutes, treated with tert-butyl alcohol (1.50 g, 16.4 mmol) and maintained at this temperature for an additional 30

minutes. The solution was cooled to 90 °C, treated with 1.4 mL of concentrated HCl and cooled to room temperature. The solution was washed with saturated aqueous NaHCO₃, and with brine and dried over anhydrous MgSO₄, filtered and concentrated to give 1-(3-chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one as a solid that was used directly in the next step: ¹H NMR (CDCl₃/300 MHz) δ 7.90 (d, J=8.66 Hz, 2H), 7.29-7.24 (m, 3H), 7.11 (dd, J=8.46, 2.21 Hz, 1H), 6.88 (d, J=8.46 Hz, 1H), 4.19 (s, 2H), 3.86 (s, 3H), 2.55 (s, 3H).


Step 5. Preparation of 1-(3-chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime.

15 1-(3-Chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime was prepared in 41% yield from the reaction of 1-(3 chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one from Step 4 with hydroxylamine by the method outlined in Example 1, Step 1: ¹H NMR (CDCl₃/300 MHz) δ 7.69 (d, J=2.22 Hz, 1H), 7.47 (dd, J=8.66, 2.22 Hz, 1H), 7.21-7.16 (m, 4H), 6.86 (d, J=8.66 Hz, 1H), 4.11 (s, 2H), 3.89 (s, 3H), 2.44 (s, 3H).

Step 6. Preparation of 3-(3-chloro-4-methoxyphenyl)-4-[4-methylsulfonylphenyl]-5-methylisoxazole.

30 3-(3-Chloro-4-methoxyphenyl)-5-methyl-4-[4-(methylthio)phenyl]isoxazole was prepared in 26% yield from 1-(3-chloro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]-ethan-1-one oxime from Step 5 and acetic anhydride by the method described in Example 4, Step 1 and then oxidized to 3-(3-chloro-4-methoxyphenyl)-5-methyl-4-[4-methylsulfonylphenyl]isoxazole with Oxone® by the 35 method described in Example 5, Step 4: Mass spectrum: MLi⁺ = 384. High resolution mass spectrum calc'd. for C₁₈H₁₇ClNO₄S (M+H): 378.0567. Found: 378.0573.

EXAMPLE 8



5

[4-[4-(Methylsulfonyl)phenyl]-3-phenyl]isoxazol-5-ylacetic acid

Step 1. Preparation of [4-[4-(methylthio)phenyl]-3-phenylisoxazol-5-yl]acetic acid.

10 [4-[4-(Methylthio)phenyl]-3-phenylisoxazol-5-yl]acetic acid was prepared in 35% yield by carboxylation of 4-[4-(methylthio)phenyl]-5-methyl-3-phenylisoxazole [Example 5, Step 3] according to the procedure detailed in Example 6, Step 4: Mass


15 spectrum: $MH^+ = 326$. High resolution mass spectrum calc'd. for $C_{18}H_{15}NO_3S$: 325.0773. Found: 325.0776.

Step 2. Preparation of [4-[4-(methylsulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetic acid.

20 [4-[4-(Methylsulfonyl)phenyl]-3-phenyl]isoxazol-5-ylacetic acid was prepared in 80% yield from [4-[4-(methylthio)phenyl]-3-phenylisoxazol-5-yl]acetic acid (Step 1) by oxidation with Oxone® according to the procedure detailed in Example 5, Step 4: Mass

25 spectrum: $MH^+ = 326$. High resolution mass spectrum calc'd. for $C_{18}H_{16}NO_5S(M+H)$: 358.0749. Found: 358.0769.

EXAMPLE 9



5 [4-[(Aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetic acid

Step 1. Preparation of 3,4-diphenyl-5-methylisoxazole.

10 A solution of desoxybenzoin keto-oxime (Example 1, Step 1) (6.00 g, 28.40 mmol) in anhydrous tetrahydrofuran (80 mL) was cooled to -20 °C. To this solution, n-butyllithium (1.6 N in hexanes, 44.4 mL) was added, via syringe, over 35 minutes, such that the 15 reaction temperature remained at or below -10 °C. The deep red solution was stirred at -10 °C for 1 hour, warmed to room temperature, then stirred at room temperature for an additional hour. Acetic anhydride (3.2 mL, 34.1 mmol) was added in one portion, and the 20 resulting suspension was stirred without temperature control for 2 hours. Water (100 mL) was added, and the solution was poured into 1 N HCl (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic solution was washed with HCl (1 N HCl, 100 mL) and 25 brine (100 mL), dried over anhydrous MgSO₄ and filtered. The resulting solution was concentrated in vacuo to yield a crude oil. The oil was applied to a column of silica gel and eluted with ethyl acetate/hexane (10-50% ethyl acetate) to yield, upon 30 concentration of the appropriate fractions, 5.0 g of 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole.

The 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole (5.00 g, 19.74 mmol) was added to 300 mg of concentrated H₂SO₄ and 30 mL of toluene. The solution was heated to reflux for 1 hour and washed with water.

5 The toluene solution was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo* and the residue used directly in the next step without further purification.

10 Step 2. Preparation of (3,4-diphenylisoxazol-5-yl)acetic acid:


(3,4-Diphenylisoxazol-5-yl)acetic acid was prepared in 53% yield by carboxylation of 3,4-diphenyl-5-methyl-isoxazole (Step 1) according to the procedure outlined in Example 6, Step 4: Mass spectrum: M^{H+} = 280. High resolution mass spectrum calc'd. for C₁₇H₁₄NO₃ (M+H): 280.0894. Found: 280.0897. Anal. Calc'd. for C₁₇H₁₃NO₃: C, 73.11; H, 4.69; N, 5.01. Found: C, 72.91; H, 4.73; N, 4.97.

20

Step 3. Preparation of [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetic acid:

[4-[4-(Aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]acetic acid was prepared in 60% yield by chlorosulfonation followed by ammonolysis of 1-(3,4-diphenylisoxazol-5-yl)acetic acid according to the procedure outlined in Example 2, Step 4: mp 61 °C. Mass spectrum: M^{H+} = 359.

EXAMPLE 10



5 4-[5-Hydroxymethyl-3-phenylisoxazol-4-
y1]benzenesulfonamide


4-[5-Methyl-3-phenyl-4-yl]benzenesulfonamide

(Example 1) (20.965 g, 66.69 mmol) and THF (1.4 L) were cooled to -78 °C (dry-ice/acetone bath) and a premeasured volume of n-BuLi (167 mL, 266.76 mmol) was added, causing the reaction solution to become bright red. After 15 minutes the dry ice/acetone bath was replaced with a NaCl/ice/water bath, the reaction was warmed to -5 °C over 15 minutes and maintained at -5 °C for 30 more minutes. The NaCl/ice/H₂O bath was replaced with a dry ice/acetone bath and the reaction was chilled to -71 °C. Oxygen was added via two 14 gauge needles (ca. 4 psi) and a similar outlet provided. Within 10 minutes the reaction, formerly a red suspension, became an ocre-yellow suspension. Oxygen addition was continued for 30 more minutes. The oxygen line and vents were removed and trimethyl phosphite (67 mL, 566.97 mmol) was added via syringe. After 15 minutes, a solution of HOAc (125 mL) and H₂O (125 mL) was added in one portion causing the solution to become a hazy bright yellow and the reaction temperature to rise to -50 °C. The dry ice bath was removed and the reaction was warmed to room temperature. Brine (700 mL) and 1 N HCl (134 mL) were added and stirred for 15 minutes. Ethyl acetate (700 mL) was added and the layers were separated. The

aqueous phase was washed with ethyl acetate (150 mL) and the organic layers were combined. The organic layer was washed with water, NaHCO_3 (5 x 100 mL) and brine, dried over anhydrous MgSO_4 , and filtered. The 5 resulting organic phase was diluted with toluene (125 mL) and concentrated *in vacuo* three times yielding a brown viscous oil. The crude product was purified by flash chromatography (silica gel, 10x18 cm column, hexane/ethyl acetate (1/2) with a step gradient to 10 hexane/ethyl acetate (1/2)) yielding a yellow solid (11.25 g). The product was dissolved in ethyl acetate (500 mL) and acetone (60 mL). Partial concentration of this solution and addition of hexane yielded a yellow solid which was collected by vacuum filtration. This 15 solid was dissolved in a minimum of acetone and added to hot H_2O (800 mL at 70 °C) yielding the desired product as a very fine crystalline yellow product (7.89 g, 36%): mp 188-189 °C. ^1H NMR (DMSO-d_6) δ 7.81 (d, J = 8.26 Hz, 2 H), 7.26-7.55 (m, 9 H), 5.77 (t, J = 4.84, 1 H), 4.54 (d, J = 4.84, 2 H). Anal. Calc'd. for 20 $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_4\text{S}$: C, 58.17; H, 4.27; N, 8.48. Found: C, 58.22; H, 4.31; N, 8.50. Mass spectrum: M+H^+ : 331.

EXAMPLE 11

25




[4-[(4-(aminosulfonyl)phenyl)-3-phenylisoxazol-5-yl]carboxylic acid

30 To a solution of 4-[5-hydroxymethyl-3-phenyl-4-yl]benzenesulfonamide (Example 10) (0.64 g, 1.94 mmol)

in acetone at -78 °C (dry ice-acetone bath) was added carefully Jones reagent (0.7 mL of 2.44 M CrO₃ in aqueous H₂SO₄ solution). The reaction was warmed to 0 °C and an additional 0.7 mL (2.44 M CrO₃ in aqueous H₂SO₄ solution) was added. The reaction was warmed to room temperature and stirred overnight. Isopropanol (2 mL) was added and was stirred for 2 hour. The reaction was diluted with ethyl acetate, washed with H₂O, dried over anhydrous MgSO₄, filtered through Celite® and 10 concentrated in vacuo yielding a solid. Recrystallization of this solid from toluene yielding the desired product (0.075 g, 11%) as a tan solid: mp >300 °C. ¹H NMR (DMSO-d₆) δ 7.70 (d, J = 8.46 Hz, 2H), 7.08-7.50 (m, 9H).

15

EXAMPLE 12



20

4-[5-Hydroxy-3-phenylisoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 3,4-diphenylisoxazolin-5-one.

To a stirred solution of the deoxybenzoin oxime (50.59 g, 239 mmol) in anhydrous THF (1 L) under nitrogen atmosphere, and chilled to -78 °C (dry ice/acetone bath) was added n-BuLi (375 mL of 1.6 M in hexanes, 599 mmol) via cannula over 15 minutes. After twenty minutes at -78 °C, the dry ice/acetone bath was replaced with a NaCl/ice/H₂O and the reaction was 25 warmed to 0 °C over 1 hour. The NaCl/ice/H₂O bath was replaced with a dry ice/acetone bath. When -78 °C was reached, the reaction was transferred to 1500 cc of 30

powdered dry ice and the resulting yellow mixture was let stand overnight at room temperature. The clear, straw colored solution was mixed with 700 mL of 3 N HCl. The reaction was heated to reflux for 1 hour and 5 cooled to room temperature. The reaction was diluted with brine (500 mL) and the layers were separated. The aqueous layer was extracted with dichloromethane/ethyl acetate (2/1) (400 mL). The organic layers were combined and washed with brine (200 mL), dried over 10 anhydrous MgSO₄, filtered and concentrated yielding a brown solid. The solid was re-dissolved in warm THF and hexanes were added yielding a fluffy off-white crystalline solid (30.4 g, 54%). A second crop was obtained (12.66 g, 22%): mp 162-163 °C (dec.). This 15 material was suitable for use without further purification.


Step 2. Preparation of 4-[5-hydroxy-3-phenyl-4-yl]benzenesulfonamide.

20 3,4-Diphenyloxazolin-5-one from step 1 (15.6 g, 65.75 mmol) was added carefully to ClSO₃H (160 mL) chilled in a NaCl/ice bath. After 2 hours, the crude reaction mixture was carefully poured over ice, yielding the crude sulfonyl chloride as a precipitate 25 which was collected by vacuum filtration. The solid was dissolved in dichloromethane yielding two phases which were separated, and the organic phase dried over anhydrous MgSO₄. This clear pale yellow solution was slowly added to a chilled (0 °C) saturated solution of 30 NH₃ in dichloromethane. The resulting suspension was diluted with CH₃OH and washed with KHSO₄ (0.25 M). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated in vacuo yielding a tan solid which was collected by vacuum filtration. This solid was 35 dissolved in a minimum of 1 N NaOH solution, filtered, and washed with dichloromethane. The aqueous layer was acidified with concentrated HCl yielding and off-white

solid (3.70 g, 18%): mp 207 °C (dec.). ^1H NMR (D_2O with NaOD) δ 7.48 (d, J = 8.46 Hz, 2 H), 7.38-7.20 (m, 5 H), 7.14, (d, J = 8.26, 2 H). The methanolic/aqueous KHSO_4 wash phase, upon partial evaporation yielded 5 additional desired product as a tan solid (8.94 g, 43%).

EXAMPLE 13

10



4-[3-Methyl-5-phenylisoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 1,2-diphenyl-1-butene-3-one oxime.

A solution of 1,2-diphenyl-1-butene-3-one (1.5g, 7 mmol) in EtOH (15 mL) and was added to a solution of hydroxylamine hydrochloride (500 mg, 7 mmol) and NaHCO_3 (1g) in water (7 mL). The mixture was heated to reflux 20 for 5 hours at which time thin layer chromatography indicated the reaction was incomplete. Additional hydroxylamine hydrochloride (500 mg, 7 mmol) was added and heating at reflux was continued overnight. The reaction was cooled, poured into water (100 mL) and 25 extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and the filtrate concentrated in vacuo. The crude material was chromatographed on silica gel using 5% ethyl acetate in toluene as the eluant to give 450 mg (30%) of the 30 desired oxime as a crystalline solid: mp 138-141 °C. Anal. Calc'd. for $\text{C}_{16}\text{H}_{15}\text{NO}$: C, 80.98; H, 6.37; N, 5.90. Found: C, 80.79; H, 6.25; N, 6.09.

Step 2. Preparation of 3,4-diphenyl-5-methylisoxazole

To a solution of oxime from Step 1 (450 mg, 1.9 mmol) and sodium bicarbonate (650 mg, 7.7 mmol) in 5 tetrahydrofuran (6 mL) and water (6 mL) in a vessel wrapped in aluminum foil was added a solution of potassium iodide (1.1 g, 6.6 mmol) and iodine (525 mg, 2 mmol) in water (4 mL). The reaction was heated to reflux for 7 hours and stirred at room temperature 10 overnight. Saturated aqueous sodium bisulfite solution (5 mL) was added and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and the crude material was isolated after filtration and concentration of the 15 filtrate. Chromatography on silica gel using toluene as the eluant gave 290 mg (57%) of the isoxazole as an oil which crystallized on standing: mp 92-94 °C. Anal. Calc'd for C₁₆H₁₃NO: C, 81.31; H, 5.57; N, 5.95. Found: C, 81.31, H, 5.71; N, 6.18.

20


Step 3. Preparation of 4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide.

A solution of the isoxazole from step 1 (250 mg, 1.1 mmol) in chlorosulfonic acid (1 mL) was stirred at 25 0° for 3 hours. The reaction was cautiously added to concentrated ammonium hydroxide (6 mL) in the cold (0 °C). The resultant reaction mixture was stirred at 0° for 1 hour. The reaction was cautiously diluted with 30 water and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and the filtrate concentrated in vacuo to give the crude product. This material was chromatographed on silica gel using 25% ethyl acetate in toluene as the eluant to give the desired 35 sulfonamide as a crystalline solid (110 mg, 40%): mp 185-187 °C. Anal. Calc'd. for C₁₆H₁₄N₂O₃S: C, 61.13;

H, 4.49; N, 8.91; S, 10.20. Found: C, 60.88; H, 4.61; N, 8.55; S, 10.40.

EXAMPLE 14

5



4-[3-Ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide

10 Step 1. Preparation of 1,2-diphenyl-1-pentene-3-one

Hydrogen bromide (30% in acetic acid, 30 mL) was added (15 minutes) to a solution of 1-phenyl-2-butanone (14.8 g, 0.10 mole) and benzaldehyde (10.6 g, 0.10 mole) in acetic acid (100 mL) at 0 °C and stirred at room temperature for 20 hours. The reddish mixture was poured into 750 mL cold water and stirred for 15 minutes. The material was extracted into ethyl acetate. The combined ethyl acetate extracts were washed with water (5 x 100 mL), dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography yielded the ketone as an oil, which was used directly in the next step.

25

Step 2. Preparation of 1,2-diphenyl-1-pentene-3-one oxime.

Potassium hydroxide (0.77 g, 0.014 mole) was added to a solution of hydroxylamine HCl (0.95 g, 0.014 mole) in water (4 mL). Ethyl alcohol (40 mL) was added and a white solid was filtered. The filtrate was added to a solution of 1,2-diphenyl-

1-pentene-3-one (Step 1) (2.7 g, 0.011 mole) in ethyl alcohol (10 mL). After heating to 75 °C for 3.5 hours, the solution was concentrated to an oily solid. Purification by silica gel chromatography and recrystallization from hexane gave the oxime as a white solid. Anal. Calc'd. for C₁₇H₁₇NO (251.33): C, 81.24; H, 6.82; N, 5.57. Found: C, 81.37; H, 6.87; N, 5.50.

10 Step 3. Preparation of 4,5-diphenyl-3-ethylisoxazole

A solution of NaHCO₃ (1.34 g, 0.016 mole) in water (13 mL) was added to a solution of 1,2-diphenyl-1-pentene-3-one oxime (Step 2) (1.0 g, 0.004 mole) in THF (14 mL). The reaction vessel was covered with aluminum foil. A solution of potassium iodide (2.31 g, 0.014 mole) and iodine (1.11 g, 0.0044 mole) in water (8.5 mL) was added dropwise over 5 minutes, and the resulting solution was heated to reflux for 5 hours. After cooling to room temperature, a saturated solution of sodium bisulfite (10 mL) was added. Water (50 mL) was added and the mixture was extracted into ethyl acetate (100 mL). The ethyl acetate solution was dried over NaSO₄, filtered and concentrated to an oil. Purification by silica gel chromatography yielded the isoxazole. Anal. Calc'd. for C₁₇H₁₅NO (249.32): C, 81.90; H, 6.06; N, 5.62. Found: C, 82.08; H, 5.83; N, 5.62.


30

Step 4. Preparation of 4-[3-ethyl-5-phenylisoxazolyl]benzenesulfonamide

A solution of the isoxazole (Step 3) (14 g, 0.043 mole) in chlorosulfonic acid (15 mL) was stirred at 0 °C for 4 hours. The cold solution was added dropwise very slowly to ammonium hydroxide (100 mL). After stirring for 1 hour,

hydroxide (100 mL). After stirring for 1 hour, water (100 mL) was added and the mixture was extracted into ethyl acetate (2 x 250 mL). The combined ethyl acetate extracts were dried over 5 Na_2SO_4 , filtered and concentrated to give a solid. The crude solid was purified by silica gel chromatography to give the sulfonamide as a solid: mp 167 °C (DSC). Anal. Calc'd. for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$: C, 62.18; H, 4.91; N, 8.53. Found: C, 62.20; H, 10 4.75; N, 8.48.

EXAMPLE 15




15

4-[3-Isopropyl-5-phenylisoxazol-4-yl]benzenesulfonamide

By following the method of Example 14 and by substituting 3-methyl-1-phenyl-2-butanone for 1-20 phenyl-2-butanone, the titled product was obtained: mp 205 °C (DSC). Anal. Calc'd. for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$: C, 63.14; H, 5.30; N, 8.18. Found: C, 62.80; H, 5.37; N, 7.89.

EXAMPLE 16




5 **4-[5-Phenyl-3-propylisoxazol-4-yl]benzenesulfonamide**

By substituting 1-phenyl-2-pentanone for 1-phenyl-2-butanone in the method of Example 14, the titled product was obtained: mp 167 °C (DSC).

10 Anal. Calc'd. for C₁₈H₁₈N₂O₃S: C, 63.14; H, 5.30; N, 8.18. Found: C, 62.95; H, 5.51; N, 8.01.

EXAMPLE 17




15

15 **4-[3-Ethyl-5-(4-methylphenyl)isoxazol-4-yl]benzenesulfonamide**

By following the method of Example 14 and substituting para-tolualdehyde for benzaldehyde, the titled material was prepared: mp 191 °C (DSC). Anal. Calc'd. for C₁₈H₁₈N₂O₃S: C, 63.14; H, 5.30; N, 8.18. Found: C, 63.06; H, 5.26; N, 8.10.

EXAMPLE 18



5 **4-[3-Butyl-5-phenylisoxazol-4-yl]benzenesulfonamide**

Step 1. Preparation of 1-phenyl-2-hexanone


Butyl magnesium bromide (2.0 M in THF, 200 mL, 0.4 mole) was added dropwise to a stirred cold (−5 °C) slurry of methyl phenyl acetate (9.8 g, 0.065 mole) and N,O-dimethylhydroxylamine HCl (7 g, 0.072 mole) in 600 mL THF over 1.5 hours. After stirring at room temperature for 20 hours, 1N HCl (100 mL) was added dropwise. After 1.5 hours, water (100 mL) was added and the layers were separated. The organic layer was dried over Na₂SO₄, filtered and concentrated to an oil. The hexanone was purified by silica gel chromatography.

20

Step 2. Preparation of 4-[3-butyl-5-phenylisoxazol-4-yl]benzenesulfonamide

By substituting 1-phenyl-2-hexanone for 1-phenyl-2-butanone in the method of Example 14, the titled product was obtained: mp 150 °C (DSC). Anal. Calc'd. for C₁₉H₂₀N₂O₃S: C, 64.02; H, 5.66; N, 7.86. Found: C, 63.70; H, 5.93; N, 7.75.

EXAMPLE 19



5 4-[3-Methyl-5-(4-methylphenyl)isoxazol-4-
y1]benzenesulfonamide


Step 1. Preparation of 4-(4-methylphenyl)-3-
phenyl-3-butene-2-one

10 A solution of phenylacetone (5 g, 37 mmol), p-
tolualdehyde (4.5 g, 37 mmol) and piperidine (125 mg)
in benzene (30 mL) was heated to reflux for 24 hours.
The mixture was concentrated and the crude material
was chromatographed on silica gel using mixtures of
ethyl acetate and hexane as the eluents to give 3 g of
15 the desired ketone as an oil. This material was
suitable for use without further purification.

Step 2. Preparation of 4-[3-methyl-5-(4-
methylphenyl)isoxazol-4-yl]benzenesulfonamide

20 By substituting 4-(4-methylphenyl)-3-phenyl-3-
butene-2-one (Step 1) for 1,2-diphenyl-1-pentene-3-one
in the method of Example 14, the titled product was
obtained: mp 191-193 °C. Anal. Calc'd. for
C₁₇H₁₆N₂O₃S (328.39): C, 62.18; H, 4.91; N, 8.53; S,
25 9.76. Found: C, 61.93; H, 4.95; N, 8.36; S, 9.40.

EXAMPLE 20



5 4-[5-(4-Chlorophenyl)-3-methylisoxazol-4-
 yl]benzenesulfonamide


Step 1. Preparation of 4-(4-chlorophenyl)-3-phenyl-3-butene-2-one

Following the procedure of Example 19, step 1,
10 above, phenylacetone (7.9 g, 58 mmol) was reacted with
p-chlorobenzaldehyde (8.15 g, 58 mmol) in the presence
of piperidine (125 mg) in benzene (40 mL). The crude
material was purified by recrystallization from
ethanol to give 5.5 g (45%) of the desired ketone as a
15 crystalline solid: mp 126-127 °C. Anal. Calc'd. for
C₁₆H₁₃OCl (256.73): C, 74.85; H, 5.10; Cl, 13.81.
Found: C, 74.75; H, 5.01; Cl, 13.61.

Step 2. Preparation of 4-[5-(4-chlorophenyl)-3-methylisoxazol-4-yl]benzenesulfonamide

By substituting 4-(4-chlorophenyl)-3-phenyl-3-butene-2-one (Step 1) for 1,2-diphenyl-1-pentene-3-one in the method of Example 14, the titled product (950 mg, 31%) was obtained: mp: 194-197°. Anal. Calc'd. for
25 C₁₆H₁₃N₂O₃ClS (348.81): C, 55.10; H, 3.76; N, 8.03; S, 9.19. Found: C, 55.16; H, 3.87; N, 7.72; S, 9.33.

EXAMPLE 21



5 4-[5-(4-Fluorophenyl)-3-methylisoxazol-4-
y1]benzenesulfonamide


Step 1. Preparation of 4-(4-fluorophenyl)-3-phenyl-3-butene-2-one

Following the procedure of Example 19, step 1,
10 phenylacetone (6.75 g, 50 mmol) was reacted with 4-
fluorobenzaldehyde (6.25 g, 50 mmol) in the presence of
piperidine (125 mg) in benzene (40 mL). The crude
material was recrystallized from hexane to give 7.9 g
(66%) of the desired material as a crystalline solid, mp
15 88-89 °C. Anal. Calc'd. for C₁₆H₁₃FO (240.28): C, 79.98;
H, 5.45. Found: C, 79.66; H, 5.50.

Step 2. Preparation of 4-[5-(4-fluorophenyl)-3-methylisoxazol-4-yl]benzenesulfonamide

20 By substituting 4-(4-fluorophenyl)-3-phenyl-3-
butene-2-one (Step 1) for 1,2-diphenyl-1-pentene-3-one
in the method of Example 14, the titled product (225
mg, 40%) was obtained: mp 174-175 °C. Anal. Calc'd.
for C₁₆H₁₃N₂FO₃S (332.36): C, 57.82; H, 3.94; N, 8.43;
25 S, 9.65. Found: C, 57.66; H, 3.84; N, 8.22; S, 9.78.

EXAMPLE 22



5 **3-Methyl-5-(4-methylsulfonylphenyl)-4-phenylisoxazole**

Step 1. Preparation of 4-(4-methylthiophenyl)-3-phenyl-3-butene-2-one

Following the procedure of Example 19, step 1,
 10 phenylacetone (5 g, 35 mmol) was reacted with 4-methylthiobenzaldehyde (5.25 g, 35 mmol) in the presence of piperidine (125 mg) in benzene (40 mL). The crude material was recrystallized from ethyl acetate and hexane to give the ketone (3 g, 32%): mp 15 67-68 °C. Anal. Calc'd. for C₁₇H₁₆OS (268.38): C, 76.08; H, 6.01; S, 11.95. Found: C, 75.80; H, 5.91; S, 11.89.

Step 2. Preparation of 4-(4-methylthiophenyl)-3-phenyl-3-butene-2-one oxime

A solution of the ketone from Step 1 (3 g, 11 mmol), hydroxylamine hydrochloride (765 mg, 11 mmole) and sodium acetate (905 mg, 11 mmol) in ethanol (30 mL) and water (3 mL) was heated at reflux for 90 minutes.
 25 The reaction was cooled, water (25 mL) was added and the crude oxime was filtered. Recrystallization from ethanol and water gave pure oxime (2.65 g, 85%): mp 151-152 °C. Anal. Calc'd. for C₁₇H₁₇NOS (283.39): C, 72.05; H, 6.05; N, 4.94; S, 11.31. Found: C, 71.96; H, 30 6.10; N, 4.71; S, 11.45.


Step 3. Preparation of 5-(4-methylthiophenyl)-4-phenyl-3-methylisoxazole

Following the procedure of Step 2 of Example 13, the oxime from Step 2 (500 mg, 1.7 mmol) was reacted with iodine (450 mg, 1.7 mmol) and potassium iodide (1 g, 6 mmol) in the presence of sodium bicarbonate (600 mg, 7 mmol) in tetrahydrofuran (10 mL) and water (10 mL). The crude material was chromatographed on silica gel using toluene as the eluent. The material isolated was recrystallized from ethyl acetate and hexane to give the desired isoxazole (460 mg, 96%): mp 88-90 °C. Anal. Calc'd. for C₁₇H₁₅NOS (281.38): C, 72.57; H, 5.37; N, 4.98; S, 11.40. Found: C, 72.19; H, 5.49; N, 4.66; S, 11.79.

Step 4. Preparation of 3-methyl-5-(4-methylsulfonylphenyl)-4-phenylisoxazole

To a solution of the isoxazole from Step 3 (450 mg, 1.6 mmol) in tetrahydrofuran (6 mL) and methanol (12 mL), was added dropwise a solution of Oxone® (1.6 g) in water (6 mL) at room temperature. The reaction was stirred for 2 hours, diluted with water and filtered. The crude product was recrystallized from ethyl acetate and hexane to give pure sulfone (475 mg, 95%): mp 183-185 °C. Anal. Calc'd. for C₁₇H₁₅NO₃S (313.38): C, 65.16; H, 4.82; N, 4.47; S, 10.23. Found: C, 65.06; 4.93; N, 4.31; S, 10.37.

EXAMPLE 23



30

4-[3-Methyl-4-phenylisoxazol-5-yl]benzenesulfonamide

Step 1. Preparation of 3-(4-trimethylsilylethylsulfonylphenyl)-4-phenyl-5-methylisoxazole

Lithium diisopropylamide was prepared in

5 tetrahydrofuran (15 mL) from diisopropylamine (850 mg, 8.4 mmol) and n-butyllithium (4.2 mL of 1.84 M in THF, 7.7 mmol) at -70 °C under argon. A solution of 5-(4-methylsulfonylphenyl)-4-phenyl-3-methylisoxazole from Example 22 (2.0 g, 6.4 mmol) in tetrahydrofuran (15 mL)

10 was added at -70 °C over 10 minutes and stirred for an additional 45 minutes. A solution of trimethylsilyliodomethane (2.0 g, 9.6 mmol) in tetrahydrofuran (10 mL) was added cold over 10 minutes, stirred for 15 minutes and warmed to 25 °C. After

15 stirring for 24 hours, water was added and the mixture was extracted with ethyl acetate. The organic extracts were dried over magnesium sulfate. After filtration and concentration, the crude silyl ether was purified with silica gel chromatography using mixtures of ethyl acetate and toluene to give 2.0 g of desired compound.

20 This material was used without further purification.

Step 2. Preparation of 4-[3-methyl-4-phenylisoxazol-5-yl]benzenesulfonamide

25 A solution of the silyl ether from Step 1 (2.0 g, 5 mmol) and tetra-n-butylammonium fluoride (15 mL of 1 M in tetrahydrofuran, 15 mmol) in tetrahydrofuran (16 mL) was heated to reflux for 2 hours under an argon atmosphere. After cooling to room temperature,


30 a solution of sodium acetate (1.85 g, 22.5 mmoles) in water (10 mL) was added, followed by hydroxylamine-O-sulfonic acid (2.85 g, 25 mmol). The reaction mixture was stirred for 18 hours at room temperature. Water and ethyl acetate were added and the organic phase was

35 separated and dried over magnesium sulfate. The dried solution was filtered and concentrated in vacuo. The crude product was chromatographed using mixtures of

ethyl acetate and toluene as eluents. The chromatographed product was recrystallized from ethyl acetate and hexane to give the desired sulfonamide (1.0 g, 64%): mp 187-188 °C. Anal. Calc'd. for 5 C₁₆H₁₄N₂O₃S (314.36): C, 61.13; H, 4.49; N, 8.91; S, 10.20. Found: C, 61.19; H, 4.57; N, 8.82; S, 10.23.

EXAMPLE 24

10



4-[3-Methyl-5-(3-chlorophenyl)isoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 4-(3-chlorophenyl)-3-phenyl-3-butene-2-one

Following the procedure of Example 19, step 1, phenylacetone (5 g, 37 mmol) was reacted with 3-chlorobenzaldehyde (5.25 g, 37 mmol) in the presence of piperidine (125 mg) in benzene (30 mL). The crude 20 ketone was recrystallized from ethyl acetate and hexane to give the desired ketone (5.5 g, 57%): mp 91-92 °C. Anal. Calc'd. for C₁₆H₁₃ClO (256.73): C, 74.85; H, 5.10. Found: C, 74.67; H, 5.19.

Step 2. Preparation of 4-(3-chlorophenyl)-3-phenyl-3-butene-2-one oxime

Following the procedure of Example 22, Step 2, a solution of the ketone from Step 1 (5.5 g, 20 mmol), hydroxylamine hydrochloride (1.5 g, 20 mmol) and 30 sodium acetate (1.7 g, 20 mmol) in ethanol and water was heated to reflux. The crude oxime was recrystallized from ethanol and water to give pure oxime (5 g, 89%): mp 161-163 °C. Anal. Calc'd. for

C₁₆H₁₄ClNO (271.75): C, 70.72; H, 5.19; N, 5.15.
 Found: C, 70.55; H, 5.25; N, 5.09.

Step 3. Preparation of 5-(3-chlorophenyl)-4-phenyl-3-methylisoxazole


Following the procedure of Step 2 of Example 13, the oxime from Step 2 (5 g, 18 mmol) was reacted with iodine (4.7 g, 18 mmol) and potassium iodide (10.6 g, 63 mmol) in the presence of sodium bicarbonate (6.3 g, 10 74 mmol) in tetrahydrofuran (100 mL) and water (80 mL). The crude isoxazole was recrystallized from ethyl acetate and hexanes to give pure isoxazole (4.8 g, 95%): mp 101-103 °C. Anal. Calc'd. for C₁₆H₁₂ClNO (269.73): C, 71.25; H, 4.48; N, 5.19. Found: C, 15 71.10; H, 4.28; N, 5.00.

Step 4. Preparation of 4-[3-methyl-5-(3-chlorophenyl)isoxazol-4-yl]benzenesulfonamide

Following the procedure of Example 14, Step 4, 20 the isoxazole from Step 3 (2 g, 7.4 mmol) was reacted with chlorosulfonic acid (8 mL) and quenched with ammonium hydroxide. The crude product was recrystallized from ethyl acetate to give pure sulfonamide (220 mg): mp 176-178 °C. Anal. Calc'd. 25 for C₁₆H₁₃ClN₂O₃S (348.81): C, 55.10; H, 3.76; N, 8.03; S, 9.19. Found: C, 54.60; H, 3.63; N, 7.77; S, 9.21.

EXAMPLE 25

30




4-[3-Hydroxymethyl-5-phenylisoxazol-4-yl]benzenesulfonamide

To a cold (-70 °C) solution of 4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide (Example 13) (500 mg, 1.6 mmol) and tetramethylethylenediamine (560 mg, 4.8 mmol) in tetrahydrofuran (15 mL) under an argon atmosphere was added a solution of n-butyllithium (2.6 mL of 1.84 M in hexane, 4.8 mmol). The mixture was warmed to -30 °C for 5 minutes and re-cooled to -70 °C. A solution of (1R)-(-)-(10-camphorsulfonyl)oxaziridine (1 g, 4.5 mmol) in tetrahydrofuran (5 mL) was added. After stirring at -70 °C for 10 minutes, the reaction was warmed to room temperature. The reaction was poured into water and extracted with ethyl acetate. The organic extracts were dried over magnesium sulfate, filtered and concentrated. The crude product was chromatographed on silica gel using mixtures of acetone and hexane as eluents. The chromatographed product was recrystallized from ethyl acetate and hexane to give 90 mg of desired alcohol: mp 198-200 °C. Anal. Calc'd. for C₁₆H₁₄N₂O₄S (330.36): C, 58.17; H, 4.27; N, 8.48; S, 9.71. Found: C, 58.18; H, 4.51; N, 8.14; S, 9.58.

EXAMPLE 26

25




4-(4-Aminosulfonylphenyl)-5-phenyl-isoxazole-3-acetic acid

To a cold (-70 °C) solution of 4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide, Example 13 (500 mg, 1.6 mmoles) and tetramethylethylenediamine (5 mL) in tetrahydrofuran (15 mL) under an argon atmosphere

was added a solution of n-butyllithium (2.6 mL of 1.84 M in hexane, 4.8 mmol) over 5 minutes. The reaction was warmed to -30 °C for 5 minutes and recooled to -70 °C. Carbon dioxide was bubbled into the mixture for 10 minutes and the temperature was warmed to 25 °C. The reaction was poured into 1M hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and concentrated. The crude product was chromatographed on silica gel using mixtures of ethyl acetate and toluene containing 1% acetic acid as eluents to give 45 mg of desired carboxylic acid as a glass. Anal. Calc'd. for C₁₇H₁₄N₂O₅S (358.37): C, 56.98; H, 3.94; N, 7.82; S, 8.95. Found: C, 56.65; H, 4.09; N, 7.61; S, 9.11.

15

EXAMPLE 27



20 **3-Methyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole**

Step 1. Preparation of 4-phenyl-3-(4-methylthiophenyl)-3-butene-2-one

4-Methylthiophenylacetone was synthesized
25 according to the procedure by G. Y. Lesher described in U. S. Patent 4,517,192, Jan. 31, 1983. Following the procedure of Example 19 (Step 1), 4-methylthiophenylacetone (11.2 g, 62 mmol) was reacted with benzaldehyde (6.6 g, 62 mmol) in the presence of
30 piperidine (150 mg) in benzene (75 mL). The crude material was chromatographed using mixtures of ethyl acetate and hexane as eluents to give the desired ketone as a crystalline solid (14 g, 82%): mp 91-93 °C.

Anal. Calc'd. for C₁₇H₁₆OS (268.38): C, 76.08; H, 6.01; S, 11.95. Found: C, 76.15; H, 6.08; S, 11.79.

Step 2. Preparation of 3-methyl-4-(4-


methylsulfonylphenyl)-5-phenylisoxazole

By substituting 4-phenyl-3-(4-methylthiophenyl)-3-butene-2-one for 4-(4-methylthiophenyl)-3-phenyl-3-butene-2-one in the method of Example 22, the titled product was obtained (250 mg, 79%): mp 144-145 °C.

Anal. Calc'd. for C₁₇H₁₅NO₃S (313.38): C, 65.16; H, 4.82; N, 4.47; S, 10.23. Found: C, 65.26; H, 4.78; N, 3.99; S, 10.22.

EXAMPLE 28

15




4-[3-[(4-Chlorophenyl)-2-hydroxyethyl]-5-phenylisoxazol-4-yl]benzenesulfonamide

To a cold (-70 °C) solution of 4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide (Example 13) (250 mg, 0.8 mmol) and tetramethylethylenediamine (277 mg, 2.4 mmol) in tetrahydrofuran (5 mL) under an argon atmosphere was added n-butyllithium (1.3 mL of 1.84 M in hexane, 2.4 mmol). The solution was warmed to -40 °C for 15 minutes, re-cooled to -70 °C, and a solution of 4-chlorobenzaldehyde (337 mg, 2.4 mmol) in tetrahydrofuran (3 mL) was added. The mixture was warmed to room temperature over 30 minutes, poured into water (25 mL) and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate. The crude product was chromatographed on silica gel using

mixtures of acetone and hexane as eluents to give 165 mg of desired product as a crystalline solid: mp 165-167 °C. Anal. Calc'd. for C₂₃H₁₉ClN₂O₄S(454.93): C, 60.72; H, 4.21; N, 6.16; S, 7.05. Found: C, 60.33; H, 5 4.34; N, 5.87; S, 6.74.

EXAMPLE 29



10

3-Ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole

Step 1. Preparation of N-methoxy-N-methyl-4-(methylthio)benzensulfonamide

15 To a solution of 4-(methylthio)phenylacetic acid (18.3 g, 0.100 mol) in methylene chloride (200 mL) was added 1,1'-carbonyldiimidazole (16.3 g, 0.100 mol) portionwise. The mixture was stirred at room temperature for 20 minutes, and *N*,*O*-
20 dimethylhydroxylamine hydrochloride (9.8 g, 0.100 mol) was added. The reaction mixture was stirred overnight at room temperature, diluted with ether (500 mL) and washed successively with 1N hydrochloric acid, saturated aqueous sodium bicarbonate and brine. The 25 organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated in vacuo to give 20.9 g of N-methoxy-N-methyl-4-(methylthio)-benzensulfonamide as a clear oil (93%).

30 Step 2. Preparation of 1-(4-methylthiophenyl)-2-butanone

To a solution of ethyl magnesium bromide (29 mL of 1.0 M tetrahydrofuran solution, 0.029 mol) was

rapidly added a solution of N-methoxy-N-methyl-4-(methylthio)benzenesulfonamide from Step 1 (2.15 g, 9.5 mmol) in 10 mL of dry tetrahydrofuran at -10°C. The reaction mixture was stirred at -10°C for 10 minutes, 5 then warmed to room temperature over 1 hour. The reaction was quenched with 100 mL of 5% potassium bisulfate and extracted with methylene chloride. The organic layer was washed with water, brine, dried over magnesium sulfate and filtered. The filtrate was 10 concentrated to give the butanone (1.4 g, 76%) as a colorless oil which crystallized upon standing: mp 39-41 °C. Anal. Calc'd. for C₁₁H₁₄OS: C, 68.00; H, 7.26; S, 16.50. Found: C, 68.10; H, 7.38; S, 16.27.

15 Step 3. Preparation of 2-(4-methylthiophenyl)-1-phenyl-1-pentene-3-one

A mixture of 1-(4-methylthiophenyl)-2-butanone from Step 2 (9.74 g; 50 mmol), benzaldehyde (5.85 g, 55 mmol) and piperidine (0.5 mL) in toluene (200 mL) 20 was heated at reflux with a Dean-Stark trap for 16 hours. The mixture was cooled and solvent was removed *in vacuo*. The residue was partitioned between dichloromethane and water. The organic layer was washed successively with saturated ammonium chloride 25 solution, water and brine, dried over magnesium sulfate and filtered. The crude pentenone was recrystallized from ethyl acetate and hexane to give 8.64 g of 2-(4-methylthiophenyl)-1-phenyl-1-pentene-3-one (60%) as light yellow crystals: mp 98-99 °C. 30 Anal. Calc'd. for C₁₈H₁₈OS: C, 76.56; H, 6.42; N, 11.35. Found: C, 76.58; H, 6.17; N, 11.35.

Step 4. Preparation of 2-(4-methylthiophenyl)-1-phenyl-1-pentene-3-one oxime

35 To a suspension of pentenone from Step 3 (8.6 g, 0.031 mol) in 100 mL of ethanol was added a solution of sodium acetate (2.5 g, 0.031 mol) in 10 mL of

water, followed by hydroxylamine hydrochloride (2.1 g, 0.031 mol). The mixture was heated at reflux for 4 hours. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The 5 organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was recrystallized from ethyl acetate and hexane to give 2.28 g of the oxime (25%) as yellow crystals: mp (DSC) 174-177 °C. Anal. 10 Calc'd. for C₁₈H₁₉NOS: C, 72.69; H, 6.44; N, 4.71; S, 10.78. Found: C, 72.52; H, 6.23; N, 4.58; S, 10.63.

Step 5. Preparation of 3-ethyl-4-(4-methylthiophenyl)-5-phenylisoxazole

15 To a solution of the oxime from Step 4 (2.21 g, 0.0074 mol) in 25 mL of tetrahydrofuran was added a solution of sodium bicarbonate (2.62 g, 0.031 mol) in 20 mL of water, followed by a solution of potassium iodide (4.56 g, 0.028 mol) and iodine (2.07 g, 0.0082 mol) in 30 mL of water. The reaction mixture was heated to reflux for 3 hours. After cooling, the mixture was treated with 100 mL of saturated aqueous potassium bisulfate solution and extracted with ethyl acetate. The organic layer was washed with brine, 20 dried over magnesium sulfate and filtered. The filtrate was concentrated and the residue was purified by chromatography on silica gel (ethyl acetate/hexane, 5:95) to afford 2.1 g (96%) of the isoxazole as a brownish solid: mp (DSC) 85-87 °C. Anal. Calc'd. for 25 C₁₈H₁₇NOS: C, 73.19; H, 5.80; N, 4.74; S, 10.85. 30 Found: C, 73.03; H, 5.49; N, 4.55; S, 10.86.


Step 6. Preparation of 3-ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole

35 To a solution of the isoxazole from Step 5 (1.88 g, 6.4 mmol) in 50 mL of methanol was added a solution of OXONE® (7.82 g, 0.0127 mol) in 35 mL of water.

The mixture was stirred at room temperature for 2 hours, then diluted with 500 mL of water. The precipitate was filtered and purified by chromatography on silica gel (ethyl acetate/acetone, 5 1:1) to give 1.73 g (83%) of 3-ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole as a white solid: mp (DSC) 130-131 °C. Anal. Calc'd. For C₁₈H₁₇NO₃S: C, 66.03, H, 5.23, N, 4.28, S, 9.79. Found: C, 66.07, H, 5.20, N, 4.28, S, 9.85.

10

EXAMPLE 30



15 4-[3-Ethyl-5-(4-fluorophenyl)isoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 3-ethyl-5-(4-fluorophenyl)-4-phenylisoxazole


20 By substituting 4-fluorobenzaldehyde for benzaldehyde, and 1-phenyl-2-butanone for 1-(4-methylthiophenyl)-2-butanone in the method of Example 29 (Steps 3-5), the isoxazole was obtained as a yellow solid (9.5 g, 95%): mp 61-63 °C. Anal. Calc'd. for C₁₇H₁₄FNO: C, 76.39; H, 5.28; N, 5.24. Found: C, 25 75.75; H, 4.98; N, 5.06.

Step 2. Preparation of 4-[3-ethyl-5-(4-fluorophenyl)isoxazol-4-yl]benzenesulfonamide

30 To the isoxazole from Step 1 (4.83 g, 0.018 mol) was added chlorosulfonic acid (20 mL) slowly at 0 °C. The mixture was stirred at this temperature for 30 minutes and 3 hours at room temperature. The reaction mixture was added carefully to a cooled aqueous

solution of ammonia hydroxide over 40 minutes. After stirring for 15 minutes, the mixture was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate and 5 filtered. The filtrate was concentrated and the residue was purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give the sulfonamide as a white solid (3.5 g, 56%): mp (DSC) 171-172°C. Anal. Calc'd. for C₁₇H₁₅FN₂O₃S: C, 58.95; H, 4.36; N, 8.09; 10 S, 9.26. Found: C, 58.75; H, 4.43; N, 7.99; S, 9.42.


EXAMPLE 31



15

4-[3-Ethyl-5-(3-fluorophenyl)isoxazol-4-yl]benzenesulfonamide

By substituting 3-fluorobenzaldehyde for 4-fluorobenzaldehyde in the method of Example 30, the 20 isoxazole was obtained as a yellow solid (0.97 g, 34%): mp (DSC) 152-154 °C. Anal. Calc'd. for C₁₇H₁₅FN₂O₃S: C, 58.95; H, 4.36; N, 8.09; S, 9.26. Found: C, 58.58; H, 4.39; N, 7.88; S, 9.27.


EXAMPLE 32

5 **4-[3-Ethyl-5-(3-methylphenyl)isoxazol-4-yl]benzenesulfonamide**

By substituting 3-methylbenzaldehyde for 4-fluorobenzaldehyde in the method of Example 30, the isoxazole was obtained as a yellow solid (2.45 g, 38%):
 10 mp (DSC) 80-83 °C. Anal. Calc'd. for C₁₈H₁₈N₂O₃S: C, 63.14; H, 5.30; N, 8.18; S, 9.36. Found: C, 62.71; H, 5.25; N, 8.16; S, 9.56.

EXAMPLE 33


15



15 **4-[3-Ethyl-5-(2-fluorophenyl)isoxazol-4-yl]benzenesulfonamide**

20 By substituting 2-fluorobenzaldehyde for 4-fluorobenzaldehyde in the method of Example 30, the isoxazole was obtained as a yellow solid (1.25 g, 34%): mp (DSC) 150-151 °C. Anal. Calc'd. for C₁₇H₁₅FN₂O₃S: C, 58.95; H, 4.36; N, 8.09; S, 9.26.
 25 Found: C, 58.88; H, 4.48; N, 8.01; S, 9.52.

Example 34



5 [4-[(4-aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid

Step 1. Preparation of 2-[4-aminosulfonylphenyl]-1-phenyl-ethan-1-one.

Chlorosulfonic acid (1781 g, 1018 mL, 15.29 mol)
 10 was treated portionwise with deoxybenzoin (400 g, 2.04 mol) at such a rate that the internal temperature was maintained between 5 and 15 °C. The mixture was warmed to room temperature and maintained at that temperature for an additional 14 hours. The mixture
 15 was poured cautiously into ice water. The crude sulfonyl chloride was filtered and added portionwise to a solution of acetone (600 mL) and concentrated NH₄OH (551 mL, 8.15 mol), yielding a pale yellow suspension. The crude precipitate was collected by
 20 vacuum filtration, and triturated with boiling acetone (1.5 L). Filtration afforded 2-[4-aminosulfonylphenyl]-1-phenyl-ethan-1-one (162 g, 29%) as an off-white powder. ¹H NMR (DMSO-d₆, 300 MHz)
 25 8.05 (d, J = 7.25 Hz, 2H), 7.76 (d, J = 8.26 Hz, 2H),
 7.65 (t, J = 7.85 Hz, 1H), 7.54 (t, J = 7.85 Hz, 2H),
 7.44 (d, J = 8.26, 2H), 7.30 (br s, 2H), 4.52 (s, 2H).

Step 2. Preparation of 2,5-dimethyl-1-[4-(2-oxo-2-phenylethyl)phenylsulfonyl]-1H-pyrrole.

30 Thionyl chloride (25 mL, 0.34 mol) was added dropwise to ethanol (540 mL). The reaction was heated to reflux for 15 minutes and cooled. The solution was treated with 2-[4-aminosulfonylphenyl]-1-phenyl-ethan-

1-one from Step 1 (20.0 g, 72.64 mmol) and acetonylacetone (12.8 mL, 108.96 mmol), and reheated to reflux for 30 minutes. After cooling to room temperature, the solution was poured into rapidly stirred saturated aqueous Na_2CO_3 and ice (1500 mL).
5 The aqueous phase was extracted with ethyl acetate (2 X 700 mL). The combined organics were washed with brine, dried over MgSO_4 , filtered and concentrated in vacuo, yielding a brown oil. The oil was diluted with ethyl acetate (200 mL) and hexane (2000 mL), dried with MgSO_4 , gravity filtered, then purified through a short silica gel column with hexane and ethyl acetate (1:1) as eluant. The material was concentrated in vacuo and crystallized from hexane/ethyl acetate. The 10 solid was isolated by filtration and air dried to afford 2,5-dimethyl-1-[(4-(2-oxo-2-phenylethyl)phenyl)sulfonyl]-1H-pyrrole (12.2 g, 49%) as a brown solid: mp 94.6-98.8 °C. ^1H NMR (DMSO-d_6 /300 MHz) 8.05 (d, J = 7.25 Hz, 2H), 7.76 (d, J = 15 8.26 Hz, 2H), 7.65 (t, J = 7.85 Hz, 1H), 7.54 (t, J = 7.85 Hz, 1H), 7.44 (d, J = 8.26 Hz, 2H), 7.30 (br s, 2H), 4.52 (s, 2H). Mass spectrum: M+H obs. at m/z = 354.

25 Step 3. Preparation of 2-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-1-phenyl-ethan-1-one oxime.

2,5-Dimethyl-1-[(4-(2-oxo-2-phenylethyl)phenyl)sulfonyl]-1H-pyrrole from Step 2 (15.87 g, 46.48 mmol), hydroxylamine hydrochloride (6.46 g, 92.96 mmol) and sodium acetate (7.63 g, 92.96 mmol) were mixed and heated to reflux for 14 hours. Heating was discontinued and the solution was gravity filtered while still hot. The filtrate was diluted with water (10 mL) and material crystallized. The 30 oxime was isolated by filtration to give 2-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-1-phenyl-ethan-1-one oxime, as a fluffy tan solid (13.65 g, 80%): mp 123.2-125.7 °C. ^1H NMR (CDCl_3 /300 MHz) 7.73 (br s, 1H),

7.64-7.50 (m, 4H), 7.39-7.32 (m, 5H), 5.84 (s, 2H), 4.23 (s, 2 H), 2.36 (s, 6H). Anal. Calc'd for C₂₀H₂₀N₂O₃S · 3.66% H₂O: C, 62.81; H, 5.68; N, 7.32. Found: C, 62.78; H, 5.25; N, 7.25.

5

Step 4. Preparation of [4-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid.


A stirred, chilled (0 °C) solution of
10 diisopropylamine (4.64 mL, 35.42 mmol) in THF (20 mL) was treated with n-butyllithium (6.20 mL of 10.0 M in hexanes, 35.42 mmol) via syringe over 5 minutes. The solution was stirred at 0 °C for 15 minutes, yielding a ca. 1.8 M solution of LDA in THF and hexanes. A
15 chilled (-78 °C), solution of 2-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-1-phenyl-ethan-1-one oxime from Step 3 (3.97 g, 10.77 mmol) in THF (40 mL) was treated with the LDA stock solution (15.0 mL, 27.0 mmol) via syringe. The reaction was stirred at -78 °C
20 for 20 minutes, warmed to -5 °C, then chilled to -78 °C again. To this dark solution was added 3-methyl glutaric anhydride (2.07 g, 16.16 mmol). The cooling bath was removed, and the reaction was warmed to room temperature for 2 hours. Saturated NH₄Cl and
25 concentrated HCl were added until pH <2 was obtained. The reaction was extracted with ethyl acetate. The combined organic phases were washed with KHSO₄ solution (0.25 M) and brine, dried over MgSO₄, filtered and concentrated. The crude material was
30 purified by flash chromatography (hexane/ethyl acetate (1:1) with 2% acetic acid), yielding [4-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid as a brown foam (2.40 g) which was utilized without further purification.

35

Step 5. Preparation of [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid

The [4-[4-[2,5-dimethylpyrrol]-sulfonyl]phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid from Step 4 was dissolved in trifluoroacetic acid (20 mL) and water (7 mL) and 5 heated to reflux for 6 hours. The reaction was cooled to room temperature, concentrated under high vacuum, diluted with ethanol and concentrated *in vacuo*, yielding a black oil. The crude material was dissolved in NaHCO₃ solution (pH adjusted to 12 with 1 10 N NaOH solution) and washed with ether. The resulting aqueous phase was acidified to pH 2 with concentrated HCl, and extracted with dichloromethane/ethyl acetate (1:1). The combined organic phases were dried over MgSO₄, filtered and concentrated *in vacuo*, yielding a 15 dark brown oil. This crude material was partially purified by passing through a plug of silica gel using hexane/ethyl acetate (1:1) with 2% acetic acid as eluant, yielding a clear oil. Trituration of the oil with dichloromethane yielded, upon collection by 20 vacuum filtration, [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-methylbutan-1-oic acid (0.219 g, 5%) as an off-white solid: mp 147.9-149.0 °C. ¹H NMR (CDCl₃ with DMSO-d₆/300 MHz) δ 7.80 (d, J = 8.46 Hz, 2H), 7.30-7.14 (m, 9H), 6.35 (s, 2H), 2.88-2.55 25 (m, 2H), 2.40-2.20 (m, 2H), 2.09-2.04 (m, 1H), 0.90 (d, J = 6.85 Hz, 3H). Mass spectrum M+H obs at m/z 401. High resolution mass spectrum calc'd. 401.1171. Found: 401.1174.

EXAMPLE 35



[[4-[4-(Aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-methoxy]acetic acid

Step 1. Preparation of 5-[4-[4-[N-[2,5-dimethylpyrrol-sulfonyl]phenyl]-3-phenylisoxazol-5-yl]-methoxy]acetic acid.

A solution of 2,5-dimethyl-1-[(4-(2-oximino-2-phenylethyl)phenyl)sulfonyl]-1H-pyrrole (Example 34, Step 3) (5.19 g, 14.09 mmol) in tetrahydrofuran (90 mL) was chilled to -78 °C and treated with LDA (22.0 mL, 30.99 mmol in THF) via syringe. After stirring for 30 minutes, the dry ice bath was removed and the reaction was warmed to 0 °C over 40 minutes. The solution was chilled to -78 °C and diglycolic acid anhydride (1.80g, 15.50 mmol) in THF (10 mL) was added via syringe. The reaction was warmed to room temperature and stirred for 2 hours. The reaction was quenched with saturated NH₄Cl solution and concentrated HCl was added to pH 1. The layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo, yielding a dark brown oil. This oil was purified by flash chromatography using hexane/ethyl acetate (1:1) (with 2% acetic acid) as the eluant, yielding a brown foam (3.035 g, 45%). The brown foam was dissolved in THF (50 mL) and treated with concentrated H₂SO₄ (2 mL). The solution was heated to reflux for 1 hour, cooled to room temperature, poured into ice and extracted with dichloromethane. The combined organic phases were washed with KHSO₄ solution (0.25 M), dried over MgSO₄, filtered and concentrated, yielding 5-[4-[4-[N-[2,5-dimethylpyrrol-sulfonyl]phenyl]-3-phenylisoxazol-5-yl]-methoxy]acetic acid as a brown foam (2.28 g, 35%). ¹H NMR (CDCl₃/300 MHz) 7.66 (d, J = 8.57 Hz, 2H), 7.47-7.35 (m, 7 H), 5.88 (s, 2H), 4.71 (s, 2H), 4.26 (s, 2 H), 2.39 (s, 6H). Mass spectrum M+H obs at


m/z 467. High resolution mass spectrum: calc'd. 467.1277. Found: 467.1268. Anal. Calc'd for C₂₄H₂₂N₂O₆S: C, 61.79; H, 4.75; N, 6.00. Found: C, 62.32; H, 5.07; N, 5.82.

5

Step 2. Preparation of [4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-O-methylglycolic acid.

5-[4-[4-[N-[2,5-Dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]]-methyloxyacetic acid from Step 10 1 (1.097 g, 2.35 mmol) was dissolved in a mixture of TFA (12 mL) and water (4 mL) and heated to 60 °C for 6 hours. The clear brown solution was cooled to room temperature and concentrated under high vacuum, yielding a solid. The solid was dissolved in ethyl acetate, washed with aqueous KHSO₄ solution (0.25 M), and with brine, dried over MgSO₄, filtered, decolorized with carbon, and heated to gentle reflux. The suspension was cooled to room temperature, filtered through diatomaceous earth, and concentrated 20 in vacuo, yielding a brown solid. This solid was dissolved in a minimum of aqueous NaHCO₃ solution and washed with ethyl acetate. The resulting aqueous solution was acidified with concentrated HCl to pH 2, causing the formation of a precipitate. This 25 precipitate was collected by vacuum filtration, yielding 5-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-methyloxy]acetic acid (0.94 g, 100%) as a tan powder: mp 186.7-191.5 °C. ¹H NMR (DMSO-d₆/300 MHz) 13.5-12.0 (br s, 1H), 7.82 (d, J = 8.46 Hz, 2H), 7.50 - 7.33 (m 9 H), 4.68 (s, 2H), 4.13 (s, 2H). Mass spectrum (M+H obs at m/z 389). High resolution mass spectrum calc'd.: 388.0729. Found: 388.0722. Anal. Calc'd. for C₁₈H₁₆N₂O₆S 0.94% H₂O: C, 55.14; H, 4.22; N, 7.14. Found: C, 55.16; H, 4.06; N, 35 6.83.

EXAMPLE 36



4-[4-[4-(Aminosulfonyl)phenyl]]-3-phenylisoxazol-5-
5 yl]butanoic acid

Step 1. Preparation of 4-[4-[4-[N-[2,5-dimethylpyrroll-sulfonyl]phenyl]3-phenylisoxazol-5-yl]butan-1-oic acid.


10 A solution of 2,5-dimethyl-1-[(4-(2-oximino-2-phenylethyl)phenyl)sulfonyl]-1H-pyrrole (Example 34, Step 3) (6.21 g, 16.85 mmol) in THF (100 mL) was chilled (-78 °C) and treated with n-butyllithium (23.17 mL, 37.08 mmol) via syringe. The reaction was
15 warmed to 0 °C, cooled back to -40 °C, and treated with a solution of one equivalent of glutaric anhydride in THF (5 mL). The solution was warmed to room temperature and maintained at this temperature for 2 hours. The crude reaction was quenched with
20 saturated NH₄Cl and concentrated HCl was added until the pH was 2. The resulting mixture was extracted with ethyl acetate and the combined organic phases were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*, yielding a brown oil. A
25 solution of the brown oil (3.10 g) in THF (50 mL) was treated with concentrated H₂SO₄ (2 mL) and heated to reflux for 2 hours. The reaction was cooled to room temperature, diluted with brine and the layers separated. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined. The
30 combined phases were washed with water until the washes were pH 5 or higher. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*,

yielding a brown oil. This oil was purified by flash chromatography using hexane/ethyl acetate (3:1) (with 22% acetic acid), yielding the 4-[4-[4-[N-[2,5-dimethylpyrrol]-sulfonyl]phenyl]]-3-phenylisoxazol-5-yl]butan-1-oic acid (1.327 g, 17% based upon oxime) as a tan foam, which was suitable for use without further purification. ^1H NMR ($\text{CDCl}_3/300$ MHz) 7.65 (d, $J = 8.66$ Hz, 2H), 7.43-7.25 (m, 7 H), 5.88 (s, 2H), 2.88 (t, $J = 8.4$ Hz, 2H), 2.48-2.37 (m, 8 H), 2.18-2.02 (m, 2H).

Step 2. Preparation of 4-[4-[4-(aminosulfonyl)phenyl]]-3-phenylisoxazol-5-yl]butanoic acid.

4-[4-[4-[N-[2,5-Dimethylpyrrol]-sulfonyl]phenyl]]-3-phenylisoxazol-5-yl]butan-1-oic acid from Step 1 (1.27 g, 2.734 mmol) was dissolved in TFA (20 mL) and water 6.7 mL), and heated to 72 °C for 7 hours. The reaction was concentrated under high vacuum using toluene to chase trace TFA. The crude product was dissolved in a minimum of aqueous NaHCO_3 and washed with ether. The resulting aqueous phase was acidified with concentrated HCl, yielding a precipitate that was isolated by filtration to afford 4-[4-[4-(aminosulfonyl)phenyl]]-3-phenylisoxazol-5-yl]butan-1-oic acid (0.756 g, 72%) as a powder: mp 203.8-206.9 °C. ^1H NMR ($\text{DMSO-d}_6/300$ MHz) 12.13 (br s, 1H), 7.82 (d, $J = 8.46$ Hz, 2H), 7.50-7.25 (m, 9 H), 2.82 (t, $J = 7.45$ Hz, 2H), 2.28 (t, $J = 7.25$ Hz, 2H), 1.95-1.75 (m, 2H). Anal. Calc'd. for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_5\text{S}$: C, 59.06; H, 4.70; N, 7.25. Found: C, 59.10; H, 4.78; N, 7.18.

EXAMPLE 37



4-[5-Cyano-3-phenylisoxazol-4-yl]benzenesulfonamide

5

Step 1. Preparation of [4-[4-[N-2,5-dimethylpyrrolsulfonyl]phenyl-3-phenylisoxazol-5-yl]carboxylic acid.

To a chilled (-78 °C), stirred solution of 2,5-dimethyl-1-[(4-(2-oximino-2-phenylethyl)phenyl)sulfonyl]-1H-pyrrole (Example 34, Step 3) (6.41 g, 17.40 mmol) in THF (100 mL) was added freshly prepared LDA in THF/hexane [made from n-butyllithium (3.8 mL, 10.0 M in hexanes and diisopropylamine (5.02 mL, 38.27 mmol) in THF (25 mL)]. The resulting dark solution was stirred at -78 °C for 30 minutes, warmed to 0 °C over 40 minutes and chilled to about -25 °C. Dimethyl oxalate (2.88 g, 24.36 mmol) in THF (5 mL) was added via syringe. The resulting solution was warmed to room temperature and stirred for 2 hours. The reaction was quenched with saturated NH₄Cl solution, followed by the addition of sufficient concentrated HCl to adjust the pH to 2. The layers were separated and the aqueous phase was extracted with ethyl acetate. The organic layers were combined and washed with KHSO₄ (0.25 M aqueous solution) and brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting crude material was purified by passage through a silica plug using ethyl acetate as the eluant. Upon concentration in vacuo, [4-[4-[N-2,5-dimethylpyrrolsulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxylic acid was obtained as a brown foam (6.021 g) and was of sufficient purity to

be used without further purification. Mass spectrum: M+H obs. at m/z 423. Anal. Calc'd for C₂₂H₁₈N₂O₅S · 0.55% H₂O: C, 62.20; H, 4.33; N, 6.59. Found: C, 62.28; H, 4.78; N, 6.32.

5

Step 2. Preparation of methyl [4-[4-[N-2,5-dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxylate,

[4-[4-[N-2,5-Dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxylic acid from Step 1 (4.99 g) was dissolved in TFA (75 mL) and water (25 mL) and heated to 50 °C for 11 hours. The reaction was cooled to room temperature and concentrated under high vacuum to yield a brown solid. A portion of the solid (3.75 g) was added to a freshly prepared solution of SOCl₂ (13 mL) in methanol (250 mL). The reaction was heated to reflux for 2 hours, cooled to room temperature and concentrated in vacuo, yielding a black solid. This crude material was purified by flash chromatography using hexane/ethyl acetate (2:1 gradient to 1:1 ratio), yielding methyl [4-[4-[N-2,5-dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxylate (1.30 g, 25%) as a green oil, and was sufficiently pure to be used without further purification. ¹H NMR (CDCl₃/300 MHz) 7.65 (d, J = 8.46 Hz, 2H), 7.42 (d, J = 8.46 Hz, 3H), 7.38-7.26 (m, 4H), 5.88 (s, 2H), 3.90 (s, 3H), 2.39 (s, 6 H).

Step 3. Preparation of [4-[4-[N-2,5-dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide

Ammonia gas was added to a solution of methyl [4-[4-[N-2,5-dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxylate from Step 2 (1.25 g, 2.86 mmol) in THF (5 mL) and EtOH (10 mL) at 5 °C for 20 minutes. The vessel was sealed and stirred at room temperature for 60 hours (pressure was 23 psi). The reaction was carefully vented and concentrated in

vacuo, and the crude material was crystallized from ethyl acetate/isooctane and collected by vacuum filtration, yielding [4-[4-[N-2,5-dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide (96 mg, 80%) as a tan powder: mp 196 °C (dec). ^1H NMR (DMSO-d₆/300 MHz) 8.44 (br s, 1H), 8.04 (br s, 1H), 7.71 (d, J = 8.46 Hz, 2H), 7.51 (d, J = 8.46 Hz, 2H), 7.49-7.41 (m, 1H), 7.37 (t, J = 7.65 Hz, 2H), 7.22 (d, J = 8.46, 2H), 5.96 (s, 2H), 2.30 (s, 6H).

Step 4. Preparation of [4-[4-aminosulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide.

[4-[4-[N-2,5-Dimethylpyrrol]sulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide from Step 3 (0.692 g, 1.64 mmol) was dissolved in TFA (15 mL) and water (5 mL) and the solution was heated to 81 °C for 6 hours. The solution was cooled to room temperature and concentrated under high vacuum to yield a brown solid. This solid was triturated with ethyl acetate and the solid was collected by vacuum filtration, yielding [4-[4-aminosulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide (0.388 g, 69%) as a gray powder: mp 263.7-278.6 °C. ^1H NMR (DMSO-d₆/300 MHz) 8.40 (br s, 1H), 8.03 (s, 1H), 7.77 (d, J = 8.26 Hz, 2H), 7.45-7.28 (m, 9H).


Step 5. Preparation of 4-[5-cyano-3-phenylisoxazol-4-yl]benzenesulfonamide.

A stirred suspension of [4-[4-aminosulfonyl]phenyl]-3-phenylisoxazol-5-yl]carboxamide from Step 4 (0.307 g, 0.894 mmol) in POCl₃ (5 mL) was heated to 105 °C for 5 hours. The reaction was cooled to room temperature and concentrated under high vacuum. Toluene was added and the mixture was reconcentrated. The resulting solid was passed through a silica plug using ethyl acetate as eluant. The eluant was washed with NaHCO₃.

solution, KHSO_4 solution, and with brine, dried over MgSO_4 , filtered and concentrated *in vacuo*, yielding 4-[5-cyano-3-phenylisoxazol-4-yl]benzenesulfonamide as a tan powder (0.204 g, 70%): mp 218.0-219.4 °C. ^1H NMR (DMSO- d_6 /300 MHz) 7.93 (d, J = 8.26, 2 H), 7.61 (d, J = 8.26, 2H), 7.57-7.40 (m, 7H). Anal. Calc'd. for $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}_3\text{S}$: C, 59.07; H, 3.41; N, 12.92. Found: C, 59.01; H, 3.65; N, 12.44.

10

Example 38




4-[5-Chloro-3-phenylisoxazol-4-yl]benzenesulfonamide

15 Phosphorus oxychloride (15 mL) was added to a mixture of 4-[5-hydroxy-3-phenylisoxazol-5-yl]benzenesulfonamide (Example 12) (1.117 g, 3.53 mmol) and triethylamine (0.73 mL, 0.53 g, 5.30 mmol), and heated to 70 °C for 5 hours. After cooling to 20 room temperature, the reaction was concentrated *in vacuo*. Toluene was added and the resulting solution was concentrated *in vacuo*, yielding a brown oil. The oil was dissolved in ethyl acetate (50 mL) and washed with 1 N HCl solution and with brine, dried over MgSO_4 , filtered and concentrated *in vacuo*, yielding 4-[5-chloro-3-phenylisoxazol-4-yl]benzenesulfonamide as a brown solid (0.943 g, 84%): mp 186.1-187.4 °C. ^1H NMR (CDCl_3 with CD_3CN) 7.85 (d, J = 8.46 Hz, 2H), 7.40-7.25 (m, 9H). Mass spectrum $\text{M}+\text{H}$ obs at m/z 335.

25 30 High resolution mass spectrum calc'd. for $\text{C}_{15}\text{H}_{12}\text{ClN}_2\text{O}_3\text{S}$ ($\text{M}+\text{H}$): 335.0274. Found: 335.0271.

Example 39




4-[5-Trifluoromethansulfonyloxy-3-phenylisoxazol-4-yl]benzenesulfonamide

5

A suspension of 4-[5-hydroxy-3-phenylisoxazol-4-yl] benzenesulfonamide (Example 12) (0.275 g, 0.869 mmol), pyridine (0.077 mL, 0.076 g, 0.956 mmol), and DMAP (0.011 g, 0.087 mmol) in dichloromethane was 10 chilled to -78 °C, and treated via syringe with trifluoromethanesulfonic anhydride (0.160 mL, 0.270 g, 0.956 mmol). The reaction was stirred for 1 hour at -78 °C, and for 3 hours at room temperature. The resulting mixture was washed with NaHCO₃ solution, and 15 with aqueous KHSO₄, dried over MgSO₄, filtered and concentrated *in vacuo*, yielding a tan semi-solid. This material was purified by flash chromatography, yielding 4-[5-trifluoromethansulfonyloxy-3-phenylisoxazol-4-yl]benzenesulfonamide (0.123 g, 32%) 20 as a white crystalline solid: mp 129.9-135.3 °C. ¹H NMR (DMSO-d₆) 7.70 (d, J = 8.26 Hz, 2H), 7.65-7.35 (m, 7 H), 7.31 (br s, 2H). ¹⁹F NMR (DMSO-d₆) 74.19. Mass spectrum m+H obs at m/z 449. High resolution mass spectrum calc'd. for C₁₆H₁₂F₃N₂O₆S₂ (M+H): 25 449.0089. Found: 449.0084.

Example 40



5 [5-Methyl-3-(4-methylthiophenyl)isoxazol-4-yl]-4-pyridine

Step 1. Preparation of 1-(4-thiomethylphenyl)-2-(4-pyridyl)-ethan-1-one.

Methyl 4-(methylthio)benzoate (8.77 g, 48 mmol), 10 4-picoline (4.47 g, 48 mmol), and dimethoxy ethyl ether (150 mL) were stirred at room temperature, and sodium hydride (60% in glycerine) (5.76 g, 144 mmol) was added. The mixture was heated to reflux for 72 hours, poured into ice water, and extracted with ethyl 15 acetate (3 X 100 mL). The combined organics were washed with water (2 X 50 mL) and dried over MgSO_4 . Hexanes were slowly added until a yellow solid precipitated which was collected by filtration (4.1 g, 35%). ^1H NMR (DMSO-d_6 /300 MHz) 8.5 (d, $J=4.4$ Hz, 2H), 20 7.9 (d, $J=8.5$ Hz, 2H), 7.4 (d, $J=8.3$ Hz, 2H), 7.3 (d, $J=4.4$ Hz, 2H), 4.4 (s, 2H), 2.5 (s, 3H).

Step 2. Preparation of 1-(4-thiomethylphenyl)-2-(4-pyridyl)-ethan-1-one-oxime.

25 1-(4-Thiomethylphenyl)-2-(4-pyridyl)-ethan-1-one from Step 1 (3.0 g, 12 mmol) and hydroxylamine hydrochloride (0.9 g, 13 mmol) were dissolved in ethanol (150 mL) and heated to reflux overnight. The mixture was cooled, water was added, and the solution 30 was extracted with ethyl acetate (2 X 100 mL). The combined extract was washed with water (2 X 50 mL), dried over MgSO_4 , and concentrated. The material was recrystallized from ethyl acetate/hexanes to afford a

yellow solid (3.1 g) which was used in the next step without further purification or characterization.

Step 3. Preparation of 4-[5-methyl-5-hydroxy-4-(4-pyridyl)isoxazoline-3-yl]thioanisole.


1 - (4-Thiomethylphenyl)-2-(4-pyridyl)-ethan-1-one-oxime from Step 2 (3.0 g, 12 mmol) was dissolved in tetrahydrofuran (150 mL) and cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ ethylbenzene, 13.2 mL, 26.4 mmol) was added dropwise maintaining the temperature below -65 °C. After stirring for 0.5 hour, acetic anhydride (3.68 g, 36 mmol) was added. The reaction mixture was slowly warmed to -30 °C and poured into ice water. The resulting aqueous solution was extracted with ethyl acetate (3 X 50 mL). The combined extract was washed with brine and with water, and dried over MgSO₄. The resulting crude material was used in the next step without further purification or characterization.

Step 4. Preparation of 4-[5-methyl-4-(4-pyridyl)isoxazol-3-yl]thioanisole.

Sulfuric acid (30 mL) was cooled to -78 °C and 4-[5-methyl-5-hydroxy-4-(4-pyridyl)isoxazoline-3-yl]thioanisole from Step 3 (3.2 g, 11 mmol) was added. The cooling bath was removed and the mixture was stirred for 1 hour, and poured into ice water. The mixture was diluted with dichloromethane (50 mL) and treated with solid NaHCO₃ until the mixture was neutral to pH paper. This solution was extracted with dichloromethane (3 X 50 mL). The combined extract was washed with water, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography, eluting with ethyl acetate:hexane (1:1). The appropriate fractions were concentrated and recrystallized from ethyl acetate/hexane to yield a yellow solid (0.4 g, 7.5%): mp 120.6-125.5 °C. ¹H

NMR ($\text{CDCl}_3/300$ MHz) 8.6 (d, $J=5.4$ Hz, 2H), 7.3 (d, $J=8.7$ Hz, 2H), 7.2 (d, $J=8.7$ Hz, 2H), 7.1 (d, $J=6.0$ Hz, 2H), 2.5 (s, 3H). High resolution mass spectrum calc'd. for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{SO}(\text{M}+\text{H})$: 283.0905. Found:
 5 283.0861.

Example 41



10 4-[5-Methyl-4-phenylisoxazol-3-yl]benzenesulfonamide

Step 1. Preparation of 1-(4-bromophenyl)-2-phenylethan-1-one.

4-Bromobenzaldehyde (10.0 g, 54 mmol),
 15 dichloromethane (100 mL), and zinc iodide (5 mg) were stirred at 0 °C under nitrogen and treated with trimethylsilyl cyanide (5.95 g, 60 mmol) dropwise. The reaction was stirred for 16 hours, then water (5 mL) was added dropwise. The mixture was washed with brine (2 X 30 mL), dried over MgSO_4 , and concentrated under high vacuum. The resulting oily residue was dissolved in tetrahydrofuran (150 mL) and cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 30 mL, 60 mmol) was added dropwise, maintaining the temperature below -60 °C. This solution was stirred for 0.5 hour then treated with benzyl bromide (10.26 g, 60 mmol). The solution was warmed to -15 °C and poured into a stirred solution of 1N hydrochloric acid (150 mL) and trifluoroacetic acid (10 mL). After stirring for 1 hour, the mixture was extracted with ethyl acetate (2 X 50 mL). The combined extract was washed with brine

(2 X 50 mL) and concentrated. The resulting dark oily residue was treated with 2.5 N sodium hydroxide, filtered and recrystallized from acetone/ethanol/water to afford a light brown solid (11.5 g, 77%): mp 111.4-5 111.5.

Step 2. Preparation of 1-(4-bromophenyl)-2-phenyl-ethan-1-one oxime.

1-(4-Bromophenyl)-2-phenyl-ethan-1-one from Step 10 1 (10.16 g, 37 mmol), ethanol (100 mL), water (50 mL), hydroxylamine hydrochloride (5.14 g, 74 mmol), and sodium acetate (10.07 g, 74 mmol) were combined and heated to 75 °C for 2 hours. The mixture was added to water (100 mL) and the precipitated oxime was isolated 15 by filtration to afford a yellow solid (7.07 g, 66%): mp 136.5-136.9 °C.

Step 3. Preparation of 4-[5-methyl-4-phenylisoxazol-3-yl]bromobenzene.

20 1-(4-Bromophenyl)-2-phenyl-ethan-1-one oxime from Step 2 (5.8 g, 20 mmol) and tetrahydrofuran (150 mL) were stirred at -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 22 mL, 22 mmol) 25 was added dropwise, maintaining the temperature below -50 °C. The solution was warmed to -30 °C and treated with N-acetyl imidazole (2.42 g, 22 mmol). The mixture was stirred until the temperature reached 0 °C. The solution was then poured into 1 N 30 hydrochloric acid (50 mL), extracted with ethyl acetate (100 mL) and the layers separated. The organic layer was washed with brine (2 X 50 mL), dried over MgSO₄ and concentrated. The resulting mixture was purified by flash column chromatography, eluting 35 with ethyl acetate:hexane (1:4). After the appropriate fractions were concentrated, the material was dissolved in methanol and a crystal of p-toluenesulfonic acid was added. After heating to

reflux for 16 hours, the mixture was concentrated and recrystallized from ethanol/water. A white solid was collected by filtration (3.8 g, 60%): mp 108.1-108.7 °C. ^1H NMR (acetone- d_6 /300 MHz) 7.6 (d, $J=8.4$ Hz, 5 H), 7.4 (m, 5H), 7.3 (m, 2H), 2.4 (s, 3H). Anal. Calc'd. for $\text{C}_{16}\text{H}_{12}\text{BrNO}$: C, 61.17; H, 3.85; N, 4.46. Found: C, 61.07; H, 3.88; N, 4.45.


10 Step 4. Preparation of 4-[5-methyl-4-phenylisoxazol-3-yl]benzenesulfonamide.

4-[5-Methyl-4-phenylisoxazol-3-yl]bromobenzene from Step 3 (1.73 g, 5.5 mmol) and tetrahydrofuran (100 mL) were stirred at -78 °C under nitrogen. Butyllithium (1.6 M in hexanes, 4.1 mL, 6.6 mmol) was added dropwise, maintaining the temperature below -60 °C. After stirring at -78 °C for 0.5 hour, sulfur dioxide gas was passed through a stainless steel needle above the surface of the solution. After 1 minute, the solution changed color from orange to clear, and after 10 minutes pH paper indicated an acidic reaction. Gas addition was ceased and the cooling bath was removed. After 1 hour, the mixture was concentrated to 25 mL and hexane (100 mL) was added. A white precipitate formed that was isolated by filtration. This solid was dissolved in water (50 mL) and sodium acetate (4.5 g, 55 mmol), and hydroxylamine-O-sulfonic acid (0.75 g, 6.6 mmol) were added. The resulting mixture was stirred at room temperature overnight and extracted with ethyl acetate (2 X 50 mL). The combined extract was washed with brine, dried over MgSO_4 , and concentrated. A white solid was recrystallized from dichloromethane/hexane (0.8 g, 46%): mp 150.9-152.3 °C. ^1H NMR (acetone- d_6 /300 MHz) 7.9 (d, $J=9.7$ Hz, 2H), 7.6 (d, $J=9.7$ Hz, 2H), 7.4 (m, 3H), 7.3 (m, 2H), 6.7 (bs, 2H), 2.5 (s, 3H). Anal. Calc'd. for $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_3\text{S}$: C, 61.13; H, 4.49; N, 8.91. Found: C, 61.18; H, 4.52; N, 8.85.

High resolution mass spectrum calc'd. (M+H) :
315.0803. Found : 315.0793.

Example 42

5



4-[3-(3,5-Difluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide

10 Step 1. Preparation of 1-(3,5-difluorophenyl)-2-phenyl-ethan-1-one.
 3,5-Difluorobenzaldehyde (10.0 g, 70 mmol), dichloromethane (100 mL) and zinc iodide (5 mg) were stirred at 0 °C under nitrogen. Trimethylsilyl cyanide (7.64 g, 77 mmol) was added dropwise with a slight exotherm. The reaction proceeded for 16 hours, then water (5 mL) was added dropwise. The mixture was washed with brine (2 X 30 mL), dried over MgSO₄, and concentrated under high vacuum. The resulting oily residue was dissolved in tetrahydrofuran (150 mL) and cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 38.5 mL, 77 mmol) was added dropwise, maintaining the temperature below -60 °C. The solution was stirred for 0.5 hour, and benzyl bromide (13.17 g, 77 mmol) was added. The cooling bath was removed and the mixture was stirred until the temperature reached -15 °C when the mixture was poured into a stirred solution of 1N hydrochloric acid (150 mL) and trifluoroacetic acid (10 mL). After stirring for one hour, the mixture was extracted with

ethyl acetate (2 X 50 mL). The combined extract was washed with brine (2 X 50 mL) and concentrated. The resulting dark oily residue was treated with 2.5 N sodium hydroxide and extracted with ether (3 X 50 mL).

5 The combined extract was washed with water and dried over MgSO₄. The solution was concentrated and the residue crystallized from ether/hexane to afford of a yellow solid (15.0 g, 92%). This material was used in the next step without further purification or

10 characterization.

Step 2. Preparation of 1-(3,5-difluorophenyl)-2-phenyl-ethan-1-one oxime.

1-(3,5-Difluorophenyl)-2-phenyl-ethan-1-one from Step 1 (5.00 g, 21.6 mmol), ethanol (110 mL), water (30 mL), hydroxylamine hydrochloride (3.00 g, 43.1 mmol), and sodium acetate (5.87 g, 43.1 mmol) were combined and heated to 75 °C for 2 hours. The mixture was added to water (100 mL), and the material separated and was isolated by filtration to afford a yellow solid (2.1 g, 39%). This material was used in the next step without further purification or characterization.

25 Step 3. Preparation of 3-(3,5-difluorophenyl)-4-phenyl-5-methyl isoxazole.

1-(3,5-Difluorophenyl)-2-phenyl-ethan-1-one oxime from Step 2 (1.9 g, 7.7 mmol) and tetrahydrofuran (100 mL) were stirred at -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 9.5 mL, 19 mmol) was added dropwise, maintaining the temperature below -50 °C. The solution was warmed to -20 °C, N-acetyl imidazole (1.06 g, 9.6 mmol) was added, and the reaction was maintained at -20 °C for an additional hour. The solution was poured into 1 N hydrochloric acid (50 mL), extracted with ethyl acetate (100 mL) and the layers separated. The organic layer was

washed with brine (2 X 50 mL), dried over $MgSO_4$, and concentrated. The resulting mixture was purified by flash column chromatography, eluting with ethyl acetate:hexane (1:4). After the appropriate fractions 5 were concentrated, the material was dissolved in methanol and p-toluenesulfonic acid (10 mg) was added. The solution was heated to reflux for 16 hours, and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated aqueous $NaHCO_3$ 10 and with water, dried over $MgSO_4$ and concentrated to afford a light brown oil (1.3 g, 62%). This material was used without further purification or characterization.


15 Step 4. Preparation of 4-[5-methyl-3-(3,5-difluorophenyl)isoxazol-4-yl]benzenesulfonamide.

Chlorosulfonic acid (40 mL) was cooled to -78 °C and treated dropwise with 3-(3,5-difluorophenyl-4-phenyl-5-methylisoxazole from Step 3 dissolved in a 20 minimum amount of dichloromethane (6 mL). The cooling bath was removed and the mixture was stirred for 6 hours, whereupon the mixture was added dropwise to ice water (500 mL). Ammonium hydroxide (100 mL) and ethyl acetate (100 mL) were added and the mixture was 25 stirred for 16 hours at room temperature. The layers were separated and the organic layer was washed with brine and with water, dried over $MgSO_4$, and concentrated. The product was purified by flash column chromatography, eluting with ethyl acetate:hexane (1:1). The appropriate fractions were 30 concentrated to afford a yellow oil that crystallized upon standing (0.3 g, 21%): mp 58.9-62.2 °C. 1H NMR (acetone-d₆/300 MHz) 8.0 (d, $J=9.3$ Hz, 2H), 7.5 (d, $J=9.3$ Hz, 2H), 7.2 (m, 1H), 7.0 (m, 2H), 6.7 (bs, 2H), 35 2.8 (s, 3H). Anal. Calc'd. for $C_{16}H_{12}F_2N_2O_3S$: C, 53.80; H, 3.60; N, 7.84. Found: C, 53.86; H, 3.72; N, 7.56. High resolution mass spectrum calc'd. (M+H): 351.0615. Found: 351.0626.

7.56. High resolution mass spectrum calc'd. (M+H): 351.0615. Found: 351.0626.

Example 43


5



4-[3-(4-Bromophenyl)-5-methyl-soxazol-4-yl]benzenesulfonamide

10 Chlorosulfonic acid (25 mL) was cooled to -78 °C and then treated with 4-[5-methyl-4-phenylisoxazol-3-yl]bromobenzene (Example 41, Step 3) (1.5 g, 4.8 mmol). The cooling bath was removed and the mixture was stirred for 4 hours, then added dropwise to ice water (500 mL). Ammonium hydroxide (100 mL) and ethyl acetate (100 mL) were added and the mixture was stirred at room temperature for 16 hours. The layers were separated and the organic layer was washed with brine and with water, dried over MgSO₄, and 15 concentrated. The product was crystallized from ethanol/water to yield a white solid (0.6 g, 32%): mp 151.9-153.2 °C. ¹H NMR (acetone-d₆/300 MHz) 7.9 (d, J=8.3 Hz, 2H), 7.6 (d, J= 8.3 Hz, 2H), 7.4 (d, J=8.7 Hz, 2H), 7.3 (d, J=8.7 Hz, 2H), 6.7 (bs, 2H), 2.5 (s, 3H). Anal. Calc'd. for C₁₆H₁₃BrN₂O₃S: C, 48.87; H, 3.33; N, 7.12. Found: C, 48.90; H, 3.37; N, 7.04. High resolution mass spectrum calc'd. (M+H): 392.9909. Found: 392.9887.

Example 44



5 4-[5-Difluoromethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one.

10 Aluminum chloride (42.17 g, 316 mmol) and
dichloromethane (350 mL) were cooled to 2 °C and
phenylacetylchloride (40.50 g, 262 mmol) in
dichloromethane (30 mL) was added. 2-Fluoroanisole
(32.77 g, 260 mmol) in dichloromethane (30 mL) was
added. The cooling bath was removed, and the mixture
15 was stirred for 1 hour. The reaction mixture was
poured into concentrated HCl (150 mL), filtered
through diatomaceous earth, washed with saturated
aqueous NaHCO₃, dried over MgSO₄, and concentrated. A
white solid was obtained by crystallization from
20 dichloromethane/hexane (29.2 g, 46%): mp 105-106 °C.

Step 2. Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one.

Chlorosulfonic acid (75 mL) was cooled to 0 °C and treated portionwise with 1-(3-fluoro-4-methoxyphenyl)-2-phenyl-ethan-1-one from Step 1 (15.24 g, 62.4 mmol). The cooling bath was removed and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with dichloromethane (100 mL) and added dropwise to ice water (500 mL). Ammonium hydroxide (250 mL) was added and the mixture

was stirred for 16 hours. A white solid was collected by filtration (8.1 g, 40%). This material was used in the next step without further purification or characterization.

5

Step 3. Preparation of 1-(3-fluoro-4-methoxyphenyl)-2-(4-aminosulfonylphenyl-ethan-1-one oxime.


1-(3-Fluoro-4-methoxyphenyl)-2-(4-aminosulfonyl)phenyl-ethan-1-one from Step 2 (3.0 g, 9.3 mmol), ethanol (100 mL), water (10 mL), hydroxylamine hydrochloride (1.29 g, 18.6 mmol), and sodium acetate (1.53 g, 18.6 mmol) were combined and heated to 75 °C for 2 hours. The mixture was added to water (100 mL) and the oxime was isolated by filtration to afford a white solid (2.8 g, 89%): mp 183.9-186.0 °C. ¹H NMR (acetone-d₆/300 MHz) 10.7 (s, 1H), 7.8 (d, J=9.3 Hz, 2H), 7.5 (m, 4H), 7.1 (t, J=9.8 Hz, 2H), 6.5 (bs, 2H), 4.3 (s, 2H), 3.9 (s, 3H). Anal. Calc'd. for C₁₅H₁₅FN₂O₄S: C, 53.25; H, 4.47; N, 8.28. Found: C, 53.01; H, 4.51; N, 8.12.

Step 4. Preparation of 4-[5-difluoromethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide

1-(3-Fluoro-4-methoxyphenyl)-2-(4-aminosulfonylphenyl-ethan-1-one oxime from Step 3 (2.0 g, 5.9 mmol), and triethylamine (0.60 g, 5.9 mmol) were dissolved in tetrahydrofuran (100 mL) and treated with bis(1,2-chlorodimethylsilyl)ethane (1.27 g, 5.9 mmol) at room temperature. After 15 minutes, the solution was cooled to -78 °C and lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 7.75 mL, 19.5 mmol) was added dropwise. The solution was warmed to -15 °C, and ethyl difluoroacetate (0.89 g, 6.5 mmol) was added. After stirring 0.5 hour, trifluoroacetic acid (40 mL) and water (10 mL) were added. The resulting dark mixture was heated to reflux for 20

hours, concentrated, dissolved in ethyl acetate (100 mL), washed with brine, saturated aqueous NaHCO_3 , and water, dried over MgSO_4 , and concentrated. A dark oily solid was crystallized from ethyl acetate/hexane 5 to give a white solid (0.3 g, 13%): mp 188.2-190.0 °C. ^1H NMR (acetone- d_6 /300 MHz) 8.0 (d, $J=8.4$ Hz, 2H), 7.6 (d, $J=8.7$ Hz, 2H), 7.2 (m, 3H), 7.1 (t, $J=51.9$ Hz, 1H), 6.7 (bs, 2H), 3.9 (s, 3H). Anal. Calc'd. for $\text{C}_{17}\text{H}_{13}\text{F}_3\text{N}_2\text{O}_4\text{S}$: C, 51.26; H, 3.29; N, 7.03. Found: C, 10 51.35; H, 3.33; N, 6.89.

Example 45



15 **4-[5-Difluoromethyl-3-(4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide**

Step 1. Preparation of 1-(4-methoxyphenyl)-2-phenylethan-1-one.

20 4-Anisaldehyde (7.35 g, 54 mmol), dichloromethane (100 mL), and zinc iodide (10 mg) were stirred at 0 °C under nitrogen and treated dropwise with trimethylsilyl cyanide (5.95 g, 60 mmol). The reaction was stirred for 4 hours, then water (5 mL) was added 25 dropwise. The mixture was washed with brine (2 x 30 mL), dried over MgSO_4 , and concentrated under high vacuum. The resulting oily residue was dissolved in tetrahydrofuran (150 mL) and cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in 30 heptane/tetrahydrofuran/ethylbenzene, 30 mL, 60 mmol) was added dropwise, maintaining the temperature below -60 °C. The solution was stirred for 1 hour, then

treated with benzyl bromide (10.26 g, 60 mmol). The cooling bath was removed and the mixture was stirred until the temperature reached -10 °C. The solution was poured into a stirred solution of 1N hydrochloric acid 5 (150 mL) and trifluoroacetic acid (10 mL). After stirring for 1 hour, the mixture was extracted with ethyl acetate (2 X 50 mL). The combined extract was washed with brine (2 X 50 mL) and concentrated. Sodium hydroxide (2.5 N) was added until basic to pH 10 paper. This mixture was stirred for 2 hours and extracted with ether (2 X 50 mL). The combined extract was washed with brine and water, dried over $MgSO_4$, and concentrated. After recrystallization from ether/hexane, a tan solid was collected by filtration 15 (4.2 g, 34%): mp 76.7-77.7 °C. 1H NMR (acetone- d_6 /300 MHz) 8.0 (d, $J=8.7$ Hz, 2H), 7.3 (m, 5H), 7.0 (d, $J=9.3$ Hz, 3H), 4.3 (s, 2H), 3.9 (s, 3H). Anal. Calc'd. for $C_{15}H_{14}O_2$: C, 79.62; H, 6.24. Found: C, 79.39; H, 6.25.

20

Step 2. Preparation of 1-(4-methoxyphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one.

Chlorosulfonic acid (30 mL) was cooled to -78 °C and treated with 1-(4-methoxyphenyl)-2-phenyl-ethan-1-25 one from Step 1 (4.0 g, 18 mmol). The mixture was warmed to 0 °C and stirred for 2 hours, then added dropwise to ice water (500 mL). Ammonium hydroxide (100 mL) and ethyl acetate (100 mL) were added and the solution was stirred for 16 hours. A sticky white 30 solid, isolated by filtration, was dissolved in boiling acetone/water, and allowed to stand overnight. A white solid was isolated by filtration (2.4 g, 44%): mp 253.7-257.7 °C. 1H NMR (DMSO- d_6 /300 MHz) 8.0 (d, $J=8.1$ Hz, 2H), 7.7 (d, $J=7.5$ Hz, 2H), 7.4 (d, $J=7.8$ Hz, 2H), 7.2 (bs, 2H), 7.0 (d, $J=7.8$ Hz, 2H), 4.4 (s, 2H), 3.8 (s, 3H). Anal. Calc'd. for $C_{16}H_{13}BrN_2O_3S$: C, 48.87; H, 3.33; N, 7.12. Found: C, 48.77; H, 3.21; N, 6.99.

Step 3. Preparation of 1-(4-methoxyphenyl)-2-(4-aminosulfonylphenyl-ethan-1-one oxime.

1-(4-Methoxyphenyl)-2-(4-aminosulfonylphenyl)-
5 ethan-1-one from Step 2 (1.8 g, 5.9 mmol), ethanol
(100 mL), water (10 mL), hydroxylamine hydrochloride
(0.82 g, 11.8 mmol), and sodium acetate (0.97 g, 11.8
mmol) were combined and heated to 75 °C for 2 hours.
The mixture was added to water (100 mL) and a white
10 solid formed that was isolated by filtration (1.3 g,
69%): mp 142.5-144.3 °C. ¹H NMR (acetone-d₆/300 MHz)
10.5 (s, 1H), 7.8 (d, J=8.4 Hz, 2H), 7.7 (d, J=8.7 Hz,
2H), 7.5 (d, J=8.4 Hz, 2H), 6.8 (d, J=9.0 Hz, 2H), 6.5
(bs, 2H), 4.3 (s, 2H), 3.8 (s, 3H).

15


Step 4. Preparation of 4-[5-difluoromethyl-3-(4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide.

1-(4-Methoxyphenyl)-2-(4-aminosulfonylphenyl-
ethan-1-one oxime from Step 3 (1.2 g, 3.7 mmol),
20 tetrahydrofuran (100 mL), and triethylamine (0.37 g,
3.7 mmol) were stirred at room temperature and treated
with bis(1,2-chlorodimethylsilyl)ethane (0.80 g, 3.7
mmol). The solution was cooled to -78 °C under
nitrogen. Lithium diisopropylamide (2.0 M solution in
25 heptane/tetrahydrofuran/ethylbenzene, 6.1 mL, 12.2
mmol) was added dropwise, and the cooling bath was
removed. When the temperature reached -15 °C, ethyl
difluoroacetate (0.51 g, 4.1 mmol) was added. After
stirring 0.5 hour, trifluoroacetic acid (30 mL) and
30 water (10 mL) were added. The resulting dark mixture
was heated to reflux for 20 hours, concentrated,
dissolved in ethyl acetate (100 mL), washed with
brine, saturated NaHCO₃, and water, dried over MgSO₄,
and concentrated. A dark oily solid was purified by
35 flash column chromatography, eluting with ethyl
acetate:hexane (1:1). The appropriate fractions were
concentrated and crystallized from ethyl
acetate:hexane to yield a white solid (0.21 g, 15%):

mp 181.6-182.6 °C. ^1H NMR (acetone- d_6 /300 MHz) 8.0 (d, $J=8.4$ Hz, 2H), 7.6 (d, $J=8.1$ Hz, 2H), 7.5 (d, $J=8.1$ Hz, 2H), 7.4 (d, $J=9.0$ Hz, 2H), 7.1 (t, $J=51.9$ Hz, 1H), 6.7 (bs, 2H), 3.8 (s, 3H). Anal. Calc'd. for 5 $\text{C}_{17}\text{H}_{14}\text{F}_2\text{N}_2\text{O}_4\text{S}$: C, 53.68; H, 3.71; N, 7.36. Found: C, 53.71; H, 3.74; N, 7.27.

Example 46

10



4-[5-Difluoromethyl-3-(4-methylphenyl)isoxazol-4-yl]benzenesulfonamide

15

Step 1. Preparation of 1-(4-methylphenyl)-2-phenylethan-1-one.

20

4-Tolualdehyde (12.01 g, 100 mmol), dichloromethane (200 mL) and zinc iodide (10 mg) were stirred at 0 °C under nitrogen and treated with trimethylsilyl cyanide (10.91 g, 110 mmol). The reaction was stirred for 4 hours, when water (5 mL) was added dropwise. The mixture was washed with brine (2 X 50 mL), dried over MgSO_4 , and concentrated under high vacuum. The resulting oily residue was dissolved in tetrahydrofuran (200 mL) and cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 55 mL, 110 mmol) was added dropwise, maintaining the temperature below -60 °C. The solution was stirred for 1 hour and then benzyl bromide (18.8 g, 110 mmol) was added. The mixture was warmed to -10 °C then the solution was poured into a stirred solution of 1N hydrochloric acid (150 mL) and trifluoroacetic acid (10 mL). After

stirring for 1 hour, the mixture was extracted with ethyl acetate (2 X 100 mL). The combined extract was washed with brine (2 X 50 mL) and concentrated.

5 Sodium hydroxide (2.5 N, 75 mL) was added and a yellow solid formed that was isolated by filtration. The yellow solid was dissolved in boiling acetone/ethanol and crystallized by the dropwise addition of water. A light yellow solid was collected by filtration (16.7 g, 79%): mp 109.6-112.0 °C. ^1H NMR (acetone-d₆/300 MHz) 8.0 (d, J=8.1 Hz, 2H), 7.3 (m, 7H), 4.3 (s, 2H), 2.4 (s, 3H). Anal. Calc'd. for C₁₅H₁₄O: C, 85.68; H, 6.71. Found: C, 85.77; H, 6.70.

15 Step 2. Preparation of 1-(4-methylphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one.

Chlorosulfonic acid (30 mL) was cooled to -78 °C and 1-(4-methylphenyl)-2-phenyl-ethan-1-one from Step 1 (4.0 g, 18 mmol) was added. The mixture was warmed to 0 °C and stirred for 2 hours, then added dropwise 20 to ice water (500 mL). Ammonium hydroxide (100 mL) and ethyl acetate (100 mL) were added and the mixture was stirred for 16 hours. A white solid formed that was isolated by filtration. The crude ketone was dissolved in boiling acetone/ethanol/water and let 25 stand overnight, whereupon a white solid formed that was collected by filtration (4.2 g, 31%): mp 250.4-255.2 °C. ^1H NMR (DMSO-d₆/300 MHz) 8.0 (d, J=8.1 Hz, 2H), 7.7 (d, J= 8.4 Hz, 2H), 7.4 (d, J=8.1 Hz, 2H), 7.3 (d, J=7.8 Hz, 2H), 7.2 (bs, 2H), 4.5 (s, 2H), 2.4 30 (s, 3H). High resolution mass spectrum calc'd. for C₁₅H₁₅NO₃S: 290.0851. Found: 290.0834.

Step 3. Preparation of 1-(4-methylphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one oxime.

35 1-(4-Methylphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one from Step 2 (3.5 g, 12 mmol), ethanol (100 mL), water (10 mL), hydroxylamine hydrochloride (1.67 g, 24 mmol), and sodium acetate (1.97 g, 24 mmol) were


combined and heated to 75 °C for 2 hours. The mixture was added to water (100 mL) and the material was isolated by filtration to afford a white solid (2.1 g, 57%): mp 163.4-165.8 °C.

5

Step 4. Preparation of 4-[5-difluoromethyl-3-(4-methylphenyl)isoxazol-4-yl]benzenesulfonamide.

1-(4-Methylphenyl)-2-(4-aminosulfonylphenyl)-ethan-1-one oxime from Step 3 (2.0 g, 6.6 mmol), tetrahydrofuran (100 mL), and triethylamine (0.67 g, 6.6 mmol) were stirred at room temperature and treated with bis(1,2-chlorodimethylsilyl)ethane (1.42 g, 6.6 mmol). The solution was cooled to -78 °C under nitrogen. Lithium diisopropylamide (2.0 M solution in heptane/tetrahydrofuran/ethylbenzene, 10.9 mL, 21.8 mmol) was added dropwise, and the cooling bath was removed. When the temperature reached -15 °C, ethyl difluoroacetate (0.82 g, 6.6 mmol) was added all at once. After stirring for 0.5 hour, trifluoroacetic acid (30 mL) and water (10 mL) were added. The resulting dark mixture was heated to reflux for 20 hours, concentrated, dissolved in ethyl acetate (100 mL), washed with brine, saturated aqueous NaHCO₃, and water, dried over MgSO₄, and concentrated. A dark oily solid was purified by flash column chromatography eluting with ethyl acetate:hexane (1:1). The appropriate fractions were concentrated and crystallized from ethyl acetate/hexane to yield a white solid (0.23 g, 10%): mp 169.0-172.3 °C. ¹H NMR (acetone-d₆/300 MHz) 8.0 (d, J=8.4 Hz, 2H), 7.5 (d, J=8.1 Hz, 2H), 7.3 (d, J=8.1 Hz, 2H), 7.2 (d, J=8.1 Hz, 2H), 7.1 (t, J=51.9 Hz, 1H), 6.7 (bs, 2H), 2.4 (s, 3H). High resolution mass spectrum calc'd. for C₁₇H₁₅F₂N₂O₃S(M+H): 365.0771. Found: 365.0779.

Example 47



5-Difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole

5

Step 1. Preparation of 2-phenylpropenoic acid.

Phenylacetic acid (45.46 g, 334 mmol), 4-(methylthio)benzaldehyde (50.35 g, 331 mmol), 10 triethylamine (34.54 g, 341 mmol) and acetic anhydride (200 mL) were heated to reflux for 0.9 hours. The reaction was cooled to 90 °C and water (200 mL) was added slowly. A yellow precipitate formed, and after cooling to room temperature, the solid was collected 15 by filtration and recrystallized from toluene to give the diarylpropenoic acid as yellow needles (48.04 g, 61%): mp 164-168 °C. ¹H NMR (acetone-d₆) 300 MHz 7.82 (s, 1H) 7.38 (m, 3H) 7.26 (m, 2H) 7.05 (m, 4H) 2.45 (s, 3H).

20

Step 2. Preparation of 2-(4-methylthiophenyl)-1-phenylethanone

The diarylpropenoic acid from Step 1 (54.10 g, 200 mmol) and triethylamine (22.92 g, 226 mmol) were 25 dissolved in toluene (260 mL), cooled to 0 °C and treated with diphenylphosphorylazide (55.35 g, 201 mmol). The reaction was stirred at room temperature 4.4 hours, poured into water, extracted with ether, dried over MgSO₄, and concentrated in vacuo. The 30 solution was heated to reflux and a vigorous evolution of gas occurred. After 1.67 hours, *tert*-butyl alcohol (10 mL, 120 mmol) was added to the reaction. After an additional 1.0 hour, concentrated hydrochloric acid

(16.5 mL) was added and the reaction was heated at 75 °C overnight (14 hours). After cooling, a white precipitate formed. The precipitate was filtered, washed with water and ethyl acetate, and dried to give 5 the ketone. The filtrate was washed with water, and brine, dried over MgSO₄, concentrated in vacuo and recrystallized from ethyl acetate/hexane to give additional ketone as a yellow powder (Total: 33.58 g, 69%): mp 123-127 °C. ¹H NMR (acetone-d₆) 300 MHz 8.06 10 (d, J=8.1 Hz, 2H) 7.51-7.62 (m, 3H) 7.25 (m, 4H) 4.35 (s, 2H) 2.46 (s, 3H).

Step 3. Preparation of 2-(4-methylthiophenyl)-1-phenylethanone oxime.

15 Hydroxylamine hydrochloride (9.76 g, 140 mmol) was dissolved in ethanol (40 mL) and stirred at room temperature with potassium hydroxide (7.98 g, 142 mmol) for 0.67 hours. Toluene (200 mL) and the ketone from Step 2 (33.58 g, 139 mmol) were added and the 20 reaction was heated to reflux for 4.0 hours. The reaction mixture was filtered while hot, and upon cooling to room temperature, gave a white precipitate which was filtered and dried to give the oxime as a white powder (20.19 g, 57%): mp 122-123.5 °C. ¹H NMR 25 (acetone-d₆) 300 MHz 10.61 (s, 1H) 7.70 (m, 2H) 7.31 (m, 3H) 7.23 (d, J=8.3 Hz, 2H) 7.18 (d, J=8.3 Hz, 2H) 4.21 (s, 2H) 2.43 (s, 3H).

Step 4. Preparation of 5-difluoromethyl-4-(4-methylthiophenyl)-3-phenylisoxazole

30 The oxime from Step 3 (14.13 g, 54.9 mmol) was dissolved in tetrahydrofuran (150 mL), cooled to -78 °C, and treated with 2.1 equivalents of n-butyllithium. The reaction was warmed to 10 °C over 35 1.9 hours, treated with ethyl difluoroacetate (7.03 g, 56.7 mmol) and stirred at room temperature for 3.2 hours. The reaction was quenched with water, extracted with ethyl acetate, washed with saturated

NaHCO₃, and brine, dried over MgSO₄, and concentrated in vacuo to give a brown oil (12.17 g). The oil was dissolved in tetrahydrofuran (50 mL) along with triethylamine (8.02 g, 79.2 mmol),

5 dimethylaminopyridine (1.13 g, 9.2 mmol), and toluenesulfonyl chloride (7.72 g, 40.5 mmol). The solution was heated to reflux for 1.8 hours, ethyl acetate was added and the reaction mixture was washed with 3N HCl, saturated NaHCO₃, and brine, dried over


10 MgSO₄, and concentrated in vacuo. The material was purified (silica gel eluting with 25% ethyl acetate/hexane) to give the isoxazole as a brown oil (6.12 g, 35%): ¹H NMR (CDCl₃) 300 MHz 7.32-7.45 (m, 5H) 7.24 (d, J=8.5 Hz, 2H) 7.16 (d, J=8.5 Hz, 2H) 6.63 (t, J=52.4 Hz, 1H) 2.51 (s, 3H). ¹⁹F NMR (acetone-d₆) 282 MHz -116.26 (d). Mass spectrum: M+=317.

Step 5. Preparation of 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole

20 The isoxazole from Step 4 (6.29 g, 19.8 mmol) was dissolved in a mixture of tetrahydrofuran, ethanol, and water (1:1:1, 60 mL). The reaction was treated with OXONE® (24.43 g, 39.7 mmol), stirred at room temperature for 1.25 hours, filtered and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated NaHCO₃, and brine, dried over MgSO₄, concentrated in vacuo and passed through a column of silica gel eluting with 50% ethyl acetate/hexane to give the sulfone as a white solid (4.74 g, 68%): mp 126-128 °C. ¹H NMR (acetone-d₆) 300 MHz 8.02 (d, J=8.7 Hz, 2H) 7.64 (d, J=8.5 Hz, 2H) 7.42-7.46 (m, 5H) 7.18 (t, J=52.0 Hz, 1H) 3.18 (s, 3H). ¹⁹F NMR (acetone-d₆) 282 MHz -118.36 (d). High resolution mass spectrum calc'd. for C₁₇H₁₄F₂NO₃S:

30 350.0662. Found: 350.0664.

EXAMPLE 48



4-[3-(3-Chlorophenyl)-5-methylisoxazol-4-
5 yl]benzenesulfonamide

Step 1. Preparation of 1-(3-chlorophenyl)-2-phenylethan-1-one.

Cyanotrimethylsilane (13.36 mL, 105.6 mmol) was
10 added to a stirred mixture of 3-chlorobenzaldehyde
(15.0 g, 108.3 mmol) and zinc iodide (0.75 g) in
anhydrous dichloromethane (100 mL) under nitrogen at
10 °C. The reaction mixture was stirred for 90
minutes and poured into aqueous sodium bicarbonate
15 (200 mL). The organic layer was washed with brine
(200 mL), dried and concentrated to afford the
cyanohydrin. A solution of tetrahydrofuran (100
mL) and lithium hexamethyldisilylamide (96.4 mL, 1
N, 96.4 mmol) was cooled to -78 °C. The cyanohydrin
20 in tetrahydrofuran (50 mL) was added slowly to the
above mixture. After 15 minutes at -78 °C,
benzylbromide (15.11 g 88.4 mmol) was added. The
reaction mixture was stirred for 1 hour and was
warmed to room temperature. The mixture was poured
25 into trifluoroacetic acid (200 mL) containing 10%
water and stirred for 2 hours. The mixture was
neutralized with solid Na₂CO₃, extracted with ethyl
acetate (300 mL), washed with brine (200 mL), dried
and concentrated. The residue was stirred with
30 aqueous NaOH (2 N, 200 mL). The solid formed was
filtered, washed with water, dried and
recrystallized from hexane to afford the desired

ketone (19.5 g, 78%): mp 153-156 °C. ^1H NMR (CDCl_3) 7.99-7.82 (m, 4H), 7.51 -7.19 (m, 5H), 4.03 (s, 2H).

5 Step 2. Preparation of 1-(3-chlorophenyl)-2-phenyl-ethan-1-one oxime.

A mixture of 1-(3-chlorophenyl)-2-phenyl-ethan-1-one from Step 1 (9.3 g, 40.4 mmol), hydroxylamine hydrochloride (7.29 g, 105.0 mmol), sodium acetate (20.6 g, 251 mmol), ethanol (90 mL) and water (90 10 mL) was heated to reflux for 4 hours, diluted with water (200 mL) and cooled. The precipitate formed was filtered, dried and recrystallized from hexane/ethyl acetate to afford the desired oxime (8.2 g, 83%): mp 120-121 °C. ^1H NMR (CDCl_3) 7.62- 15 7.21 (m, 9H), 4.20 (s, 2H).


Step 3. Preparation of 4-[5-methyl-3-(3-chlorophenyl)isoxazol-4-yl]benzenesulfonamide.

Butyllithium (11.8 mL, 1.6 N, 18.9 mmol) was 20 added to a solution of 1-(3-chlorophenyl)-2-phenyl-ethan-1-one oxime from Step 2 (2.11 g, 8.60 mmol) in dry tetrahydrofuran (45 mL) at -78 °C. The reaction mixture was stirred for 30 minutes at -78 °C, warmed to 0 °C, then cooled again to -78 °C. Ethyl acetate 25 (0.832 g, 9.45 mmol) was added to the reaction mixture and warmed to room temperature. The reaction mixture was quenched with saturated NH_4Cl , extracted with ethyl acetate, dried over MgSO_4 , filtered and concentrated in vacuo. Chromatographic 30 purification of the residue (silica gel flash chromatography, hexane:ethyl acetate (2:1)) afforded the desired hydrate. The hydrate was added to chlorosulfonic acid (10 mL) at 0 °C and stirred for 3 hours. The reaction was diluted with 35 dichloromethane (25 mL), then poured carefully into an ice-water mixture. The quenched reaction mixture was extracted with dichloromethane (200 mL). The organic layer was added to ammonium hydroxide (200

mL) and stirred for 18 hours. The organic layer was separated, washed with brine (100 mL), dried (MgSO_4) and concentrated. Flash chromatography on silica gel (1:1 ethyl acetate, hexane) of the residue 5 afforded the desired product as a crystalline material (0.40 g): mp 72-83 °C. ^1H NMR (CDCl_3) 7.93 (d, 2H, $J = 8.5$ Hz), 7.46-7.13 (m, 6H), 5.4 (s, 2H), 2.46 (s, 3H). FABMS Calc'd. for $\text{C}_{16}\text{H}_{13}\text{ClN}_2\text{O}_3\text{S}$: 348 (M $^+$). Found = 348.

10

EXAMPLE 49



15

4-[3-(3,4-Difluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide

Step 1. Preparation of 1-(3,4-difluorophenyl)-2-phenyl-ethan-1-one.

Cyanotrimethylsilane (13.36 mL, 105.6 mmol) was 20 added to a stirred mixture of 3,4-difluorobenzaldehyde (15.0 g, 105.6 mmol) and zinc iodide (0.90 g) in anhydrous dichloromethane (100 mL) under nitrogen at 10 °C. The mixture was stirred for 90 minutes and was poured into aqueous 25 NaHCO_3 (200 mL). The organic layer was washed with brine (200 mL), dried over MgSO_4 , filtered and concentrated to afford the cyanohydrin. A solution of tetrahydrofuran (100 mL) and lithium hexamethyldisilylamide (118.0 mL, 1N, 118.0 mmol) 30 was cooled to -78 °C. The cyanohydrin in tetrahydrofuran (50 mL) was added slowly to the above mixture. After 15 minutes at -78 °C,

benzylbromide (18.06 g 106.67 mmol) was added. The mixture was stirred for 1 hour and warmed to room temperature. The mixture was poured into trifluoroacetic acid (90%), stirred for 2 hours, and 5 neutralized with solid Na_2CO_3 . The mixture was extracted with ethyl acetate (300 mL), washed with brine (200 mL), dried, and concentrated. The residue was stirred with aqueous NaOH (2 N, 200 mL). The solid formed was filtered, washed with water, 10 dried and recrystallized from hexane to afford the desired ketone (13.55 g, 55%): mp 116-121 °C. ^1H NMR (CDCl_3) 7.86-7.75 (m, 2H), 7.37-7.18 (m, 7H), 4.23 (s, 2H).

15 Step 2. Preparation of 1-(3,4-difluorophenyl)-2-phenyl-ethan-1-one oxime.


A mixture of 1-(3,4-difluorophenyl)-2-phenyl-ethan-1-one from Step 1 (12.5 g, 53.88 mmol), hydroxylamine hydrochloride (9.4 g, 135.4 mmol) and 20 sodium acetate (268.5 mmol) in ethanol/water (1:1, 250 mL) was heated to reflux for 4 hours. Upon addition of water (200 mL) a precipitate formed. The precipitate was filtered, dried and recrystallized from hexane to afford the desired 25 oxime (10 g, 75%): mp 81-82 °C. ^1H NMR (CDCl_3) 7.5 -7.06 (m, 9H), 4.18 (s, 2H).

Step 3. Preparation of 4-[5-methyl-3-(3,4-difluorophenyl)isoxazol-4-yl]benzenesulfonamide.

30 Butyllithium (18.1 mL, 1.6 N, 45 mmol) was added to a solution of 1-(3,4-difluorophenyl)-2-phenyl-ethan-1-one oxime from Step 2 (5.505 g, 20.5 mmol) in dry tetrahydrofuran (200 mL) at -78 °C. The reaction mixture was stirred for 30 minutes at 35 -78 °C, warmed up to 0 °C, then cooled to -78 °C. Ethyl acetate (1.801 g, 20.45 mmol) was added to the reaction mixture and the mixture was warmed to room temperature. The reaction mixture was quenched with


saturated ammonium chloride solution, extracted with ethyl acetate, dried over $MgSO_4$ and concentrated in vacuo. The desired hydrate was obtained by purifying the residue (silica gel flash chromatography, hexane:ethyl acetate (2:1)). The hydrate was added to chlorosulfonic acid (10 mL) at 0 °C and stirred for 3 hours. The mixture was diluted with dichloromethane (25 mL), then poured carefully in to ice-water mixture. The mixture was extracted with dichloromethane (200 mL) and the organic layer was added to ammonium hydroxide (200 mL) and stirred for 18 hours. The organic layer was separated, washed with brine (100 mL), dried over $MgSO_4$ and concentrated in vacuo. Flash chromatography on silica gel (1:1 ethyl acetate/hexane) of the residue afforded the desired product as a crystalline material (0.360 g): mp 149-153 °C. 1H NMR ($CDCl_3$) 7.88 (d, 2H, $J=7.85$ Hz), 7.25 (d, 2H, $J=8.25$ Hz), 7.04-7.19 (m, 3H), 3.28 (s, 2H), 2.41 (s, 3H). FABMS Calc'd for $C_{16}H_{12}F_2N_2O_3S$: 350 (M+). Found = 350.

Example 50



Methyl 4-hydroxybenzoate (152.0 mg, 1.00 mmol), 4-[5-chloromethyl-3-phenylisoxazol-4-yl]-benzenesulfonamide [Example 1(k), 300.0 mg, 0.86 mol], 5 and potassium carbonate (200 mg, 1.44 mmol) were mixed together in dimethylformamide (5.0 mL) for 168 hours at room temperature. The solution was poured into ethyl acetate (100 mL), and washed with saturated aqueous NaHCO_3 (2 x 50 mL) and brine (2 x 50 mL). The 10 organic phase was dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude product was purified by flash chromatography over silica gel, eluting with hexanes and ethyl acetate. The appropriate fractions were combined and concentrated to afford methyl 4-[(4-[4- 15 [4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5- yl)methoxy]benzoate as a white foam (149 mg, 37%). ^1H NMR (CDCl_3) 3.90 (s, 3H), 4.87 (bs, 2H), 5.17 (s, 2H), 6.96 (d, 2H, $J=8.7$ Hz), 7.35-7.44 (m, 7H), 7.91 (d, 2H, $J=8.7$ Hz), 7.98 (d, 2H, $J=9.1$ Hz). Mass spectrum 20 calc'd. for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_6\text{S}$: 464. Found: 465 ($\text{m}+\text{H}^+$).

Example 51




25 4-[(4-[(4-aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl)methoxy]benzoic acid

Methyl 4-[[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]methoxy]benzoate (Example 50) (65.0 mg, 0.14 mmol) was dissolved in tetrahydrofuran/methanol/water (5.0 mL 7:2:1) and 5 lithium hydroxide (10 mg, 0.250 mmol) was added. The solution was heated to reflux for 4 hours and cooled to room temperature. The solvent was removed *in vacuo* and the crude product was purified by preparative high pressure liquid chromatography using a C18 reverse 10 phase column. The appropriate fractions were combined and concentrated to afford pure 4-[[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]methoxy]benzoic acid as a white crystalline material (38 mg, 60%): mp 206.4-207.9 °C. ^1H NMR CD_3OD 5.29 (s, 2H), 7.01 (d, 2H, 8.4 Hz), 7.25-7.45 15 (m, 7H), 7.84-7.97 (m, 4H). Mass spectrum calc'd. for $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}_6\text{S}$: 450. Found: 451 ($\text{m}+\text{H}^+$).

Example 52

20



4-[3-Phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl]benzenesulfonamide

25 Step 1: Preparation of [[4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfonyl]carbamic acid, 1,1-dimethylethylester
 To a stirred suspension of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide (Example 1) (10.42 g, 33.1 mmol) in dichloromethane (100 mL) was 30 added di-*tert*-butyldicarbonate (7.59 g, 34.80 mmol), dimethylaminopyridine (0.202 g, 1.66 mmol) and

triethylamine (5.07 mL, 3.68 g, 36.4 mmol). The resulting homogeneous solution was stirred overnight. The reaction was diluted with ethyl acetate and dichloromethane, washed with KHSO_4 solution (0.25 M), 5 brine, dried over MgSO_4 , filtered and concentrated in vacuo yielding a white powder. The powder was dissolved in hot ethyl acetate and diluted with isooctane, yielding $[[4-(5\text{-methyl-3-phenylisoxazol-4-yl})\text{phenyl}]\text{sulfonyl}]\text{-carbamic acid, 1,1-}$ 10 dimethylethylester as a fine white powder (9.94 g, 72%): mp 167.6-170.5 °C. ^1H NMR (CDCl_3) 8.01 (d, $J = 8.66$ Hz, 2H), 7.51 (s, 1H), 7.46-7.30 (m, 7H), 2.50 (s, 3H), 1.40 (s, 9H). LRMS M+H obs at m/z 415. Anal. Calc'd. for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_5\text{S}$: C, 60.86; H, 5.35; N, 15 6.76. Found: C, 60.79; H, 5.40; N, 6.75.

Step 2. Preparation of $[[4-[3\text{-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl}]\text{phenyl}]\text{sulfonyl}]\text{-carbamic acid, 1,1-dimethylethylester}$

20 A chilled (-78 °C), stirred solution of $[[4-(5\text{-methyl-3-phenylisoxazol-4-yl})\text{phenyl}]\text{sulfonyl}]\text{-carbamic acid, 1,1-dimethylethylester}$ from Step 1 (2.344 g, 5.655 mmol) in THF (50 mL) was treated with n-butyllithium (7.8 mL of 1.6 M in hexanes, 12.44 mmol). 25 The resulting red solution was warmed to 0 °C, cooled to -24 °C, treated with ethyl trifluoroacetate (0.34 mL, 0.40 g, 2.83 mmol) and warmed to room temperature. The reaction was quenched with saturated NH_4Cl solution and adjusted to pH 2 with 1 N HCl. The 30 mixture was extracted with ethyl acetate, dried over MgSO_4 , filtered and concentrated in vacuo. The crude product was purified by flash chromatography yielding $[[4-[3\text{-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl}]\text{phenyl}]\text{sulfonyl}]\text{-carbamic acid, 1,1-}$ 35 dimethylethylester (1.38 g, 48%) as a viscous oil of suitable purity for further elaboration.

Step 3. Preparation of 4-[3-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl]benzenesulfonamide

The [[4-[3-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl]phenyl]sulfonyl]-carbamic acid, 1,1-dimethylethylester from Step 2 was dissolved in trifluoroacetic acid (25 mL) and water (2 mL). After 4 hours, the reaction was concentrated under high vacuum, toluene was added and the mixture reconcentrated to remove trace trifluoroacetic acid. The resulting white semi-solid was dissolved in hot ethyl acetate, isooctane was added and the mixture was partially concentrated, yielding a crystalline solid. Vacuum filtration of the suspension yielded 4-[3-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl]benzenesulfonamide as a white powder (0.302 g, 29%): mp 132.1-138.7 °C. ^1H NMR ($\text{CD}_3\text{CO}_2\text{D}$) 8.01-7.90 (m, 2H), 7.53 (d, J = 8.46, 1H), 7.50-7.30 (m, 6H), 6.02 (s, 0.4H), 3.37 (s, 1H). LRMS: M+H obs at m/z 411 and $(\text{M}-\text{H}_2\text{O})+\text{H}$ obs. at m/z 429. Anal. Calc'd. for $\text{C}_{18}\text{H}_{13}\text{N}_2\text{O}_4\text{SF}\cdot 0.5\text{ H}_2\text{O}$: C, 51.58; H, 3.45; N, 6.64. Found: C, 51.28; H, 3.45; N, 6.64.

BIOLOGICAL EVALUATION

25

Rat Carrageenan Foot Pad Edema Test

The carrageenan foot edema test was performed with materials, reagents and procedures essentially as described by Winter, et al., (*Proc. Soc. Exp. Biol. Med.*, 111, 544 (1962)). Male Sprague-Dawley rats were selected in each group so that the average body weight was as close as possible. Rats were fasted with free access to water for over sixteen hours prior to the test. The rats were dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone. One hour later a subplantar injection of 0.1

mL of 1% solution of carrageenan/sterile 0.9% saline was administered and the volume of the injected foot was measured with a displacement plethysmometer connected to a pressure transducer with a digital 5 indicator. Three hours after the injection of the carrageenan, the volume of the foot was again measured. The average foot swelling in a group of drug-treated animals was compared with that of a group of placebo-treated animals and the percentage 10 inhibition of edema was determined (Otterness and Bliven, *Laboratory Models for Testing NSAIDs, in Non-steroidal Anti-Inflammatory Drugs*, (J. Lombardino, ed. 1985)). The % inhibition shows the % decrease from control paw volume determined in this procedure and 15 the data for selected compounds in this invention are summarized in Table I.

Rat Carrageenan-induced Analgesia Test

The rat carrageenan analgesia test was performed 20 with materials, reagents and procedures essentially as described by Hargreaves, et al., (*Pain*, **32**, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the 25 carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either 30 the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was 35 determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined. Results are shown in Table I.

TABLE I.

	RAT PAW EDEMA	ANALGESIA
	% Inhibition	% Inhibition
5	<u>@ 10mg/kg body weight @ 10mg/kg body weight</u>	
Example		
	1	33
	1(j)	28
10	14	27*
	10	74
	47	24
	<u>* @ 30 mg/kg</u>	

15 Evaluation of COX-1 and COX-2 activity *in vitro*

The compounds of this invention exhibited inhibition *in vitro* of COX-2. The COX-2 inhibition activity of the compounds of this invention illustrated in the Examples was determined by the 20 following methods.

a. Preparation of recombinant COX baculoviruses

Recombinant COX-1 and COX-2 were prepared as described by Gierse et al, [J. Biochem., 305, 479-84 25 (1995)]. A 2.0 kb fragment containing the coding region of either human or murine COX-1 or human or murine COX-2 was cloned into a BamH1 site of the baculovirus transfer vector pVL1393 (Invitrogen) to generate the baculovirus transfer vectors for COX-1 30 and COX-2 in a manner similar to the method of D.R. O'Reilly et al (Baculovirus Expression Vectors: A Laboratory Manual (1992)). Recombinant baculoviruses were isolated by transfecting 4 µg of baculovirus transfer vector DNA into SF9 insect cells (2×10^8) 35 along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method. See M.D. Summers and G.E. Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas

Agric. Exp. Station Bull. 1555 (1987). Recombinant viruses were purified by three rounds of plaque purification and high titer (10^7 - 10^8 pfu/mL) stocks of virus were prepared. For large scale production, SF9 5 insect cells were infected in 10 liter fermentors (0.5 $\times 10^6$ /mL) with the recombinant baculovirus stock such that the multiplicity of infection was 0.1. After 72 hours the cells were centrifuged and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) 10 containing 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The homogenate was centrifuged at 10,000xG for 30 minutes, and the resultant supernatant was stored at -80°C before being assayed for COX activity.

15

b. Assay for COX-1 and COX-2 activity

COX activity was assayed as PGE₂ formed/μg protein/time using an ELISA to detect the prostaglandin released. CHAPS-solubilized insect cell 20 membranes containing the appropriate COX enzyme were incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10 μM). Compounds were pre-incubated with the enzyme for 10-20 minutes prior 25 to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme was stopped after ten minutes at 37 °C/room temperature by transferring 40 μl of reaction mix into 160 μl ELISA buffer and 25 μM indomethacin. The PGE₂ formed was 30 measured by standard ELISA technology (Cayman Chemical). Results are shown in Table II.

TABLE II.

	Example	COX-2	COX-1
		<u>ID₅₀ μM</u>	<u>ID₅₀ μM</u>
5	1	<0.1	>100
	1a	<0.1	17.4
	1b	<0.1	13.2
	1c	<0.1	6.2
	1d	<0.1	25.8
10	1e	<0.1	37.7
	1f	0.2	54
	1g	<0.1	>100
	1h	<0.1	4.7
	1i	<0.1	8.6
15	1j	<0.1	>100
	1k	<0.1	50.7
	1l	1.5	>100
	1m	51	>100
	1n	<0.1	>100
20	1o	0.1	>100
	2	0.9	17.4
	3	2.6	0.6
	4	3	>100
	4a	<0.1	90.5
25	4b	<0.1	>100
	4c	<0.1	66.5
	4d	<0.1	44
	4e	2	>100
	4f	>100	>100
30	5	4.0	>100
	6	35.7	>100
	7	86.7	>100
	8	>100	>100
	9	1.4	>100
35	10	0.2	>100
	11	35	
	12	2.5	>100
	13	<0.1	6.4

TABLE II. (cont.)

Example		COX-2	COX-1
		<u>ID₅₀ μM</u>	<u>ID₅₀ μM</u>
5	14	<0.1	100
	15	0.1	59
	16	3.1	>100
	17	2.1	>100
	18	0.6	>100
10	19	8.7	>100
	20	4.7	>100
	21	5.2	>100
	22	5.3	>100
	23	0.2	56
15	24	8.4	>100
	25	79	>100
	26	69.5	>100
	27	46	>100
	28	0.1	>100
20	29	0.3	>100
	30	<0.1	41
	31	1.3	>100
	32	0.5	76
	33	<0.1	26
25	34	3.5	>100
	35	5.1	>100
	36	1.5	>100
	37	20	>100
	38	<0.1	>100
30	39	0.9	>100
	40	91	2.3
	41	57.5	81
	42	22.5	>100
	43	0.6	>100
35	44	1.7	>100
	45	<0.1	16
	46	0.5	100
	47	<0.1	>100

TABLE II. (cont.)

	Example	COX-2	COX-1
		<u>ID₅₀ μM</u>	<u>ID₅₀ μM</u>
5	48	0.3	93
	49	1.0	>100
	50	<0.1	>100
	51	19	>100
10	52		

Biological paradigms for testing the cytokine-inhibiting activity of these compounds are found in WO95/13067, published 18 May 1995.

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this combination therapy in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of 5 factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain 10 active ingredients in the range of about 0.1 to 2000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.5 and about 20 mg/kg body 15 weight and most preferably between about 0.1 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

In the case of psoriasis and other skin conditions, it may be preferable to apply a topical 20 preparation of compounds of this invention to the affected area two to four times a day.

For inflammations of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream, or 25 as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or 30 a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as 35 propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of

the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be 5 administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the 10 reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent 15 is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known 20 manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which 25 acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base 30 which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and 35 sodium lauryl sulfate, among others.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active

compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable 5 consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl 10 palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid 15 paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active 20 ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.


For therapeutic purposes, the active compounds of 25 this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered *per os*, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic 30 acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and 35 then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl

cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile 5 powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame 10 oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Although this invention has been described with respect to specific embodiments, the details of these 15 embodiments are not to be construed as limitations.

What is claimed is:

1. A compound of Formula I



5

wherein R¹ is selected from alkyl, carboxyalkyl, alkoxy carbonyl, aminocarbonyl, aminocarbonylalkyl, alkoxy carbonylalkyl, carboxyl, cyano, alkoxy, haloalkoxy, aralkoxy, heteroaralkoxy, cycloalkylalkoxy, alkylthio, aralkylthio, heteroaralkylthio, cycloalkylalkylthio, alkoxyalkyl, aralkoxyalkyl, alkylthioalkyl, aralkylthioalkyl, alkylaminoalkyl, aryloxyalkyl, arylthioalkyl, hydroxyl, amino, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo, heterocycloalkyl, aralkyl, halo, alkylamino, aralkylamino, N-alkyl-N-aralkylamino, heteroaralkylamino, N-alkyl-N-heteroaralkylamino, N-alkyl-N-cycloalkylalkylamino, alkoxyalkyloxyalkyl, aryl(hydroxylalkyl), haloalkylsulfonyloxy, 10 arylcarbonyloxyalkyl, arylcarbonylthioalkyl, alkoxy carbonyloxyalkyl, carboxyalkoxyalkyl, carboxyaryloxyalkyl, alkoxy carbonylaryloxyalkyl, alkylaminocarbonyloxyalkyl, alkoxy carbonylthioalkyl, and alkylaminocarbonylthioalkyl;

20 wherein R² is selected from alkylsulfonyl, hydroxysulfonyl, and aminosulfonyl; and wherein R³ is selected from cycloalkyl, cycloalkenyl, aryl and heterocyclo; wherein R³ is optionally substituted at a substitutable position with 25 one or more radicals independently selected from alkyl, cyano, carboxyl, alkoxy carbonyl, haloalkyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, 30 hydroxylalkyl, haloalkylsulfonyloxy, and aminosulfonyloxy;

aminoalkyl, nitro, alkoxyalkyl, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, halo, alkoxy and alkylthio;

provided R^2 is aminosulfonyl when the R^2 -
5 substituted phenyl radical is at isoxazole position 3;
or a pharmaceutically-acceptable salt thereof.


2. Compound of Claim 1 wherein R^1 is selected from hydroxyl, amino, lower alkyl, lower carboxyalkyl, lower 10 alkoxycarbonyl, aminocarbonyl, carboxyl, cyano, lower aminocarbonylalkyl, lower alkoxycarbonylalkyl, lower alkoxy, lower haloalkoxy, lower aralkoxy, lower heteroaralkoxy, lower cycloalkylalkoxy, lower alkylthio, lower aralkylthio, lower heteroaralkylthio, 15 lower cycloalkylalkylthio, lower alkoxyalkyl, lower alkoxyalkyloxyalkyl, lower aralkoxyalkyl, lower alkylthioalkyl, lower aralkylthioalkyl, lower alkylaminoalkyl, lower aryloxyalkyl, lower arylthioalkyl, lower hydroxyalkyl, lower haloalkyl, 20 lower cycloalkyl, lower cycloalkylalkyl, 5- or 6-membered heterocyclo, lower heterocycloalkyl, lower aralkyl, halo, lower haloalkylsulfonyloxy, lower aryl(hydroxylalkyl), lower alkylamino, lower aralkylamino, lower N-alkyl-N-aralkylamino, lower 25 heteroaralkylamino, lower N-alkyl-N-heteroaralkylamino, lower N-alkyl-N-cycloalkylalkylamino, lower arylcarbonyloxyalkyl, lower alkoxy carbonyloxyalkyl, lower alkylaminocarbonyloxyalkyl, lower carboxyalkoxyalkyl, lower carboxyaryloxyalkyl, lower 30 alkoxycarbonylaryloxyalkyl, lower alkoxycarbonylthioalkyl, and lower alkylaminocarbonylthioalkyl; wherein R^2 is selected from lower alkylsulfonyl, hydroxysulfonyl, and aminosulfonyl; and wherein R^3 is selected from lower 35 cycloalkyl, lower cycloalkenyl, aryl, and heteroaryl; wherein R^3 is optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfinyl, lower alkyl, cyano,

carboxyl, lower alkoxycarbonyl, lower haloalkyl,
hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino,
lower alkylamino, lower arylamino, lower aminoalkyl,
nitro, halo, lower alkoxy, lower alkylsulfonyl,
5 aminosulfonyl, and lower alkylthio; or a
pharmaceutically-acceptable salt thereof.

3. Compound of Claim 2 wherein R¹ is selected from
hydroxyl, lower alkyl, carboxyl, halo, lower
10 carboxyalkyl, lower alkoxycarbonylalkyl, lower aralkyl,
lower alkoxyalkyl, lower alkoxyalkyloxyalkyl, lower
aralkoxyalkyl, lower haloalkyl, lower
haloalkylsulfonyloxy, lower hydroxylalkyl, lower
aryl(hydroxylalkyl), lower carboxyalkoxyalkyl, lower
15 carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl,
lower cycloalkyl and lower cycloalkylalkyl; wherein R²
is selected from methylsulfonyl, hydroxysulfonyl, and
aminosulfonyl; and wherein R³ is selected from phenyl
and 5-6 membered heteroaryl; wherein R³ is optionally
20 substituted at a substitutable position with one or
more radicals independently selected from lower
alkylsulfinyl, lower alkyl, cyano, carboxyl, lower
alkoxycarbonyl, lower haloalkyl, hydroxyl, lower
hydroxyalkyl, lower haloalkoxy, amino, lower
25 alkylamino, lower arylamino, lower aminoalkyl, nitro,
halo, lower alkoxy, aminosulfonyl, and lower alkylthio;
or a pharmaceutically-acceptable salt thereof.

4. Compound of Claim 3 wherein R¹ is selected
30 from hydroxyl, methyl, ethyl, propyl, isopropyl, butyl,
tert-butyl, isobutyl, pentyl, isopentyl, neopentyl,
hexyl, chloro, carboxyl, carboxypropyl, carboxymethyl,
carboxyethyl, carboxybutyl, carboxypentyl,
methoxycarbonylmethyl, methoxycarbonylethyl,
35 methoxymethyl, methoxyethyloxymethyl, benzyloxymethyl,
phenylethoxymethyl, fluoromethyl, difluoromethyl,
chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl, fluoromethyl,

difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, hydroxymethyl, hydroxylpropyl,
hydroxylethyl, trifluoromethylsulfonyloxy, 2-(4-
chlorophenyl)-2-hydroxylethyl, carboxymethoxymethyl,
5 (4-carboxyphenyl)oxymethyl, (4-
methoxycarbonylphenyl)oxymethyl, cyclohexyl,
cyclobutyl, cyclopentyl, cycloheptyl, cyclohexylmethyl,
cyclohexylethyl, cyclobutylethyl, cyclopentylmethyl,
cycloheptylpropyl, and lower aralkyl selected from
10 benzyl and phenylethyl, wherein the phenyl ring is
optionally substituted at a substitutable position with
fluoro, chloro, bromo, iodo, methyl, and methoxy;
wherein R² is selected from methylsulfonyl,
hydroxysulfonyl, and aminosulfonyl; and wherein R³ is
15 selected from phenyl, pyridyl, thienyl, thiazolyl,
oxazolyl and furyl; wherein R³ is optionally
substituted at a substitutable position with one or
more radicals independently selected from
trifluoromethoxy, N-methylamino, N,N-dimethylamino, N-
20 ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-
N-ethylamino, phenylamino, N-methyl-N-phenylamino,
methylsulfinyl, ethylsulfinyl, methyl, ethyl,
isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl,
cyano, carboxyl, methoxycarbonyl, fluoromethyl,
25 difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, pentafluoroethyl,
heptafluoropropyl, fluoromethyl, difluoroethyl,
difluoropropyl, dichloroethyl, dichloropropyl,
hydroxyl, hydroxymethyl, amino, nitro, fluoro, chloro,
30 bromo, iodo, methoxy, ethoxy, propoxy, n-butoxy,
pentoxy, hexyloxy, methylenedioxy, aminosulfonyl,
methylthio, ethylthio, butylthio, and hexylthio; or a
pharmaceutically-acceptable salt thereof.



wherein R⁴ is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower 5 alkoxy carbonyl alkyl, lower aralkyl, lower alkoxy alkyl, lower alkoxyalkyloxy alkyl, lower aralkoxy alkyl, lower halo alkyl, lower halo alkylsulfonyloxy, lower hydroxyl alkyl, lower aryl(hydroxyl alkyl), lower carboxy alkox y alkyl, lower carboxy aryl oxy alkyl, lower 10 alkoxy carbonyl aryl oxy alkyl, lower cyclo alkyl and lower cyclo alkyl alkyl; wherein R⁵ is selected from methyl, hydroxy, and amino; and wherein R⁶ is selected from aryl and 5-6 membered hetero aryl; wherein R⁶ is 15 optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxy carbonyl, lower halo alkyl, hydroxyl, lower hydroxyl alkyl, lower halo alkoxy, amino, lower alkylamino, lower arylamino, lower amino alkyl, nitro, 20 halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

6. Compound of Claim 5 wherein R⁴ is selected from hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, 25 tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, chloro, carboxyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, methoxymethyl, methoxyethoxy methyl, benzyloxymethyl, 30 phenylethoxymethyl, fluoromethyl, difluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl,

difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, hydroxymethyl, hydroxylpropyl,
hydroxylethyl, trifluoromethylsulfonyloxy, 2-(4-
chlorophenyl)-2-hydroxylethyl, (4-
5 carboxyphenyl)oxymethyl, carboxymethoxymethyl, (4-
methoxycarbonylphenyl)oxymethyl, cyclohexyl,
cyclobutyl, cyclopentyl, cycloheptyl, cyclohexylmethyl,
cyclohexylethyl, cyclobutylethyl, cyclopentylmethyl,
cycloheptylpropyl, and lower aralkyl selected from
10 benzyl and phenylethyl, wherein the phenyl ring is
optionally substituted at a substitutable position with
fluoro, chloro, bromo, iodo, methyl, and methoxy; and
wherein R⁶ is selected from phenyl and 3-pyridyl;
wherein R⁶ is optionally substituted at a substitutable
15 position with one or more radicals independently
selected from trifluoromethoxy, N-methylamino, N,N-
dimethylamino, N-ethylamino, N,N-dipropylamino, N-
butylamino, N-methyl-N-ethylamino, phenylamino, N-
methyl-N-phenylamino, methylsulfinyl, ethylsulfinyl,
20 methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl,
pentyl, hexyl, cyano, carboxyl, methoxycarbonyl,
fluoromethyl, difluoromethyl, trifluoromethyl,
chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl, fluoromethyl,
25 difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, hydroxyl, hydroxymethyl, amino,
aminomethyl, nitro, fluoro, chloro, bromo, iodo,
methoxy, ethoxy, propoxy, n-butoxy, pentoxy, hexyloxy,
methyleneedioxy, methylthio, ethylthio, butylthio, and
30 hexylthio; or a pharmaceutically-acceptable salt
thereof.

7. Compound of Claim 6 selected from compounds, and
their pharmaceutically acceptable salts, of the group
35 consisting of

[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]-3-
methylbutan-1-oic acid;

[[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
yl]methoxy]acetic acid;
4-[4-[4-(aminosulfonyl)phenyl]]-3-phenylisoxazol-5-
yl]butanoic acid;
5 4-[5-cyano-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-chloro-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-phenyl-5-(trifluoromethansulfonyloxy)isoxazol-4-
yl]benzenesulfonamide;
4-[3-(3,5-difluorophenyl)-5-methylisoxazol-4-
10 yl]benzenesulfonamide;
4-[3-(4-bromophenyl)-5-methylisoxazol-4-
yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(3-fluoro-4-methoxyphenyl)isoxazol-
4-yl]benzenesulfonamide;
15 4-[5-difluoromethyl-3-(4-methylphenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[5-difluoromethyl-3-(4-methoxyphenyl)isoxazol-4-
yl]benzenesulfonamide;
5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-
20 phenylisoxazole;
4-[3-(3-chlorophenyl)-5-methylisoxazol-4-
yl]benzenesulfonamide;
4-[3-(3,4-difluorophenyl)-5-methylisoxazol-4-
yl]benzenesulfonamide;
25 methyl 4-[4-[4-(aminosulfonyl)phenyl]-3-
phenylisoxazol-5-methoxy]benzoate;
4-[[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-
yl]methoxy]benzoic acid;
4-[5-ethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
30 4-[3-phenyl-5-propylisoxazol-4-yl]benzenesulfonamide;
4-[5-isopropyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-butyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-isobutyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
35 4-[5-cyclohexyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-neopentyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;

4-[5-cyclohexylmethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-(4-chlorophenyl)methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

5 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-chloromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonic acid;

10 4-[3-phenyl-5-propylisoxazol-4-yl]benzenesulfonic acid;

4-[5-methoxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-(3-hydroxypropyl)-3-phenylisoxazol-4-yl]benzenesulfonamide;

15 4-[3-(4-chlorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

4-[3-(4-fluorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methylphenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

20 4-[3-(3-chloro-4-methylphenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

4-[5-methyl-3-(3-pyridyl)isoxazol-4-yl]benzenesulfonamide;

25 4-[3-(3-fluorophenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-30 yl]carboxylic acid;

4-[5-hydroxy-3-phenyl-4-isoxazolyl]benzenesulfonamide;

4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide;

4-[3-(3-fluoro-4-methoxyphenyl)-5-methyl-isoxazol-4-yl]benzenesulfonamide;

35 5-methyl-4-[4-(methylsulfonyl)phenyl]-3-phenyl-isoxazole;


4-[3-phenyl-5-(3,3,3-trifluoro-2-oxopropyl)isoxazol-4-yl]benzenesulfonamide;

3-(3-chloro-4-methoxyphenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl]isoxazole;
 [4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]acetic acid;
 5 [4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]propanoic acid;
 ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]propanoate;
 [3-(3-fluoro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]isoxazol-5-yl]acetic acid; and
 10 [4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]propanoic acid.

8. Compound of Claim 6 which is 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof.

9. Compound of Claim 6 which is 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof.

10. A compound of Formula III




25

wherein R⁷ is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxy carbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower aryl(hydroxylalkyl), lower carboxyaryloxyalkyl, lower

alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R⁸ is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, 5 carboxyl, lower alkoxy carbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt 10 thereof.

11. A compound of Formula IV



15 wherein R⁹ is selected from lower alkyl, lower carboxyalkyl, lower alkoxy carbonylalkyl, lower alkoxyalkyloxyalkyl, lower hydroxylalkyl, and lower aralkyl; wherein R¹⁰ is one or more radicals 20 independently selected from hydrido, lower alkyl, lower haloalkyl, halo and lower alkoxy; and wherein R¹¹ is selected from methyl and amino; or a pharmaceutically-acceptable salt thereof.

25 12. Compound of Claim 11 wherein R⁹ is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, 30 methoxycarbonylethyl, methoxyethyloxymethyl, hydroxymethyl, hydroxylpropyl, hydroxylethyl, and lower aralkyl selected from benzyl and phenylethyl,

wherein the phenyl ring is optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; wherein R¹⁰ is one or more radicals independently selected from hydrido, methyl, 5 ethyl, isopropyl, butyl, *tert*-butyl, isobutyl, pentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, 10 dichloropropyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, *n*-butoxy, pentoxy, and methylenedioxy; and wherein R¹¹ is methyl or amino; or a pharmaceutically-acceptable salt thereof.

15 13. Compound of Claim 12 selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

20 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-isopropyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-phenyl-3-propylisoxazol-4-yl]benzenesulfonamide;
4-[3-ethyl-5-(4-methylphenyl)isoxazol-4-
25 yl]benzenesulfonamide;
4-[3-butyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[3-methyl-5-(4-methylphenyl)isoxazol-4-
30 yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-methylisoxazol-4-
yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-3-methylisoxazol-4-
35 yl]benzenesulfonamide;
4-[3-methyl-5-(3-chlorophenyl)isoxazol-4-
yl]benzenesulfonamide;
4-[3-hydroxymethyl-5-phenylisoxazol-4-
40 yl]benzenesulfonamide;
4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-acetic
acid;
3-methyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;

4-[3-[2-(4-chlorophenyl)-2-hydroxyethyl]-5-phenylisoxazol-4-yl]benzenesulfonamide;

3-ethyl-4-(4-methylsulfonylphenyl)-5-phenylisoxazole;

4-[3-ethyl-5-(4-fluorophenyl)isoxazol-4-5]benzenesulfonamide;

4-[3-ethyl-5-(3-fluorophenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-ethyl-5-(3-methylphenyl)isoxazol-4-yl]benzenesulfonamide;

10 4-[3-ethyl-5-(2-fluorophenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-ethyl-5-(2-methylphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[5-(3-chloro-4-methoxyphenyl)-3-ethylisoxazol-4-15]benzenesulfonamide;

4-[3-ethyl-5-(3-fluoro-4-methoxyphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-ethoxyethyloxymethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;

20 4-[3-ethyl-5-(3-fluoro-4-methylphenyl)isoxazol-4-yl]benzenesulfonamide;

4-[3-isobutyl-5-phenylisoxazol-4-yl]benzenesulfonamide;

4-[3-benzyl-5-phenylisoxazol-4-yl]benzenesulfonamide;

4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-25 propanoic acid;


4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-butanoic acid;

4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-pentanoic acid; and

30 4-(4-aminosulfonylphenyl)-5-phenyl-isoxazole-3-hexanoic acid.

14. A compound of Formula V

164



wherein R¹² is one or more radicals independently selected from hydrido, halo, lower haloalkyl, lower alkoxy and lower alkyl; wherein R¹³ is selected from lower alkyl, lower carboxyalkyl, lower alkoxycarbonylalkyl and lower aralkyl; and wherein R¹⁴ is selected from methyl and amino; or a pharmaceutically-acceptable salt thereof.

10

15. Compound of Claim 14 wherein R¹² is one or more radicals independently selected from hydrido, methyl, ethyl, isopropyl, butyl, *tert*-butyl, isobutyl, pentyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, *n*-butoxy, pentoxy, and methylenedioxy; and wherein R¹³ is selected from methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, and lower aralkyl selected from benzyl and phenylethyl, wherein the phenyl ring is optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; or a pharmaceutically-acceptable salt thereof.

25
30

16. Compound of Claim 15 selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

5 4-[4-(4-chlorophenyl)-3-methylisoxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-3-methylisoxazol-5-yl]benzenesulfonamide;
3-methyl-5-(4-methylsulfonylphenyl)-4-phenylisoxazole;
10 4-[3-methyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-propanoic acid;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-butanoic acid;
15 5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-pentanoic acid;
5-(4-aminosulfonylphenyl)-4-phenyl-isoxazole-3-hexanoic acid;
4-[3-ethyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
20 4-[3-isopropyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-isobutyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-benzyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-propyl-4-phenylisoxazol-5-yl]benzenesulfonamide;
4-[3-methyl-4-(4-methylphenyl)isoxazol-5-
25 yl]benzenesulfonamide;
4-[3-methyl-4-(4-trifluoromethylphenyl)isoxazol-5-yl]benzenesulfonamide;
4-[3-ethyl-4-(4-methylphenyl)isoxazol-5-
30 yl]benzenesulfonamide;
4-[3-ethyl-4-(4-trifluoromethylphenyl)isoxazol-5-yl]benzenesulfonamide; and
4-[3-ethyl-4-(4-fluorophenyl)isoxazol-5-
35 yl]benzenesulfonamide.

17. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or
16; or a pharmaceutically-acceptable salt thereof.

18. A method of treating inflammation or an
5 inflammation-associated disorder in a subject, said
method comprising treating the subject having or
susceptible to said disorder with a therapeutically-
effective amount of a compound of Claim 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16; or a
10 pharmaceutically-acceptable salt thereof.

19. The method of Claim 18 for use in treatment of
inflammation.

15 20. The method of Claim 18 for use in treatment of
an inflammation-associated disorder.

21. The method of Claim 20 wherein the
inflammation-associated disorder is arthritis.

20 22. The method of Claim 20 wherein the
inflammation-associated disorder is pain.

23. The method of Claim 20 wherein the
25 inflammation-associated disorder is fever.

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 96/01869

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D261/08 C07D413/04 C07D261/18 C07D261/12 C07D261/10
A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 00501 (MERCK FROSST CANADA INC) 5 January 1995 cited in the application see claims ---	1-6, 17-23
A	EP,A,0 633 254 (TAIHO PHARMACEUTICAL CO LTD) 11 January 1995 cited in the application see claims ---	1-4, 17-23
A	EP,A,0 026 928 (CDC LIFE SCIENCES) 15 April 1981 cited in the application see claims ---	1-4, 17-23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Δ document member of the same patent family

Date of the actual completion of the international search

22 May 1996

Date of mailing of the international search report

04. 06. 96

Name and mailing address of the ISA

European Patent Office, P.B. 8010 Pottenbach 2
NL - 2200 HV Rijswijk
Tel. (+ 31-70) 340-3010, Tx. 31 651 epo nl
Fax: (+ 31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

Intern	Application No
PCT/US 96/01869	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 549 797 (TAIHO PHARMACEUTICAL CO LTD) 7 July 1993 cited in the application see claims ----	1-4, 17-23
A	EP,A,0 623 603 (TAIHO PHARMACEUTICAL CO LTD) 9 November 1994 see claims -----	1-4, 17-23

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 96/01869

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-23 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern'l Application No

PCT/US 96/01869

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9500501	05-01-95	US-A- 5474995 AU-B- 1269495 AU-B- 6967494 CA-A- 2163888 WO-A- 9518799 EP-A- 0705254 FI-A- 956119 NO-A- 955256 PL-A- 312196 ZA-A- 9404501		12-12-95 01-08-95 17-01-95 05-01-95 13-07-95 10-04-96 19-12-95 23-02-96 01-04-96 13-03-95
EP-A-0633254	11-01-95	AU-B- 658629 US-A- 5399577 AU-B- 1740592 CA-A- 2102209 WO-A- 9219604		27-04-95 21-03-95 21-12-92 02-11-92 12-11-92
EP-A-0026928	15-04-81	CA-A- 1128526 AT-T- 5967 JP-C- 1343017 JP-A- 56059764 JP-B- 61006067 US-A- 4327222		27-07-82 15-02-84 14-10-86 23-05-81 24-02-86 27-04-82
EP-A-0549797	07-07-93	JP-A- 4134077 AU-B- 650484 AU-B- 8631891 CA-A- 2091897 WO-A- 9205162 US-A- 5318970		07-05-92 23-06-94 15-04-92 22-03-92 02-04-92 07-06-94
EP-A-0623603	09-11-94	JP-A- 6135948 AU-B- 5345094 US-A- 5478856 CA-A- 2126972 WO-A- 9410157		17-05-94 24-05-94 26-12-95 11-05-94 11-05-94

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.